U.S. patent application number 16/999123 was filed with the patent office on 2021-02-18 for methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species.
The applicant listed for this patent is Adimab, LLC. Invention is credited to Juergen Hermann Nett, Maximiliano Vasquez, K. Dane Wittrup.
Application Number | 20210047387 16/999123 |
Document ID | / |
Family ID | 1000005180966 |
Filed Date | 2021-02-18 |
View All Diagrams
United States Patent
Application |
20210047387 |
Kind Code |
A1 |
Nett; Juergen Hermann ; et
al. |
February 18, 2021 |
METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM
PARENTAL HOMODIMERIC ANTIBODY SPECIES
Abstract
Methods for purifying multispecific antibodies on interest
(MAIs) that co-engage at least two different antigens or epitopes
(also referred to targets, used interchangeably throughout), from
compositions comprising the MAI and parental homodimeric antibody
species are provided, as well as reagents which may be used to
practice such methods.
Inventors: |
Nett; Juergen Hermann;
(Lebanon, NH) ; Wittrup; K. Dane; (Lebanon,
NH) ; Vasquez; Maximiliano; (Lebanon, NH) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Adimab, LLC |
Lebanon |
NH |
US |
|
|
Family ID: |
1000005180966 |
Appl. No.: |
16/999123 |
Filed: |
August 21, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15565494 |
Oct 10, 2017 |
10787500 |
|
|
PCT/US16/26620 |
Apr 8, 2016 |
|
|
|
16999123 |
|
|
|
|
62249180 |
Oct 30, 2015 |
|
|
|
62146116 |
Apr 10, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/52 20130101;
B01D 15/363 20130101; B01D 15/168 20130101; B01J 39/26 20130101;
C07K 2317/21 20130101; B01D 15/166 20130101; B01D 15/362 20130101;
C07K 2317/515 20130101; B01J 41/20 20130101; B01D 15/3847 20130101;
B01D 15/36 20130101; C07K 1/18 20130101; C07K 2317/31 20130101;
C07K 16/00 20130101 |
International
Class: |
C07K 16/00 20060101
C07K016/00; C07K 1/18 20060101 C07K001/18; B01D 15/36 20060101
B01D015/36; B01D 15/38 20060101 B01D015/38; B01D 15/16 20060101
B01D015/16; B01J 39/26 20060101 B01J039/26; B01J 41/20 20060101
B01J041/20 |
Claims
1-59. (canceled)
60. An ion exchange eluant comprising either: (i) CAPS, CHES, TAPS,
HEPPSO, MOPSO, MES, acetic acid, formic acid, and a salt; or (ii)
methylamine, 1,2-ethanediamine, 1-methylpiperazine,
1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt.
61. (canceled)
62. The ion exchange eluant according to claim 60, with the proviso
that the eluant does not include TRIS, piperazine, or
imidazole.
63. (canceled)
64. (canceled)
65. The ion exchange eluant according claim 60, wherein the salt is
selected from the group consisting of NaCl, KCl, or
Na.sub.2SO.sub.4.
66. The ion exchange eluant according claim 60, wherein the eluant
is suitable for use in the purification of an MAI from a
composition comprising the MAI and parental homodimeric antibody
species.
67. The ion exchange eluant according to claim 60, wherein the
eluant comprises at least one salt at a concentration range
selected from the group consisting of: 0 mM to about 100 mM; 0 mM
to about 60 mM; 0 mM to about 50 mM; 0 mM to about 40 mM; 0 mM to
about 30 mM; 0 mM to about 20 mM; 0 mM to about 10 mM; 0 mM to
about 5 mM; about 10 mM to about 200 mM; about 10 mM to about 100
mM; about 10 mM to about 50 mM; about 10 mM to about 40 mM; about
10 mM to about 30 mM; about 10 mM to about 20 mM; about 20 mM to
about 200 mM; about 20 mM to about 100 mM; about 20 mM to about 50
mM; about 20 mM to about 30 mM; about 30 mM to about 200 mM; about
30 mM to about 100 mM; and about 30 mM to about 50 mM; and about 5
mM to about 15 mM.
68. The ion exchange eluant according to claim 60, wherein each
sample of the eluant comprises at least one salt at a concentration
of about 10 mM.
69. The ion exchange eluant according to claim 60, wherein the salt
is NaCl.
70. The ion exchange eluant according to claim 60, wherein each
sample of the eluant comprises NaCl at a concentration of about 10
mM.
71. The ion exchange eluant according to claim 60, wherein the ion
exchange eluant comprises one or more antibodies.
72. The ion exchange eluant according to claim 71, wherein the one
or more antibodies comprise either a first parental homodimeric
antibody species or a second parental homodimeric antibody
species.
73. The ion exchange eluant according to claim 72, wherein the
difference in isoelectric point (pI) between the first and second
parental homodimeric antibody species is less than 0.5 pH
units.
74. The ion exchange eluant according to claim 73, wherein the
different isoelectric points are actual isoelectric points or
calculated isoelectric points and either: a. the difference in the
actual isoelectric point of the first heavy chain polypeptide and
the actual isoelectric point of the second heavy chain polypeptide
is less than 0.50 pH unit, less than 0.45 pH unit; less than 0.40
pH unit; less than 0.35 pH unit; less than 0.30 pH unit; less than
0.25 pH unit; less than 0.20 pH unit; less than 0.15 pH unit; less
than 0.14 pH unit; less than 0.13 pH unit; less than 0.12 pH unit;
less than 0.11 pH unit; less than 0.10 pH unit; less than 0.09 pH
unit; less than 0.08 pH unit; less than 0.07 pH unit; less than
0.06 pH unit less than 0.04 pH unit; less than 0.03 pH unit; less
than 0.025 pH unit; less than 0.02 pH unit; or pH values that are
between any of the preceding values; b. the difference in the
actual isoelectric point of the first parental homodimeric antibody
species and the actual isoelectric point of the second parental
homodimeric antibody species is less than 0.50 pH unit; less than
0.45 pH unit; less than 0.40 pH unit; less than 0.35 pH unit; less
than 0.30 pH unit; less than 0.25 pH unit; less than 0.20 pH unit;
less than 0.15 pH unit; less than 0.14 pH unit; less than 0.13 pH
unit; less than 0.12 pH unit; less than 0.11 pH unit; less than
0.10 pH unit; less than 0.09 pH unit; less than 0.08 pH unit; less
than 0.07 pH unit; less than 0.06 pH unit less than 0.04 pH unit;
less than 0.03 pH unit; less than 0.025 pH unit; less than 0.02 pH
unit; or pH values that are between any of the preceding values; c.
the difference in the calculated isoelectric point of the first
heavy chain polypeptide and the calculated isoelectric point of the
second heavy chain polypeptide is less than 0.50 pH unit; less than
0.45 pH unit; less than 0.40 pH unit; less than 0.35 pH unit; less
than 0.30 pH unit; less than 0.25 pH unit; less than 0.20 pH unit;
less than 0.15 pH unit; less than 0.14 pH unit; less than 0.13 pH
unit; less than 0.12 pH unit; less than 0.11 pH unit; less than
0.10 pH unit; less than 0.09 pH unit; less than 0.08 pH unit; less
than 0.07 pH unit; less than 0.06 pH unit less than 0.04 pH unit;
less than 0.03 pH unit; less than 0.025 pH unit; less than 0.02 pH
unit; or pH values that are between any of the preceding values; or
d. the difference in the calculated isoelectric point of the first
parental homodimeric antibody species and the calculated
isoelectric point of the second parental homodimeric antibody
species is less than 0.50 pH unit; less than 0.45 pH unit; less
than 0.40 pH unit; less than 0.35 pH unit; less than 0.30 pH unit;
less than 0.25 pH unit; less than 0.20 pH unit; less than 0.15 pH
unit; less than 0.14 pH unit; less than 0.13 pH unit; less than
0.12 pH unit; less than 0.11 pH unit; less than 0.10 pH unit; less
than 0.09 pH unit; less than 0.08 pH unit; less than 0.07 pH unit;
less than 0.06 pH unit less than 0.04 pH unit; less than 0.03 pH
unit; less than 0.025 pH unit; less than 0.02 pH unit; or pH values
that are between any of the preceding values.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit of U.S.
Provisional Patent Application Ser No. 62/146,116, filed Apr. 10,
2015, and U.S. Provisional Patent Application Ser. No. 62/249,180,
filed Oct. 30, 2015, the entire contents of which are incorporated
herein by reference.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is hereby
incorporated by reference in its entirety. The ASCII copy, created
on Apr. 7, 2016, is named 2009186-0170_SL.txt and is 145,072 bytes
in size.
FIELD OF THE INVENTION
[0003] The present invention relates, inter alia, methods of
separating and purifying multispecific antibodies from homodimeric
species, such as parental homodimeric species, and reagents useful
for carrying out the methods.
BACKGROUND OF THE INVENTION
[0004] All references cited herein, including patents, patent
applications, and non-patent publications referenced throughout are
hereby expressly incorporated by reference in their entireties for
all purposes.
[0005] Antibodies and antibody-based molecules represent attractive
candidates as diagnostic tools and therapeutics. To date more than
30 therapeutic monoclonal antibodies have been approved for and
successfully applied in diverse indication areas including cancer,
organ transplantation, autoimmune and inflammatory disorders,
infectious disease, and cardiovascular disease.
[0006] However, the majority of these antibodies are monospecific
antibodies, which recognize a single epitope and can be selected to
either activate or repress the activity of a target molecule
through this single epitope. Many physiological responses, however,
require crosslinking, "cross-talk" or co-engagement of or between
two or more different proteins or protein subunits to be triggered.
An important example is the activation of heteromeric, cell-surface
receptor complexes. For these receptor complexes, activation is
normally achieved through ligand interaction with multiple domains
on different proteins resulting in proximity-associated activation
of one or both receptor components.
[0007] Multispecific antibodies, such as bispecific antibodies,
represent attractive molecules as a means to address and
therapeutically exploit some of these more complex physiological
processes, and disease states associated therewith, as they can
co-engage multiple epitopes or antigens.
[0008] One approach to generating bispecific antibodies has to use
antibody fragments to make bispecifics. Because the considerable
diversity of the antibody variable region (Fv) makes it possible to
produce an Fv that recognizes virtually any antigen or epitope, the
typical approach to fragment-based multispecifics generation is the
introduction of new variable regions, in the context of, e.g.,
single-chain variable fragments (scFvs), tandem scFvs, Fabs,
diabodies, chain diabodies, Fab.sub.2 bispecifics and the like;
see, e.g., Chames et al., Br. J. Pharmacol, Vol. 157(2):220-233
(2009)), or non-native formats including such fragments. Because
such fragments lack the complex quaternary structure of a full
length antibody, variable light and heavy chains can be linked in
single genetic constructs. While these formats can often be
expressed at high levels in bacteria and may have favorable
penetration benefits due to their small size, they clear rapidly in
vivo and can present manufacturing obstacles related to their
production and stability. A principal cause of these drawbacks is
that antibody fragments typically lack the constant region of the
antibody with its associated functional properties, including
larger size, high stability, and binding to various Fc receptors
and ligands that maintain long half-life in serum (i.e. the
neonatal Fc receptor FcRn) or serve as binding sites for
purification (i.e. protein A and protein G).
[0009] More recent work has attempted to address the shortcomings
of fragment-based bispecifics by engineering dual binding into full
length antibody-like formats (Wu et al., 2007, Nature Biotechnology
25[11]:1290-1297; U.S. Ser. No. 12/477,711 (published as US
2009/0311253); Michaelson et al., 2009, mAbs 1[2]:128-141;
PCT/US2008/074693 (published as WO 2009/032782); Zuo et al., 2000,
Protein Engineering 13[5]:361-367; U.S. Ser. No 09/865,198; Shen et
al., 2006, J Biol Chem 281[16]:10706-10714; Lu et al., 2005, J Biol
Chem 280[20]:19665-19672; PCT/US2005/025472 (published as WO
2006/020258).
[0010] Still others have attempted to generate bispecific
antibodies that are in the native IgG format (i.e., contain two
heavy chains and two light chains that interact in the same
orientation as found in native (i.e., "wild-type") IgGs. However,
the most straightforward way of producing a bispecific antibody
(expressing two antibodies in a single cell) gives rise to multiple
species in addition to the species of interest, because the
respective heavy chains form both homo- and heterodimers, and the
two respective light chains can pair with either heavy chain.
[0011] Significant effort has been devoted to addressing this
heterogeneity issue, either by engineering mutations into either
one or more of the immunoglobulin chains in order to drive the
desired heterodimerization between chains, or to enable
purification schemes that facilitate separation of the desired
heterodimeric antibody from other undesired antibody species.
[0012] U.S. Pat. Nos. 5,731,168, 5,807,706, 5,821,333, 7,642,228,
and 7,695,936, and other equivalents describe the generation of
heteromultimeric antibodies comprising two different heavy chains
having different antigen specificities and a common light chain,
wherein each heavy chain has been modified to order to engineer
heterodimer interaction interfaces into the Fc regions. The
modifications comprise engineering targeted mutations into the CH3
domain of each heavy chain, wherein in one heavy chain a cavity is
generated and in the other heavy chain a complementary protuberance
is generated, such that the protuberance engages and inserts within
the cavity, thus driving heterodimerization of the two heavy
chains.
[0013] WO2013/136186 describes the generation of heteromultimeric
antibodies comprising two different heavy chains having different
antigen specificities, wherein at least one heavy chain has been
modified in order reduce or eliminate binding of the CH1 region of
the at least one heavy chain to the CaptureSelect.RTM. IgG-CH1
affinity reagent. However, the end result of this approach is the
generation of antibodies containing non-native amino acid
sequences, thus greatly increasing the likelihood of generating
antibodies possessing a heightened risk of increased
immunogenicity, undesirably altered Fc effector function, and other
untoward liabilities, relative to antibodies that do not contain
such non-native amino acid sequences.
[0014] WO 2007/114325 and corresponding application publication No.
US 2009/0263392 teach the purification of certain bispecific
antibodies comprising common light chains that have been modified
by engineering specific amino acid mutations in each heavy chain
constant region of the antibodies for the purpose of increasing the
difference in the isoelectric point (pI) between each heavy chain.
The engineered heterodimeric bispecific antibodies are then
subjected to ion exchange chromatography and separated from
homodimeric parental species on the basis of the enhancement in the
pI difference resultant from the engineered, pI
difference-increasing mutations in the two heavy chains in the
heterodimeric species. However, as with the methods disclosed in WO
2013/136186, as the methods disclosed in WO 2007/114325 and US
2009/0263392 require the introduction of non-native amino acid
sequence into the Fc region, the end result being the generation of
antibodies possessing a heightened risk of increased
immunogenicity, undesirably altered Fc effector function, and other
untoward liabilities, relative to antibodies that do not contain
such non-native amino acid sequences.
[0015] WO 2014/078729 teaches that proteins, such as monoclonal
antibodies have mostly charged and polar amino acids at the surface
in aqueous environments, and that the surface residues can undergo
multiple chemical and enzymatic modifications, leading to
heterogeneous mixtures of protein variant contaminants
characterized by differences on their electrostatic surface. The
reference further teaches methods of analyzing single antibody
species for the presence of such contaminating variants of the
species, such as charge variants, degradation products, etc., by
using pH and ionic strength gradients in ion exchange
chromatography procedures (see Examples therein). The elution
buffers used in the exemplified methods include piperazine, Tris,
and imidazole. The reference does not demonstrate the purification
of a multispecific heavy chain-heterodimeric antibody of interest
(MAI) from a composition comprising the MAI and each of the two
parental heavy chain-homodimeric antibody species from which the
heavy chains of the MAI are derived. Additionally, Hefti et al.,
Anal Biochem., Vol. 295(2), pages 180-185 (2001) teach that the
presence of imidazole in protein compositions often results in the
generation of protein aggregates, and thus potentially complicating
any chromatographic process in which imidazole is included in
either a loading or an elution buffer when trying to separate or
purify individual antibody species from a composition comprising
multiple antibody species.
[0016] Gramer et al., (mAbs, Vol. 5(6), pages 962-973 (2013))
report the production of stable bispecific antibodies in the IgG1
format by controlled Fab-arm exchange. The method involves
introduction of mutations into the CH3 regions of parental heavy
chains, which drive heterodimerization of the two different heavy
chains after reduction of the two parental species (described
below); expression of the mutated parental homodimeric monospecific
antibodies; purification of the parental homodimeric antibodies;
subjecting the expressed parental homodimeric antibody samples to
appropriate reducing conditions, such that inter-heavy chain
disulfide bonds are reduced while maintaining disulfide linkage
between heavy chains and light chains; subjecting the reduced
antibodies to (re)-oxidizing conditions in order to facilitate
disulfide linkage formation between the two different parental
heavy chains; separation of the heterodimeric antibody species from
residual parental homodimeric species (and other impurities).
Gramer also teach that "because the nature of any homodimeric pair
may vary quite significantly, cationic exchange chromatography is
not likely to be generally applicable" to the separation or
purification of a desired heterodimeric species from parental
homodimeric species.
[0017] There remains, therefore, a need for the provision of
methods for preparing and/or purifying multispecific antibodies of
interest (MAIs) from compositions comprising an MAI and parental
homodimeric antibody species), which do not require engineering the
MAI (or the parental antibodies) in order to facilitate either the
formation of the purification of the heterodimeric antibodies of
interest from the parental homodimeric species. This need is
particularly great for cases in which the multispecific antibodies
of interest are to be in native (i.e., "wild-type") format, such as
a native IgG isotype format (e.g., IgG1, IgG2, IgG3, IgG4, and
hybrids thereof).
SUMMARY OF THE INVENTION
[0018] The present invention provides, inter alia, methods of
purifying multispecific antibodies of interest (MAIs) (referred to
interchangeably throughout as "multispecific antibodies", "heavy
chain-heterodimeric antibodies", "multi specific antibodies of
interest", "multi specific antibody analogs", "analogs", or
"antibody analogs"), which advantageously co-engage at least two
different antigens or epitopes (also referred to "targets", used
interchangeably throughout) comprising a heterodimer comprising a
first polypeptide comprising a first heavy chain (HC) variable
region and a second polypeptide comprising a second HC variable
region, from compositions comprising the MAI and at least two
corresponding parental homodimeric antibody species. In some
embodiments a first such parental homodimeric antibody species
comprises one copy of the first polypeptide comprising the first HC
variable region and a second such parental homodimeric antibody
species comprises one copy of the second polypeptide comprising the
second HC variable region. In some embodiments, a first such
parental homodimeric antibody species comprises two copies of the
first polypeptide comprising the first HC variable region and a
second such parental homodimeric antibody species comprises two
copies of the second polypeptide comprising the second HC variable
region. In some embodiments, a first such parental homodimeric
antibody species comprises more than two copies (i.e., three or
more copies) of the first polypeptide comprising the first HC
variable region and a second such parental homodimeric antibody
species comprises more than two copies (i.e., three or more copies)
of the second polypeptide comprising the second HC variable
region.
[0019] In certain embodiments which may be used alone or in
combination with any other embodiments disclosed herein, the
composition comprising the MAI and the at least two corresponding
homodimeric species is expressed by a population of host cells,
such as prokaryotic host cells or eukaryotic host cells; bacterial
host cells; yeast host cells; mammalian host cells; insect host
cells; Pichia yeast cells; Saccharomyces cerevisiae yeast host
cells; and the like. In certain embodiments which may be used alone
or in combination with any other embodiments disclosed herein, the
composition comprising the MAI and the at least two corresponding
homodimeric species is expressed by a population of host cells
comprising such host cells that have been transformed with nucleic
acid encoding the at least two homodimeric species.
[0020] In certain embodiments which may be used alone or in
combination with any other embodiments disclosed herein, the MAI
comprises an antibody. In certain embodiments which may be used
alone or in combination with any other embodiments disclosed
herein, the MAI comprises an immunoglobulin. In certain embodiments
which may be used alone or in combination with any other
embodiments disclosed herein, the MAI comprises an IgG. In certain
embodiments which may be used alone or in combination with any
other embodiments disclosed herein, the MAI comprises an Ig isotype
hybrid. In certain embodiments which may be used alone or in
combination with any other embodiments disclosed herein, the MAI
comprises an IgG1/IgG2 hybrid, and IgG1/IgG3 hybrid, or an
IgG1/IgG4 hybrid. In certain embodiments which may be used alone or
in combination with any other embodiments disclosed herein, the MAI
comprises an IgG1/IgG4 hybrid.
[0021] In certain embodiments which may be used alone or in
combination with any other embodiments disclosed herein, the
invention provides a method of purifying a multispecific antibody
of interest (MAI), wherein the MAI comprises a heterodimer
comprising a first heavy chain polypeptide comprising a first heavy
chain (HC) variable region and a second heavy chain polypeptide
comprising a second HC variable region, wherein the first and the
second variable regions have different antigen specificities and
different isoelectric points, the method comprising: [0022] i)
obtaining a composition comprising the MAI, a first parental
homodimeric antibody species comprising either at least one copy of
the first heavy chain polypeptide or at least two copies of the
first heavy chain polypeptide, and a second parental homodimeric
antibody species comprising either at least one copy of the second
heavy chain polypeptide or at least two copies of the second heavy
chain polypeptide; and [0023] ii) performing chromatography whereby
the MAI is separated from the first and the second parental
homodimeric antibody species; [0024] thereby purifying the MAI. In
certain embodiments, which may be used alone or in combination with
any other embodiments disclosed herein, the performing step ii)
comprises: [0025] contacting the composition with a chromatographic
material forming a composition-chromatographic material complex;
and [0026] performing an elution step wherein the chromatographic
material-composition complex is contacted with an sample of eluant
that is capable of eluting the MAI and parental homodimeric
antibody species in a pH-dependent manner. In certain embodiments,
the different isoelectric points are actual isoelectric points. In
certain other embodiments, the different isoelectric points are
calculated isoelectric points.
[0027] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
comprises at least two buffering agents that each has a different
negative log acid dissociation constant (pKa).
[0028] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
inventive methods further comprise preparing or equilibrating
either: [0029] the composition; or [0030] the
composition-chromatographic material complex; [0031] in a first
sample of the eluant at a desired starting pH prior performing the
elution step.
[0032] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
inventive methods further comprise flowing a volume of a second
sample of the eluant that is prepared at a desired ending pH
through the chromatographic material-composition complex.
[0033] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, a pH
gradient is generated as the eluant flows through the
chromatographic material-composition complex.
[0034] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
inventive methods comprise a pH gradient that is generated as the
eluant flows through the chromatographic material-composition
complex, wherein the pH gradient comprises a step pH gradient
phase.
[0035] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, a pH
gradient is generated as the eluant flows through the
chromatographic material-composition complex, wherein the pH
gradient comprises a linear pH gradient phase.
[0036] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, a pH
gradient is generated as the eluant flows through the
chromatographic material-composition complex, wherein the pH
gradient comprises a step pH gradient phase and linear pH gradient
phase.
[0037] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, a pH
gradient is generated as the eluant flows through the
chromatographic material-composition complex, wherein the pH
gradient each comprises two or more step pH gradient phases and a
linear pH gradient phase.
[0038] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the pH
gradient comprises a step pH gradient phase prior to a linear pH
gradient phase.
[0039] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the pH
gradient comprises a step pH gradient phase subsequent to a linear
pH gradient phase.
[0040] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the pH
gradient comprises an essentially linear pH gradient phase.
[0041] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the pH
gradient is an essentially linear pH gradient phase.
[0042] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the MAI,
the first parental homodimeric antibody species, and the second
parental homodimeric antibody species each elute from the
chromatographic material in essentially distinguishable elution
volumes.
[0043] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the MAI,
the first parental homodimeric antibody species, and the second
parental homodimeric antibody species each elute from the
chromatographic material in a pH-dependent manner.
[0044] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
comprises either: [0045] at least two; [0046] at least three;
[0047] at least four; [0048] at least five; [0049] at least six;
[0050] at least seven; or [0051] eight; [0052] of the following
buffering agents: Ncyclohexyl-3-aminopropanesulfonic acid (CAPS),
N-Cyclohexyl-2-aminoethanesulfonic acid (CHES),
N-Tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS),
N-(2-Hydroxyethyl)piperazine-N'-(2-hydroxypropanesulfonic acid)
(HEPPSO), 3-morpholino-2-hydroxypropanesulfonic acid sodium salt,
3-(N-morpholinyl)-2-hydroxypropanesulfonic acid (MOPSO),
2-(N-morpholino)ethanesulfonic acid (MES), acetic acid, and formic
acid; or [0053] at least two; [0054] at least three; [0055] at
least four; [0056] at least five; or [0057] at least six; of the
following buffering agents: methylamine, 1,2-ethanediamine,
1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine.
[0058] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
comprises either: [0059] (i) CAPS, CHES, TAPS, HEPPSO, MOPSO, MES,
acetic acid, formic acid, and a salt; or [0060] (ii) methylamine,
1,2-ethanediamine, 1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt.
[0061] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
comprises: [0062] at least two; [0063] at least three; [0064] at
least four; [0065] at least five; [0066] at least six; [0067] at
least seven; or [0068] eight; [0069] of the following buffering
agents: Ncyclohexyl-3-aminopropanesulfonic acid (CAPS),
N-Cyclohexyl-2-aminoethanesulfonic acid (CHES),
N-Tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS),
N-(2-Hydroxyethyl)piperazine-N'-(2-hydroxypropanesulfonic acid)
(HEPPSO), 3-morpholino-2-hydroxypropanesulfonic acid sodium salt,
3-(N-morpholinyl)-2-hydroxypropanesulfonic acid (MOPSO),
2-(N-morpholino)ethanesulfonic acid (MES), acetic acid, and formic
acid; [0070] with the proviso that the eluant does not include any
of the following: imidazole; piperazine,
tris(hydroxymethyl)aminomethane (TRIS).
[0071] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
consists essentially of either: (i) CAPS; CHES; TAPS; HEPPSO;
MOPSO; MES; acetic acid; and formic acid; and optionally at least
one salt. or [0072] (ii) methylamine, 1,2-ethanediamine,
1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt.
[0073] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
consists of either: [0074] (i) CAPS, CHES, TAPS, HEPPSO, MOPSO,
MES, acetic acid, formic acid, and a salt; or [0075] (ii)
methylamine, 1,2-ethanediamine, 1-methylpiperazine,
1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt.
[0076] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
comprises at least one salt selected from the group consisting of:
NaCl, KCl, and Na.sub.2SO.sub.4.
[0077] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, each
sample of the eluant comprises at least one salt at a concentration
range selected from the group consisting of: 0 mM to about 100 mM;
0 mM to about 60 mM; 0 mM to about 50 mM; 0 mM to about 40 mM; 0 mM
to about 30 mM; 0 mM to about 20 mM; 0 mM to about 10 mM; 0 mM to
about 5 mM; about 10 mM to about 200 mM; about 10 mM to about 100
mM; about 10 mM to about 50 mM; about 10 mM to about 40 mM; about
10 mM to about 30 mM; about 10 mM to about 20 mM; about 20 mM to
about 200 mM; about 20 mM to about 100 mM; about 20 mM to about 50
mM; about 20 mM to about 30 mM; about 30 mM to about 200 mM; about
30 mM to about 100 mM; and about 30 mM to about 50 mM; and about 5
mM to about 15 mM.
[0078] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, each
sample of the eluant comprises at least one salt at a concentration
of about 10 mM.
[0079] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, each
sample of the eluant comprises NaCl at a concentration of about 10
mM.
[0080] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
difference between the actual isoelectric point of a first heavy
chain polypeptide derived from a first heavy chain parental
homodimeric antibody species and the actual isoelectric point of
the second polypeptide derived from a second heavy chain parental
homodimeric antibody species is less than 7.0 pH units; less than
6.5 pH units; less than 6.0 pH units; less than 5.5 pH units; less
than 5.0 pH units; less than 4.5 pH units; less than 4.0 units;
less than 3.5 pH units; less than 2.5 pH units; less than 2.4 pH
units; less than 2.3 pH units; less than 2.2 pH units; less than
2.1 pH units; less than 2.0 pH units; less than 1.9 pH units; less
than 1.8 pH units; less than 1.7 pH units; less than 1.6 pH units;
less than 1.5 pH units; less than 1.4 pH units; less than 1.3 pH
units, less than 1.2 pH units; less than 1.1 pH units; less than
1.0 pH unit; less than 0.95 pH unit; less than 0.90 pH unit; less
than 0.85 pH unit; less than 0.80 pH unit; less than 0.75 pH unit;
less than 0.70 pH unit; less than 0.65 pH unit; less than 0.60 pH
unit; less than 0.55 pH unit; less than 0.50 pH unit; less than
0.45 pH unit; less than 0.40 pH unit; less than 0.35 pH unit; less
than 0.30 pH unit; less than 0.25 pH unit; less than 0.20 pH unit;
less than 0.15 pH unit; less than 0.14 pH unit; less than 0.13 pH
unit; less than 0.12 pH unit; less than 0.11 pH unit; less than
0.10 pH unit; less than 0.09 pH unit; less than 0.08 pH unit; less
than 0.07 pH unit; less than 0.06 pH unit less than 0.04 pH unit;
less than 0.03 pH unit; less than 0.025 pH unit; less than 0.02 pH
unit; or pH values that are between any of the preceding
values.
[0081] In certain embodiments, the difference between: the actual
isoelectric point of a first antibody, such as a first
immunoglobulin, first IgG, or first parental homodimeric antibody
species; and the actual isoelectric point of a second antibody,
such as a second immunoglobulin, second IgG, or second parental
homodimeric antibody species; is less than 7.0 pH units; less than
6.5 pH units; less than 6.0 pH units; less than 5.5 pH units; less
than 5.0 pH units; less than 4.5 pH units; less than 4.0 units;
less than 3.5 pH units; less than 2.5 pH units; less than 2.4 pH
units; less than 2.3 pH units; less than 2.2 pH units; less than
2.1 pH units; less than 2.0 pH units; less than 1.9 pH units; less
than 1.8 pH units; less than 1.7 pH units; less than 1.6 pH units;
less than 1.5 pH units; less than 1.4 pH units; less than 1.3 pH
units, less than 1.2 pH units; less than 1.1 pH units; less than
1.0 pH unit; less than 0.95 pH unit; less than 0.90 pH unit; less
than 0.85 pH unit; less than 0.80 pH unit; less than 0.75 pH unit;
less than 0.70 pH unit; less than 0.65 pH unit; less than 0.60 pH
unit; less than 0.55 pH unit; less than 0.50 pH unit; less than
0.45 pH unit; less than 0.40 pH unit; less than 0.35 pH unit; less
than 0.30 pH unit; less than 0.25 pH unit; less than 0.20 pH unit;
less than 0.15 pH unit; less than 0.14 pH unit; less than 0.13 pH
unit; less than 0.12 pH unit; less than 0.11 pH unit; less than
0.10 pH unit; less than 0.09 pH unit; less than 0.08 pH unit; less
than 0.07 pH unit; less than 0.06 pH unit less than 0.04 pH unit;
less than 0.03 pH unit; less than 0.025 pH unit; less than 0.02 pH
unit; or pH values that are between any of the preceding
values.
[0082] In certain embodiments, the difference between the actual
isoelectric point of a first parental homodimeric antibody species
and the actual isoelectric point of a second parental homodimeric
antibody species is less than 7.0 pH units; less than 6.5 pH units;
less than 6.0 pH units; less than 5.5 pH units; less than 5.0 pH
units; less than 4.5 pH units; less than 4.0 units; less than 3.5
pH units; less than 2.5 pH units; less than 2.4 pH units; less than
2.3 pH units; less than 2.2 pH units; less than 2.1 pH units; less
than 2.0 pH units; less than 1.9 pH units; less than 1.8 pH units;
less than 1.7 pH units; less than 1.6 pH units; less than 1.5 pH
units; less than 1.4 pH units; less than 1.3 pH units, less than
1.2 pH units; less than 1.1 pH units; less than 1.0 pH unit; less
than 0.95 pH unit; less than 0.90 pH unit; less than 0.85 pH unit;
less than 0.80 pH unit; less than 0.75 pH unit; less than 0.70 pH
unit; less than 0.65 pH unit; less than 0.60 pH unit; less than
0.55 pH unit; less than 0.50 pH unit; less than 0.45 pH unit; less
than 0.40 pH unit; less than 0.35 pH unit; less than 0.30 pH unit;
less than 0.25 pH unit; less than 0.20 pH unit; less than 0.15 pH
unit; less than 0.14 pH unit; less than 0.13 pH unit; less than
0.12 pH unit; less than 0.11 pH unit; less than 0.10 pH unit; less
than 0.09 pH unit; less than 0.08 pH unit; less than 0.07 pH unit;
less than 0.06 pH unit less than 0.04 pH unit; less than 0.03 pH
unit; less than 0.025 pH unit; less than 0.02 pH unit; or pH values
that are between any of the preceding values.
[0083] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
difference between the calculated isoelectric point of a first
heavy chain polypeptide derived from a first heavy chain parental
homodimeric antibody species and the calculated isoelectric point
of the second polypeptide derived from a second heavy chain
parental homodimeric antibody species is less than 7.0 pH units;
less than 6.5 pH units; less than 6.0 pH units; less than 5.5 pH
units; less than 5.0 pH units; less than 4.5 pH units; less than
4.0 units; less than 3.5 pH units; less than 2.5 pH units; less
than 2.4 pH units; less than 2.3 pH units; less than 2.2 pH units;
less than 2.1 pH units; less than 2.0 pH units; less than 1.9 pH
units; less than 1.8 pH units; less than 1.7 pH units; less than
1.6 pH units; less than 1.5 pH units; less than 1.4 pH units; less
than 1.3 pH units, less than 1.2 pH units; less than 1.1 pH units;
less than 1.0 pH unit; less than 0.95 pH unit; less than 0.90 pH
unit; less than 0.85 pH unit; less than 0.80 pH unit; less than
0.75 pH unit; less than 0.70 pH unit; less than 0.65 pH unit; less
than 0.60 pH unit; less than 0.55 pH unit; less than 0.50 pH unit;
less than 0.45 pH unit; less than 0.40 pH unit; less than 0.35 pH
unit; less than 0.30 pH unit; less than 0.25 pH unit; less than
0.20 pH unit; less than 0.15 pH unit; less than 0.14 pH unit; less
than 0.13 pH unit; less than 0.12 pH unit; less than 0.11 pH unit;
less than 0.10 pH unit; less than 0.09 pH unit; less than 0.08 pH
unit; less than 0.07 pH unit; less than 0.06 pH unit less than 0.04
pH unit; less than 0.03 pH unit; less than 0.025 pH unit; less than
0.02 pH unit; or pH values that are between any of the preceding
values.
[0084] In certain embodiments, the difference between: the
calculated isoelectric point of a first antibody, such as a first
immunoglobulin, first IgG, or first parental homodimeric antibody
species; and the calculated isoelectric point of a second antibody,
such as a second immunoglobulin, second IgG, or second parental
homodimeric antibody species; is less than 7.0 pH units; less than
6.5 pH units; less than 6.0 pH units; less than 5.5 pH units; less
than 5.0 pH units; less than 4.5 pH units; less than 4.0 units;
less than 3.5 pH units; less than 2.5 pH units; less than 2.4 pH
units; less than 2.3 pH units; less than 2.2 pH units; less than
2.1 pH units; less than 2.0 pH units; less than 1.9 pH units; less
than 1.8 pH units; less than 1.7 pH units; less than 1.6 pH units;
less than 1.5 pH units; less than 1.4 pH units; less than 1.3 pH
units, less than 1.2 pH units; less than 1.1 pH units; less than
1.0 pH unit; less than 0.95 pH unit; less than 0.90 pH unit; less
than 0.85 pH unit; less than 0.80 pH unit; less than 0.75 pH unit;
less than 0.70 pH unit; less than 0.65 pH unit; less than 0.60 pH
unit; less than 0.55 pH unit; less than 0.50 pH unit; less than
0.45 pH unit; less than 0.40 pH unit; less than 0.35 pH unit; less
than 0.30 pH unit; less than 0.25 pH unit; less than 0.20 pH unit;
less than 0.15 pH unit; less than 0.14 pH unit; less than 0.13 pH
unit; less than 0.12 pH unit; less than 0.11 pH unit; less than
0.10 pH unit; less than 0.09 pH unit; less than 0.08 pH unit; less
than 0.07 pH unit; less than 0.06 pH unit less than 0.04 pH unit;
less than 0.03 pH unit; less than 0.025 pH unit; less than 0.02 pH
unit; or pH values that are between any of the preceding
values.
[0085] In certain embodiments, the difference between the
calculated isoelectric point of a first parental homodimeric
antibody species and the calculated isoelectric point of a second
parental homodimeric antibody species is less than 7.0 pH units;
less than 6.5 pH units; less than 6.0 pH units; less than 5.5 pH
units; less than 5.0 pH units; less than 4.5 pH units; less than
4.0 units; less than 3.5 pH units; less than 2.5 pH units; less
than 2.4 pH units; less than 2.3 pH units; less than 2.2 pH units;
less than 2.1 pH units; less than 2.0 pH units; less than 1.9 pH
units; less than 1.8 pH units; less than 1.7 pH units; less than
1.6 pH units; less than 1.5 pH units; less than 1.4 pH units; less
than 1.3 pH units, less than 1.2 pH units; less than 1.1 pH units;
less than 1.0 pH unit; less than 0.95 pH unit; less than 0.90 pH
unit; less than 0.85 pH unit; less than 0.80 pH unit; less than
0.75 pH unit; less than 0.70 pH unit; less than 0.65 pH unit; less
than 0.60 pH unit; less than 0.55 pH unit; less than 0.50 pH unit;
less than 0.45 pH unit; less than 0.40 pH unit; less than 0.35 pH
unit; less than 0.30 pH unit; less than 0.25 pH unit; less than
0.20 pH unit; less than 0.15 pH unit; less than 0.14 pH unit; less
than 0.13 pH unit; less than 0.12 pH unit; less than 0.11 pH unit;
less than 0.10 pH unit; less than 0.09 pH unit; less than 0.08 pH
unit; less than 0.07 pH unit; less than 0.06 pH unit less than 0.04
pH unit; less than 0.03 pH unit; less than 0.025 pH unit; less than
0.02 pH unit; or pH values that are between any of the preceding
values.
[0086] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
desired starting pH is less than 9.0; less than 8.5; less than 8.0;
less than 7.5; less than 7.0; less than 6.5; less than 6.0; less
than 5.5; less than 5.0; less than 4.5; less than 4.0; less than
3.5; or less than 3.0; or a pH values that is between any of the
preceding values.
[0087] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
desired ending pH is more than 7.0; more than 7.5; more than 8.0;
more than 8.5; more than 9.0; more than 9.5; more than 10.0; more
than 10.5; or more than 11.0; more than 11.5; more than 12.0; more
than 12.5; more than 13.0; more than 13.5; or a pH values that is
between any of the preceding values.
[0088] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
comprises at least two buffering agents and wherein the acid
dissociation constant (pKa) of each buffering agent is between
about 3 and 11.
[0089] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
comprises at least two buffering agents wherein the acid
dissociation constant (pKa) of each buffering agent is in a range
selected from the group consisting of: about 3.25 to about 3.85;
about 4.5 to about 4.85; about 6.0 to about 6.45; about 6.60 to
about 7.0; about 7.5 to about 8.15; about 8.35 to about 8.55; about
9.25 to about 9.65; and about 10.00 to about 11.5.
[0090] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
comprises at least two buffering agents wherein the acid
dissociation constant (pKa) of each buffering agent is in a
different range that is selected from the group consisting of:
about 3.25 to about 3.85; about 4.5 to about 4.85; about 6.0 to
about 6.45; about 6.60 to about 7.0; about 7.5 to about 8.15; about
8.35 to about 8.55; about 9.25 to about 9.65; and about 10.00 to
about 11.5.
[0091] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
comprises at least two buffering agents wherein the acid
dissociation constant (pKa) of each buffering agent is selected
from the group consisting of about 3.75; about 4.76; about 6.10;
about 6.90; about 8.04; about 8.44; about 9.39; and about
10.50.
[0092] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the MAI
further comprises a third polypeptide comprising a first light
chain variable region.
[0093] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the MAI
further comprises a third polypeptide and a fourth polypeptide,
wherein each of the third polypeptide and the fourth polypeptide
comprises a second light chain variable region.
[0094] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
light chain variable region and the second light chain variable
region are identical.
[0095] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the third
polypeptide and the fourth polypeptide are identical.
[0096] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
polypeptide and the second polypeptide each further comprise an Fc
region.
[0097] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
polypeptide and the second polypeptide each further comprise a
wild-type Fc region.
[0098] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
polypeptide and the second polypeptide each further comprise an
IgG1 isotype Fc region, an IgG3 isotype Fc region, an IgG3 isotype
Fc region, or an IgG4 isotype Fc region.
[0099] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
polypeptide and the second polypeptide each further comprise an
IgG1 isotype Fc region.
[0100] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
polypeptide and the second polypeptide each further comprise an Fc
region that has not been engineered in order to alter the pI of the
first parental homodimeric antibody species, the second parental
homodimeric species, or the MAI.
[0101] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
polypeptide and the second polypeptide each further comprise an
IgG1 isotype Fc region that has not been engineered in order to
alter the pI of the first parental homodimeric antibody species,
the second parental homodimeric species, or the MAI.
[0102] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, either:
the MAI is in a native antibody format; at least the first parental
homodimeric antibody species is in a native format; at least the
second parental homodimeric antibody species is in a native format;
the first parental homodimeric antibody species is in a native
format and the second parental homodimeric antibody species is in a
native format; or the MAI is in a native antibody format, the first
parental homodimeric antibody species is in a native format, and
the second parental homodimeric antibody species is in a native
format.
[0103] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, wherein
either: the MAI; the first parental homodimeric antibody species;
the second parental homodimeric antibody species; the first
parental homodimeric antibody species and the second parental
homodimeric antibody species; or the MAI, the first parental
homodimeric antibody species and the second parental homodimeric
antibody species; is in an IgG1 format, and IgG2 format, and IgG3
format, or an IgG4 format, or a hybrid format.
[0104] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
chromatography performed at essentially the same ionic
strength.
[0105] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the ionic
strength of the eluant remains essentially the same throughout the
elution step.
[0106] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
sample of the eluant and the second sample of the eluant each have
essentially the same ionic strength.
[0107] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
chromatography is ion exchange chromatography.
[0108] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
chromatography is selected from the group consisting of: cation
exchange chromatography; anion exchange chromatography; multimodal
chromatography; and mixed-mode chromatography.
[0109] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
chromatographic material is selected from the group consisting of:
an anion exchanger and a cation exchanger.
[0110] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
chromatographic material is selected from the group consisting of:
a strong cation exchanger; a strong anion exchanger; a multimodal
exchanger; and a mixed-mode exchanger.
[0111] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
chromatographic material is selected from the group consisting of a
strong cation exchanger and a strong anion exchanger. In certain
embodiments, which may be used alone or in combination with any
other embodiments disclosed herein, the chromatography further
comprises using a chromatographic material selected from the group
consisting Mustang S, Sartobind S, S03 Monolith, S Ceramic HyperD,
Poros XS, Poros HS50, Poros HS20, HS20, SPSFF, Porors GoPure HS,
Poros GoPure XS, SP-Sepharose XL (SPXL), CM Sepharose Fast Flow,
Capto Q ImpRes, Capto SP ImpRes, Capto S, Capto MMC, Fractogel Se
HiCap, Fractogel S03, Fractogel COO, Poros HQ 50, Poros PI 50,
Poros D, Mustang Q, Q Sepharose FF, SP Sepharose FF, UNOshere S,
Macro-Prep High S, DEAE, Mono S, Mono S 5/50 GL, Mono Q, Mono Q
5/50 GL, Mono S 10/100 GL, SP Sepharose HP, Source 30S, Poros XQ,
Poros HQ, Q HP, and Source 30Q.
[0112] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
chromatography further comprises using a chromatographic material
selected from Mono S, Mono S 5/50 GL, Mono Q, Mono Q 5/50 GL, SP
Sepharose HP, Source 30S, Poros XQ, Poros HQ, Q HP, and Source 30Q,
and Mono S 10/100 GL.
[0113] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
chromatographic material is an ion exchange chromatographic
material.
[0114] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
chromatographic material is selected from the group consisting of:
a cation exchange chromatographic material; an anion exchange
chromatographic material; a multimodal chromatographic material;
and a mixed-mode chromatographic material.
[0115] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the ion
exchange chromatographic material is selected from the group
consisting of Mustang S, Sartobind S, S03 Monolith, S Ceramic
HyperD, Poros XS, Poros HS50, Poros HS20, HS20, SPSFF, Porors
GoPure HS, Poros GoPure XS, SP-Sepharose XL (SPXL), CM Sepharose
Fast Flow, Capto Q ImpRes, Capto SP ImpRes, Capto S, Capto MMC,
Fractogel Se HiCap, Fractogel S03, Fractogel COO, Poros HQ 50,
Poros PI 50, Poros D, Mustang Q, Q Sepharose FF, SP Sepharose FF,
UNOshere S, Macro-Prep High S, DEAE, Mono S, Mono S 5/50 GL, Mono
Q, Mono Q 5/50 GL, Mono S 10/100 GL, SP Sepharose HP, Source 30S,
Poros XQ, Poros HQ, Q HP, and Source 30Q.
[0116] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the ion
exchange chromatographic material selected from Mono S, Mono S 5/50
GL, Mono Q, Mono Q 5/50 GL, SP Sepharose HP, Source 30S, Poros XQ,
Poros HQ, Q HP, and Source 30Q, and Mono S 10/100 GL.
[0117] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, either the
first heavy chain variable region or the second heavy chain
variable region is obtained by performing a first selection against
a first antigen from a first library comprising unique heavy chain
variable regions.
[0118] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
heavy chain variable region and the second heavy chain variable
region is obtained by performing a first selection against a first
antigen from a first library comprising unique heavy chain variable
regions.
[0119] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
heavy chain variable region is obtained by performing a first
selection against a first antigen from a first library comprising
unique heavy chain variable regions and the second heavy chain
variable region is obtained by performing a second selection
against a second antigen from a second library comprising unique
heavy chain variable regions.
[0120] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the first
heavy chain variable region is obtained by performing a first
selection against a first antigen from a first library comprising
unique heavy chain variable regions and the second heavy chain
variable region is obtained by performing a second selection
against a second antigen from a second library comprising unique
heavy chain variable regions.
[0121] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, at least
one of the libraries further comprises at least one light
chain.
[0122] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
composition is expressed by prokaryotic host cells or eukaryotic
host cells, into which nucleic acid sequences encoding the first
polypeptide and the second polypeptide have each been
introduced.
[0123] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
composition is expressed by prokaryotic host cells or eukaryotic
host cells into which nucleic acid sequences encoding the first
polypeptide and the second polypeptide have each been
introduced.
[0124] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
composition is expressed by prokaryotic host cells or eukaryotic
host cells into which nucleic acid sequences encoding the first
polypeptide, the second polypeptide, the third polypeptide, and the
fourth polypeptide have each been introduced.
[0125] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, each
encoded polypeptide is expressed by the host cells.
[0126] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
composition is expressed by the host cells.
[0127] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein,
essentially each host cell has been transformed or transfected with
the first polypeptide, the second polypeptide, the third
polypeptide, and the fourth polypeptide.
[0128] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein,
essentially each host cell expresses the MAI, the first parental
antibody species, and the second parental antibody species.
[0129] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the host
cells are selected from the group consisting of: eukaryotic cells;
fungal cells; yeast cells; insect cells; mammalian cells;
Saccharomyces cerevisiae cells; Pichia pastoris cells; mammalian
cells; COS cells; human embryonic kidney (HEK) cells; and CHO
cells.
[0130] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the ion
exchange eluant comprises a cation exchange eluant or an anion
exchange eluant for use in separating an MAI from parental
homodimeric species.
[0131] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
invention provides an ion exchange eluant comprising CAPS, CHES,
TAPS, HEPPSO, MOPSO, MES, acetic acid, formic acid, and a salt for
use in separating an MAI from parental homodimeric species.
[0132] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
invention provides an ion exchange eluant comprising CAPS, CHES,
TAPS, HEPPSO, MOPSO, MES, acetic acid, formic acid, and NaCl for
use in separating an MAI from parental homodimeric species.
[0133] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
invention provides an ion exchange eluant comprising an anion
exchange eluant for use in separating an MAI from parental
homodimeric species.
[0134] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
invention provides an anion exchange eluant comprising methylamine,
1,2-ethanediamine, 1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt for
use in separating an MAI from parental homodimeric species.
[0135] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
invention provides a cation exchange eluant comprising CAPS, CHES,
TAPS, HEPPSO, MOPSO, MES, acetic acid, formic acid, and NaCl for
use in separating an MAI from parental homodimeric species.
[0136] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
invention provides an ion exchange eluant comprising an anion
exchange eluant for use in separating an MAI from parental
homodimeric species.
[0137] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the cation
exchange eluant does not include TRIS, piperazine, or
imidazole.
[0138] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
invention provides an ion exchange eluant consisting essentially of
CAPS, CHES, TAPS, HEPPSO, MOPSO, MES, acetic acid, formic acid, and
a salt.
[0139] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
invention provides an ion exchange eluant consisting of CAPS, CHES,
TAPS, HEPPSO, MOPSO, MES, acetic acid, formic acid, and a salt.
[0140] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the salt
is selected from the group consisting of NaCl, KCl, or
Na.sub.2SO.sub.4.
[0141] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the
invention provides the ion exchange eluant according to any one of
above, wherein the eluant is used for purifying an MAI from a
composition comprising the MAI and parental homodimeric antibody
species.
[0142] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the eluant
comprises at least one salt at a concentration range selected from
the group consisting of: 0 mM to about 100 mM; 0 mM to about 60 mM;
0 mM to about 50 mM; 0 mM to about 40 mM; 0 mM to about 30 mM; 0 mM
to about 20 mM; 0 mM to about 10 mM; 0 mM to about 5 mM; about 10
mM to about 200 mM; about 10 mM to about 100 mM; about 10 mM to
about 50 mM; about 10 mM to about 40 mM; about 10 mM to about 30
mM; about 10 mM to about 20 mM; about 20 mM to about 200 mM; about
20 mM to about 100 mM; about 20 mM to about 50 mM; about 20 mM to
about 30 mM; about 30 mM to about 200 mM; about 30 mM to about 100
mM; and about 30 mM to about 50 mM; and about 5 mM to about 15
mM.
[0143] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, each
sample of the eluant comprises at least one salt at a concentration
of about 10 mM.
[0144] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, the salt
is NaCl.
[0145] In certain embodiments, which may be used alone or in
combination with any other embodiments disclosed herein, each
sample of the eluant comprises NaCl at a concentration of about 10
mM.
[0146] As the artisan will understand, any and all of the
embodiments disclosed above and throughout may be practiced in any
combination and, accordingly, all such combinations are
contemplated, and are hereby disclosed and encompassed within the
scope of the invention.
BRIEF DESCRIPTION OF THE FIGURES
[0147] FIGS. 1A and 1B provide the composition of exemplary eluants
(buffering agents and salt) as described in the Examples. The final
concentration of each listed component (buffering agent and salt)
in the exemplary eluant is provided, as well as the acid
dissociation constant (pKa) of each listed buffering agent. FIG. 1A
provides an exemplary eluant composition designed for cation
exchange procedures (but as described in the Examples, was also
used for certain anion exchanged procedures. FIG. 1B provides an
exemplary anion exchange eluant composition as used in some of the
Examples.
[0148] FIG. 2 provides a schematic representation of a cation
exchange chromatography experiment as described in Example 1, in
which a Mono S 5/50 GL column was used to separate a multispecific
antibody of interest comprising a two different heavy chain
polypeptides (heavy chain "A" and heavy chain "B") from the two
corresponding heavy chain homodimeric antibody species and two
copies of an identical light chain (i.e., a "common light chain").
The calculated isoelectric points (pIs) of the two different heavy
chains differed by 0.68 pH units ("HC .DELTA.pI: 0.68"). The
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species ("mAb A homodimer" and "mAb B
homodimer", respectively) differ by 1.33 pH units ("mAB .DELTA.pI:
1.33")). A280=absorbance units measured at a wavelength of 280 nm;
.DELTA.pI=difference in calculated isoelectric point between the
two different heavy chains; mL=elution volume in milliliters. All
antibodies (MAI and parental homodimeric species) were in the IgG1
format.
[0149] FIG. 3 provides a comparison of the ability of salt gradient
(i.e., ionic strength gradient) cation exchange chromatography and
pH gradient cationic exchange chromatography to separate four
different multispecific antibodies of interest (MAIs), each MAI
comprising: two different heavy chain polypeptides from one of four
sets of two corresponding parental homodimeric antibody species;
and two copies of an identical light chain (i.e., a "common light
chain"). The calculated isoelectric points (pIs) of the two
corresponding parental homodimeric antibody species differed by
1.33, 0.26, 0.11, and 0.1 pH units, respectively as indicated in
the Figure and as described in Example 5. The resin and buffer
compositions employed in the experiments are provided in the top
table of FIG. 3.
[0150] FIGS. 4A through 4C provide schematic representations of
independent cation exchange chromatography experiments as described
in Example 2, in which either a Mono S 5/50 GL column (FIG. 4A and
FIG. 4B) or a Mono S 10/100 GL column (FIG. 4C) was used to
separate a multispecific antibody comprising a two different heavy
chain polypeptides (heavy chain "A" and heavy chain "B") and two
copies of an identical light chain (i.e., a "common light chain")
from the two corresponding heavy chain parental homodimeric
species. The calculated pIs of the two different heavy chains
differed by 0.25 pH units; the calculated pIs the two corresponding
parental homodimeric species differed by 0.59 pH units.
A280=absorbance units measured at a wavelength of 280 nm;
.DELTA.pI=difference in calculated isoelectric point (pI) between
the two different heavy chains; mL=elution volume in milliliters.
FIG. 4A depicts the separation of 0.228 milligram (mg) of total
protein material over a linear gradient across the indicated pH
range (approximately pH 6.6-pH 8.2; see y axis). FIG. 4B depicts
the separation of 1.57 mg of total protein material over a linear
gradient across the indicated pH range (approximately pH 6.9-pH
7.9; see y axis). FIG. 4C depicts the separation of 8.88 mg of
total protein material over a linear gradient across the indicated
pH range (approximately pH 6.9-pH 7.9; see y axis). All antibodies
(MAI and parental homodimeric antibody species) were in the native
IgG1 format.
[0151] FIGS. 5A through 5E provide schematic representations of
independent cation exchange chromatography experiments as described
in Example 3, in which a Mono S 10/100 column was used to separate
a multispecific antibody comprising a two different heavy chain
polypeptides (heavy chain "A" and heavy chain "B") and two copies
of an identical light chain (i.e., a "common light chain") from the
two corresponding heavy chain homodimeric species. FIG. 5A depicts
the separation of heterodimeric and parental; species in which the
difference in calculated pI between the two heavy chains is 0.68 pH
units; the calculated isoelectric points (pIs) of the two
corresponding parental homodimeric antibody species differed by
1.33 pH units. FIG. 5B depicts the separation of heterodimeric and
parental species in which the difference in calculated pI between
the two heavy chains is 0.43 pH units; the calculated isoelectric
points (pIs) of the two corresponding parental homodimeric antibody
species differed by 0.48 pH units. FIG. 5C depicts the separation
of heterodimeric and parental species in which the difference in
calculated pI between the two heavy chains is 0.25 pH units; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.59 pH units.
FIG. 5D depicts the separation of heterodimeric and parental
species in which the difference in calculated pI between the two
heavy chains is 0.24; the calculated isoelectric points (pIs) of
the two corresponding parental homodimeric antibody species
differed by 0.26 pH units. FIG. 5E depicts the separation of
heterodimeric and parental species in which the difference in
calculated pI between the two heavy chains is 0.21; the calculated
isoelectric points (pIs) of the two corresponding parental
homodimeric antibody species differed by 0.38 pH units.
A280=absorbance units measured at a wavelength of 280 nm;
.DELTA.pI=difference in calculated isoelectric point between the
two different heavy chains; run duration=elution volume in
milliliters (mL). All antibodies (MAI and parental homodimeric
antibody species) were in the native IgG1 format.
[0152] FIGS. 6A through 6G provide schematic representations of
independent cation exchange chromatography experiments (FIGS. 6A
through 6G) as described in Example 6. A280=absorbance units
measured at a wavelength of 280 nm; .DELTA.pI=difference in
calculated isoelectric point between the two different heavy
chains; run duration=elution volume in milliliters (mL). All
antibodies (MAI and parental homodimeric antibody species) were in
the native IgG1 format. Sequences disclosed as SEQ ID NOS 40-43,
respectively, in order of appearance.
[0153] FIG. 7 illustrates that the methods disclosed herein provide
the ability to separate MAIs from compositions comprising the MAI
and its parental homodimeric antibody species when such species
differ in their heavy chains VH regions by as little as one amino
acid. IAEY is SEQ ID NO: 40; IAQY is SEQ ID NO: 41; ISKY is SEQ ID
NO: 42; VAKH is SEQ ID NO: 43.
[0154] FIGS. 8A through 8C provide schematic representations of
independent cation exchange chromatography experiments as described
in Example 4, in which the degrees of purification of antibody
species in the IgG1 format with heavy chain calculated pI
difference of 0.09 (calculated isoelectric point (pIs) of the two
corresponding parental homodimeric antibody species differed by
0.10 pH units) using each of the strong cationic exchangers Mono S
5/50 GL or Mono S 10/100 GL were compared Chromatography conditions
were as described in Example 4. All antibodies (MAI and parental
homodimeric antibody species) were in the native IgG1 format. FIG.
8A depicts the separation of heterodimeric and parental species in
which the exchanger used was Mono S 5/50 GL (column volume was 1
mL), and the pH gradient was run from pH 4.0 to pH 11.0 (pH
gradient range=7.0 pH units). FIG. 8B depicts the separation of
heterodimeric and parental species in which the exchanger used was
Mono S 10/100 GL (column volume was 8 mL), and the pH gradient was
run from pH 6.65 to 7.65 (pH gradient range=1.0 pH units). FIG. 8C
depicts the separation of heterodimeric and parental species in
which the exchanger used was Mono S 10/100 GL (column volume was 8
mL), and the pH gradient was run from pH 6.87 to 7.27 (pH gradient
range=0.4 pH unit).
[0155] FIGS. 9A through 9F depict the results of the experiments
described in Example 7.
[0156] FIGS. 10A and 10B depict the results of the experiments
described in Example 8.
[0157] FIGS. 11A and 11B, 12A and 12B, 13A and 13B, 14A and 14B,
15A and 15B, 16A and 16B, and 17A and 17B depict the results of the
experiments described in Example 9.
[0158] FIGS. 18A through 18D provide schematic representations of
independent cation exchange chromatography experiments as described
in Example 10. A280=absorbance units measured at a wavelength of
280 nm; .DELTA.pI=difference in calculated isoelectric point
between the two different heavy chains; run duration=elution volume
in milliliters (mL). All antibodies (MAI and parental homodimeric
antibody species) were in the native IgG4 format.
[0159] FIGS. 19A and 19B schematic representations of independent
cation exchange chromatography experiments as described in Example
11. A280=absorbance units measured at a wavelength of 280 nm;
.DELTA.pI=difference in calculated isoelectric point between the
two different heavy chains; run duration=elution volume in
milliliters (mL). The MAI was in the hybrid native IgG1/native IgG4
format, the first parental homodimeric antibody species was in the
native IgG1 format and the second parental homodimeric antibody
species was in the native IgG4 format.
[0160] FIGS. 20A and 20B, 21A and 21B, and 22A and 22B depict the
results of the experiments described in Example 13.
[0161] FIG. 23 depicts the results of the experiments described in
Example 13.
[0162] FIG. 24 depicts the results of the experiments described in
Example 14.
[0163] FIGS. 25A and 25B depict the results of the experiments
described in Example 15.
[0164] FIGS. 26A and 26B collectively provide a list of exemplary
chromatographic materials ("resin" and "matrix") amenable for use
in accordance with the disclosed and claimed methods and certain of
their characteristics.
DETAILED DESCRIPTION OF THE INVENTION
[0165] The invention provides, inter alia, methods for separating,
resolving, and purifying multispecific antibodies of interest
(MAIs) (referred to interchangeably herein and throughout as
"heterodimeric antibody species" or "heavy chain-heterodimeric
antibodies", alternative singular and plural forms of such terms,
and the like) from at least two different parental homodimeric
antibody species (referred to interchangeably herein and throughout
as "parental antibody species", "homodimeric parental antibody
species", "heavy chain-homodimeric parental antibody species",
"heavy chain-homodimeric parental species, and the like).
Advantageously, the disclosed methods do not require the
engineering or introduction of mutations into any of the
homodimeric parental antibody species for the purpose of enhancing
the separation, resolution, or purification of the MAI from such
parental antibody species.
[0166] The methods comprise, inter alia, obtaining a composition
comprising each of the aforementioned species and performing
chromatography, for example, ion exchange chromatography, with the
composition, whereby the MAI is separated from each of a first
parental antibody species and a second parental antibody species.
In certain embodiments, the MAI comprises a first polypeptide
comprising a first heavy chain (HC) variable region and a second
heavy chain variable region, wherein the first and the second
variable regions have different antigen specificities and different
isoelectric points (pIs). In certain embodiments, the different
isoelectric points are different actual isoelectric points. In
certain other embodiments, the different isoelectric points are
different calculated isoelectric points. In certain other
embodiments, the MAI further comprises a third polypeptide
comprising a first light chain variable region. In certain other
embodiments, the MAI further comprises a third polypeptide and a
fourth polypeptide, wherein each of the third polypeptide and the
fourth polypeptide comprises a second light chain variable region.
In certain other embodiments, the first light chain variable region
and the second light chain variable region are identical. In
certain other embodiments, the third polypeptide and the fourth
polypeptide are identical (i.e., they constitute a "common light
chain").
[0167] As will be understood by the artisan and as disclosed
throughout, "specificity" refers to the property of an antibody
which enables to react with one or more antigenic determinants,
such as one or more epitopes, of an antigen of interest, and not
with other epitopes of the antigen of interest or with other
antigens of interest. As understood in the art, antibody
specificity is dependent on chemical composition, physical forces,
energetic favorability, steric hindrance, and molecular structure
or topology of the binding site of the epitope and/or the
antibody.
[0168] As will be understood by the artisan and as disclosed
throughout, "affinity" refers to the strength, or stability of an
antibody-epitope interaction. Antibodies with better affinity for
an epitope bind relatively tightly and/or stably with the epitope,
whereas antibodies with poorer affinity for an epitope bind
relatively weakly and or less stably.
[0169] As will be understood by the artisan and as disclosed
throughout, "collecting" or "collected" antibodies having
specificity for (an) epitope(s) of an antigen of interest refers to
distinguishing (or distinguished) antibodies that have such
specificity from those antibodies that do not have such
specificity. Collecting antibodies or collected antibodies having
specificity for (an) epitope(s) of an antigen of interest need not
require physical separation of antibodies from those antibodies
that do not have such specificity in order for them to be
distinguished. However, in certain embodiments, collecting
antibodies having specificity for (an) epitope(s) of an antigen of
interest comprises physically separating such antibodies from those
antibodies that do not have such specificity. Exemplary methods and
means for collecting antibodies are known in the art, and include,
for example, flow cytometry, florescence activated cell sorting
(FACS), magnetic activated cell sorting (MACS), enzyme-linked
immunosorbent assay (ELISA), and the like, and combinations
thereof.
[0170] Any means for determining such specificity in the art may be
employed for determining such specificity in accordance with the
methods disclosed throughout, and include, for example, labelling
such antibodies with a detectable label; detecting a detectable
label; detecting a functional consequence of antibody binding to
(an) epitope of an antigen, such as competition with another
antibody known to have specificity for such epitope(s); modulation
of protein-protein or protein-ligand interaction between the
antigen of interest and a known protein interaction partner or
ligand.
[0171] As used herein and throughout, a "common light chain"
comprises polypeptide comprising a light chain variable region that
is able to stably pair independently with at least two different
heavy chain polypeptides and thereby generate, in each independent
case, an antigen binding domain comprising the heavy chain variable
region of each heavy chain polypeptide and the light chain variable
region. Accordingly, each of two copies of a common light chain is
able to stably pair with a first heavy chain polypeptide and a
second heavy chain polypeptide, such that a multispecific (e.g., a
bispecific) heterodimeric antibody MAI in the native format, such
as an IgG isotype format, such as an IgG1 format, and IgG2 format,
an IgG3 format, and/or an IgG4 format, wherein the MAI has
specificity for two different antigens.
[0172] As used herein and throughout, "stable pair" means that a
native or native-like interaction between a heavy chain polypeptide
and a light chain polypeptide, such as a common light chain, is
generated, wherein an MAI in a chemically and functionally relevant
and stable manner.
[0173] As used herein and throughout, "stable" means relatively
fixed and or permanent. Accordingly, a "stable" MAI or a "stable"
pair of associated polypeptides, for example, is one that may be
collected and/or isolated in the stable form such that that form is
essentially preserved such that the chemical and/or functional
properties of the stable form can be observed.
[0174] As used herein and throughout, "native", "wild-type",
describe structures or entities, such as molecules, polypeptides,
antibodies, formats, immunoglobulins, immunoglobulin constant
regions, Fc regions, heavy chains, light chains, IgGs, IgMs, IgAs,
IgDs, IgEs, IgG1, IgG2s, IgG3s, IgG4s, MAIs, parental homodimeric
antibody species, heavy chains from parental homodimeric antibody
species, and the like that are in a format that exists in a natural
setting, such as in an animal or animal species, such as a human or
a human species. Such "native" or "wild-type" structures or
entities do not possess or contain mutations that have been
engineered into such structure or entities for the purpose, for
example, of increasing or enhancing the ability to resolve,
separate, or purify such engineered structures or entities from
non-engineered structures or entities. For example, "native" or
"wild-type" MAIs, parental homodimeric antibody species, heavy
chains from parental homodimeric antibody species, and the like,
have not been engineered to possess mutations that increase or
enhance the difference in either the actual isoelectric point or
the calculated isoelectric point between different forms of such
MAIs, parental homodimeric antibody species, heavy chains from
parental homodimeric antibody species, in order to increase or
enhance the ability of such different forms to be separated,
resolved, or purified by performing chromatography in accordance
with the methods disclosed herein and throughout.
[0175] As used herein and throughout, "native-like" describes
structures or entities that possess a substantially large amount of
properties of a native form of such a structure or entity, or is
designed to physically and/or functionally resemble or mimic a
corresponding native structure or entity to a substantial
degree.
[0176] In certain embodiments is provided a method of purifying a
multispecific antibody of interest (MAI), wherein the MAI comprises
a heterodimer comprising a first polypeptide comprising a first
heavy chain (HC) variable region and a second polypeptide
comprising a second HC variable region, wherein the first and the
second variable regions have different antigen specificities and
different isoelectric points, the method comprising: i) obtaining a
composition comprising the MAI, a first parental antibody species
comprising one copy of the first polypeptide, and a second parental
antibody species comprising one copy of the second polypeptide; and
ii) performing chromatography whereby the MAI is separated from the
first and the second parental antibody species; thereby purifying
the MAI. In certain embodiments, the different isoelectric points
are different actual isoelectric points. In certain other
embodiments, the different isoelectric points are different
calculated isoelectric points. In certain embodiments, the
performing step ii) comprises a. contacting the composition with a
chromatographic material forming a composition-chromatographic
material complex; and b. performing an elution step wherein the
chromatographic material-composition complex is contacted with an
sample of eluant that is capable of eluting the MAI and parental
antibody species in a pH-dependent manner.
[0177] In certain embodiments is provided a method of purifying a
multi specific antibody of interest (MAI), wherein the MAI
comprises a heterodimer comprising a first polypeptide comprising a
first heavy chain (HC) variable region and a second polypeptide
comprising a second HC variable region, wherein the first and the
second variable regions have different antigen specificities and
different isoelectric points, the method comprising: i) obtaining a
composition comprising the MAI, a first parental antibody species
comprising two copies of the first polypeptide, and a second
parental antibody species comprising two copies of the second
polypeptide; and ii) performing chromatography whereby the MAI is
separated from the first and the second parental antibody species;
thereby purifying the MAI. In certain embodiments, the different
isoelectric points are different actual isoelectric points. In
certain other embodiments, the different isoelectric points are
different calculated isoelectric points. In certain embodiments,
the performing step ii) comprises a. contacting the composition
with a chromatographic material forming a
composition-chromatographic material complex; and b. performing an
elution step wherein the chromatographic material-composition
complex is contacted with an sample of eluant that is capable of
eluting the MAI and parental antibody species in a pH-dependent
manner.
[0178] In connection with the development of the inventive methods,
Applicants have surprisingly discovered that, contrary to many
prior methods, the successful practice of the inventive methods
does not require that the Fc region (or any other portion, for that
matter) of the MAI (or parental antibody species) to be engineered,
mutagenized, substituted, or otherwise altered in a manner that is
designed or purposed for enhancing either affinity- or ion
exchange-mediated resolution, separation, or purification of
heterodimeric MAI from corresponding parental homodimeric antibody
species. The disclosed and claimed methods thus advantageously
afford the preparation and purification of MAIs that do not carry
with them many of the immunogenicity, PK, and other liabilities
associated with MAIs into which such non-native mutations have been
engineered.
[0179] Accordingly, in certain embodiments is provided a method of
purifying a multispecific antibody of interest (MAI), wherein the
MAI comprises a heterodimer comprising a first polypeptide
comprising a first heavy chain (HC) variable region and a second
polypeptide comprising a second HC variable region, wherein the
first and the second variable regions have different antigen
specificities and different isoelectric points, the method
comprising: i) obtaining a composition comprising the MAI, a first
parental antibody species comprising one copy of the first
polypeptide, and a second parental antibody species comprising one
copy of the second polypeptide; and ii) performing chromatography
whereby the MAI is separated from the first and the second parental
antibody species; thereby purifying the MAI, wherein at least one
of the first polypeptide and the second polypeptide are in a native
format, such as a native IgG format, such as a native IgG1 format,
native IgG2 format, a native IgG3 format, a native IgG4 format, a
native IgG1/IgG2 hybrid format, a native IgG1/IgG3 hybrid format,
or a native IgG1/IgG4 hybrid format. In certain embodiments, the
different isoelectric points are different actual isoelectric
points. In certain other embodiments, the different isoelectric
points are different calculated isoelectric points. In certain
embodiments, the performing step ii) comprises a. contacting the
composition with a chromatographic material forming a
composition-chromatographic material complex; and b. performing an
elution step wherein the chromatographic material-composition
complex is contacted with an sample of eluant that is capable of
eluting the MAI and parental antibody species in a pH-dependent
manner.
[0180] Accordingly, in certain embodiments is provided a method of
purifying a multispecific antibody of interest (MAI), wherein the
MAI comprises a heterodimer comprising a first polypeptide
comprising a first heavy chain (HC) variable region and a second
polypeptide comprising a second HC variable region, wherein the
first and the second variable regions have different antigen
specificities and different isoelectric points, the method
comprising: i) obtaining a composition comprising the MAI, a first
parental antibody species comprising two copies of the first
polypeptide, and a second parental antibody species comprising two
copies of the second polypeptide; and ii) performing chromatography
whereby the MAI is separated from the first and the second parental
antibody species; thereby purifying the MAI, wherein at least one
of the first polypeptide and the second polypeptide are in a native
format, such as a native IgG format, such as a native IgG1 format,
native IgG2 format, a native IgG3 format, a native IgG4 format, a
native IgG1/IgG2 hybrid format, a native IgG1/IgG3 hybrid format,
or a native IgG1/IgG4 hybrid format. In certain embodiments, the
different isoelectric points are different actual isoelectric
points. In certain other embodiments, the different isoelectric
points are different calculated isoelectric points. In certain
embodiments, the performing step ii) comprises a. contacting the
composition with a chromatographic material forming a
composition-chromatographic material complex; and b. performing an
elution step wherein the chromatographic material-composition
complex is contacted with an sample of eluant that is capable of
eluting the MAI and parental antibody species in a pH-dependent
manner.
[0181] As used herein and throughout, "purifying" means separating
one species, such as a heterodimeric MAI, from other species, such
as one or more parental homodimeric species, such that an
essentially homogenous sample is generated with regard to the MAI
from a heterogeneous composition comprising the MAI and the one or
more parental homodimeric species.
[0182] As used herein and throughout, "obtaining" means
discovering, receiving, or otherwise coming into the possession of
a material, such as an MAI, a parental homodimeric antibody
species, a heavy chain variable region, an light chain variable
region, a heavy chain polypeptide comprising a heavy chain variable
region, a light chain polypeptide comprising a light chain variable
region, an MAI comprising any of the aforementioned, a parental
homodimeric antibody species comprising any of the aforementioned,
a composition comprising any of the aforementioned, and/or a
chromatographic material-composition complex comprising any of the
aforementioned. Furthermore, obtaining may refer to discovering
such materials by interrogating a library comprising variants of
such materials through the use of an antigen in order to identify
such materials having specificity for the antigen. Obtaining may
also or alternatively comprise receiving such a material from
another source or person, such as another previously identified or
characterized antibody or antibody sequence.
[0183] As used herein and throughout, a "composition" means a
fluid, such as a liquid, containing a collection of species, such
as a heterodimeric MAI and the two corresponding parental
homodimeric antibody species. Such compositions are generated by
expressing the first and second polypeptides, and optionally the
third and fourth polypeptides (which may comprise identical light
chain variable regions).
[0184] A heterodimeric multimeric antibody of interest (used
interchangeably throughout with "hetero MAI" or "MAI") means an
antibody species of interest that comprises a first polypeptide
comprising a first heavy chain (HC) variable region and a second
polypeptide comprising a second HC variable region, wherein the
first and the second heavy chain variable regions are different in
amino acid sequence and have different antigen specificities. The
first and second polypeptides are, in some embodiments, contained
in and/or derived from the heavy chain polypeptides of two
different parental homodimeric antibody species. In certain
embodiments, the MAI further comprises a third polypeptide
comprising a first light chain variable region. In further
embodiments, the MAI further comprises a fourth polypeptide
comprising a second light chain variable region. In certain
embodiments, the first and second light chain variable regions are
identical. In yet further embodiments, the third and fourth
polypeptides are identical (i.e., they constitute a "common light
chain").
[0185] A "parental homodimeric antibody species" (used
interchangeably throughout with "homodimeric parental antibody
species", "parental antibody species", "homodimeric parental
species", "homodimeric antibody species", and the like) means an
antibody species that comprises: at least one copy of a heavy chain
having one of two antigen specificities from which the
specificities of the MAI are obtained or derived, and from which
the MAI is generated; are at least two copies copy of a heavy chain
having one of two antigen specificities from which the
specificities of the MAI are obtained or derived, and from which
the MAI is generated. In certain embodiments, the polypeptides of
each parental homodimeric antibody species that comprise the first
and the second heavy chain variable regions are expressed in host
cells along with a third and fourth polypeptide comprising a first
and a second light chain variable region. In some embodiments, the
first and second light chain variable regions are identical in
amino acid sequence. In certain embodiments the third and fourth
polypeptides are identical in amino acid sequence (i.e., the third
and fourth polypeptides constitute a "common light chain"). In
certain embodiments a parental homodimeric species comprises two
copies copy of a heavy chain having one of two antigen
specificities from which the specificities of the MAI are obtained
or derived, and from which the MAI is generated.
[0186] As used herein and throughout, "chromatography" means, in
its broadest sense, the set of laboratory available in the art for
the separation or purification of species of interest from
compositions comprising the species of interest as well as other
species. The composition is contacted with the chromatographic
material, such that the various constituents of the composition may
adsorb onto the chromatographic material thus forming the
chromatographic material-composition complex. Subsequently, an
eluant is contacted with the chromatographic material-composition
complex, and differential removal, or "elution", of adsorbed
species occurs as a function of differences in affinity for each
species for the chromatographic material in the presence of the
eluant.
[0187] Chromatography may be preparative or analytical. The purpose
of preparative chromatography is to separate the components of a
mixture for more advanced use (and is thus a form of purification).
Analytical chromatography is done normally with smaller amounts of
material and is for measuring the relative proportions of analytes
in a mixture. The two are not mutually exclusive.
[0188] As used herein and throughout, "contacting" means physically
interacting, such as by covalent or non-covalent interactions.
Non-covalent interactions include, hydrophobic, hydrophilic, ionic,
cationic anionic, polar, dipolar, van der Waals forces, and the
like. Materials that have or have been "contacted" have physically
touched each other. In certain embodiments, contacting a material,
such as a chromatographic material, with a composition comprising
antibody species, such as an MAI and corresponding homodimeric
parental antibody species, etc. results in the generation of a
chromatographic material-composition complex, wherein at least two,
perhaps three or perhaps more, of all of the antibody species in
the composition physically interact with and remain attached to the
chromatographic material.
[0189] A "chromatographic material-composition complex" means a
multi-component material that is generated a physical interaction
between two materials or more materials that have not previously
come into contact or interacted. The physical interaction can be a
physiochemical interaction, such as a covalent or non-covalent
interaction between two types of molecular entities, and/or between
certain functional groups or moieties found on each of the
respective interacting materials. A chromatographic
material-composition complex may comprise one or more antibody
species of a composition, which are adsorbed onto/into a
chromatographic material upon or subsequent to contacting the
composition with the chromatographic material, such adsorption
resulting from attractive physiochemical forces or interactions
between functional groups on the chromatographic material and
certain regions or portions of the antibody species.
[0190] In some embodiments of any of the methods described herein,
the chromatographic material is a cation exchange material. In some
embodiments, the cation exchange material is a solid phase that is
negatively charged and has free cations for exchange with cations
in an aqueous solution passed over or through the solid phase. In
some embodiments of any of the methods described herein, the cation
exchange material may be a membrane, a monolith, or resin. In some
embodiments, the cation exchange material may be a resin. The
cation exchange material may comprise a carboxylic acid functional
group or a sulfonic acid functional group such as, but not limited
to, sulfonate, carboxylic, carboxymethyl sulfonic acid,
sulfoisobutyl, sulfoethyl, carboxyl, sulphopropyl, sulphonyl,
sulphoxyethyl, or orthophosphate. In some embodiments of the above,
the cation exchange chromatographic material is a cation exchange
chromatography column.
[0191] In some embodiments of any of the methods described herein,
the chromatographic material is an anion exchange material. In some
embodiments, the anion exchange chromatographic material is a solid
phase that is positively charged and has free anions for exchange
with anions in an aqueous solution passed over or through the solid
phase. In some embodiments of any of the methods described herein,
the anion exchange material may be a membrane, a monolith, or
resin. In an embodiment, the anion exchange material may be a
resin. In some embodiments, the anion exchange material may
comprise a primary amine, a secondary amine, a tertiary amine or a
quaternary ammonium ion functional group, a polyamine functional
group, or a diethylaminoethyl functional group. In some embodiments
of the above, the anion exchange chromatographic material is an
anion exchange chromatography column.
[0192] In some embodiments of any of the methods described herein,
the ion exchange material may utilize a conventional
chromatographic material or a convective chromatographic material.
The conventional chromatographic materials include, for example,
perfusive materials (e.g., poly(styrene-divinylbenzene) resin) and
diffusive materials (e.g., cross-linked agarose resin). In some
embodiments, the poly(styrene-divinylbenzene) resin can be Poros
resin. In some embodiments, the cross-linked agarose resin may be
sulphopropyl-Sepharose Fast Flow ("SPSFF") resin. The convective
chromatographic material may be a membrane (e.g., polyethersulfone)
or monolith material (e.g. cross-linked polymer). The
polyethersulfone membrane may be Mustang. The cross-linked polymer
monolith material may be cross-linked poly(glycidyl methacryl
ate-co-ethylene dimethacrylate).
[0193] In some embodiments of any of the methods of the invention,
the chromatographic material is in a chromatography column; for
example a cation exchange chromatography column or an anion
exchange chromatography column. In some embodiments, the
chromatography column is used for liquid chromatography. In some
embodiments, the chromatography column is used for high performance
liquid chromatography (HPLC). In some embodiments, the
chromatography column is an HPLC chromatography column; for
example, a cation exchange HPLC column or an anion exchange HPLC
column.
[0194] Examples of cation exchange chromatographic materials are
known in the art and include, but are not limited to, Mono S, Poros
HS, Source 30S, Mustang S, Sartobind S, S03 Monolith, S Ceramic
HyperD, Poros XS, Poros HS50, Poros HS20, Poros GoPure XS, Poros
GoPure HS, SP Sepharose FF, SP Sepharose HP, SP-Sepharose XL
(SPXL), CM Sepharose Fast Flow, Capto S, UNOsphere S, Macro-prep
High S, Capto SP ImpRes, Fractogel Se HiCap, Fractogel S03,
Fractogel COO, ProPac WCX-10 and ProPac WCX-10HT. In some
embodiments of any of the methods described herein, the cation
exchange material is Poros HS50. In some embodiments of any of the
methods described herein, the Poros HS resin may be Poros HS 50
.mu.m or Poros HS 20 .mu.m particles. In some embodiments of any of
the methods described herein, the cation exchange chromatographic
material is selected from the group consisting of Mono S, SP
Sepharose FF, Macro-prep High S, Poros GoPure XS, Poros GoPure HS,
Capto SP ImpRes, SP Sepharose HP, and Sourse 30S. In some
embodiments of any of the methods described herein, the cation
exchange chromatographic material is selected from the group
consisting of Mono S, Poros HS, SP Sepharose HP, and Source 30S. In
some embodiments of any of the methods described herein, the cation
exchange chromatographic material is selected from the group
consisting of Mono S, SP Sepharose HP, and Source 30S. In some
embodiments of any of the methods described herein, the cation
exchange chromatographic material is selected from the group
consisting of Mono S, Poros HS, and Source 30S.
[0195] Examples of anion exchange chromatographic materials are
known in the art and include, but are not limited to, Mono Q, Poros
HQ 50, Poros PI 50, Poros D, Poros XQ, Poros HQ, Capto Q ImpRes, Q
HP, Source 30Q, Mustang Q, Q Sepharose FF, Dionex ProPac 10 SAX and
Tosoh GSKgel Q STAT 7 .mu.M WAX and DEAE Sepharose. In some
embodiments of any of the methods described herein, the anion
exchange chromatographic material is selected from the group
consisting of Mono Q, Poros XQ, Poros HQ, Capto Q ImpRes, Q HP, and
Source 30Q. In some embodiments of any of the methods described
herein, the anion exchange chromatographic material is selected
from the group consisting of Mono Q, Sourse 30Q, and Q HP. An
example of a multimodal ion exchange chromatographic material is
Capto MMC.
[0196] As used herein and throughout, an "eluant" (used
interchangeably with "eluent") comprises a fluid, such as a liquid
solution that is used to remove a species that has adsorbed onto a
chromatographic material. An eluant for use in accordance with the
disclosed and claimed methods comprises at least two, at least
three, at least four, at least five, at least six, at least seven,
or at least eight different buffering agents. The choice of the
number and chemical identity may be made based on the desired pH
range through which the artisan desires to generate the essentially
linear pH gradient. The choice of this pH range may, in turn, as
disclosed herein and throughout, be made based on a determination
of the difference in the actual isoelectric points or the
calculated, or theoretical, isoelectric points (".DELTA.pI") of the
first heavy chain polypeptide and the second heavy chain
polypeptide. Alternatively, if desired, the artisan may, in turn,
as disclosed herein and throughout, choose based on a determination
of the difference in the actual isoelectric points or the
calculated, or theoretical, isoelectric points (".DELTA.pI") of a
first parental homodimeric antibody species and a second parental
homodimeric antibody species. Accordingly, the artisan may choose
to select buffering agents that have pKas that sufficiently cover
the pH range that is associated with the pIs of the polypeptides
(as well as the difference in their pIs).
[0197] As used herein and throughout, an "isoelectric point" (also
referred to herein and throughout as "pI") is the pH at which a
polypeptide or protein, such as a heavy chain polypeptide, a
parental homodimeric antibody species, an MAI, an antibody, an
immunoglobulin, an IgG, or the like, possesses no net electrical
charge, and is generally expressed as a pH value. An isoelectric
point may be a "calculated (or theoretical) isoelectric point" or
an "actual" (empirically determined) isoelectric point.
[0198] As used herein and throughout, a "calculated isoelectric
point" (or "theoretical isoelectric point") is an isoelectric point
value that is reported or determined by subjecting the primary
sequence of the polypeptide or protein to an algorithm, program,
code, etc. that is designed to provide a predictive or theoretical
pI value based on certain defined parameters of assumptions
concerning the chemical and physical properties of the polypeptide
or protein (or its constituent amino acids) and/or the solvent
components or other chemical species to which it may be exposed;
predicted secondary structural features and topology; predicted
solvent exposure of certain ionizable groups; and the like.
Non-limiting examples of tools and methods for calculating pI
include those disclosed in: Bas et al, Protein, Vol. 72(3), pp.
765-783 (2008); Stothard P, Biotechniques, Vol. 28(6), pp.
1102-1104 (2000); and the Sequence Manipulation Site (SMS), for
example, on the world wide web at hypertext protocol transfer
bioinformatics.org/sms2/. In any case, without wishing to be bound
by any theory and as the artisan will understand, when calculating
pI for a heavy chain polypeptide, a parental homodimeric antibody
species, MAI, an antibody, an immunoglobulin, an IgG, or the like,
it may be preferable to, for instance consider certain cysteine
residues, such as those that may participate in disulfide bridges,
as non-ionizable, and/or to consider suspected N-terminal
glycosylation sites as non-ionizable.
[0199] As used herein and throughout, an "actual isoelectric point"
(or "actual isoelectric point") is an isoelectric point value that
is reported or determined by measuring the pI of a physical sample
of a polypeptide or protein, such as a heavy chain polypeptide, a
parental homodimeric antibody species, an MAI, an antibody, an
immunoglobulin, an IgG, or the like (or a composition, such as a
solution, containing such sample), using methods and tool that are
available in the art.
[0200] As used herein and throughout, a "buffering agent" is an
acid or base, usually a weak acid or weak base, which is used to
maintain the acidity (pH) of a solution, such as an eluant near a
chosen value after the addition of another acid or base. That is,
the function of a buffering agent is to prevent a rapid change in
pH when acids or bases are added to the solution. Buffering agents
have variable properties--some are more soluble than others; some
are acidic while others are basic. The effective pH around which a
given buffering agent is best able to buffer a solution is
approximately around the negative log of the acid dissociation
constant ("pKa") of that buffering agent. The (negative log of an)
acid association constant is a quantitative measure of the strength
of an acid in solution. Each acid has a different pKa. It is the
equilibrium constant for a chemical reaction known as dissociation
in the context of acid-base reactions. The larger the Ka value, the
more dissociation of the molecules in solution and thus the
stronger the acid. Thus, a strong acid tends to deprotonate more
readily than a weak acid.
[0201] In certain embodiments, the eluant comprises at least two
buffering agents wherein the pKa of each buffering agent is between
about 3 and about 11.
[0202] In certain embodiments, the eluant comprises at least two
buffering agents wherein the pKa of each buffering agent is in a
range selected from the group consisting of: about 3.25 to about
3.85; about 4.5 to about 4.85; about 6.0 to about 6.45; about 6.60
to about 7.0; about 7.5 to about 8.15; about 8.35 to about 8.55;
about 9.25 to about 9.65; and about 10.00 to about 11.5.
[0203] In certain embodiments, the eluant comprises at least two
buffering agents, wherein the acid dissociation constant (pKa) of
each buffering agent is selected from the group consisting of about
3.75; about 4.76; about 6.10; about 6.90; about 8.04; about 8.44;
about 9.39; and about 10.50.
[0204] As used herein and throughout, "pH-dependent manner" means
behaving in a way that varies with a change in pH. For example,
species with different pIs will elute from a column in different
and distinguishable times and volumes of eluant if that eluant is
capable of generating a pH gradient. Such pH gradients are
generated, in certain embodiments, by preparing a sample of the
eluant at a desired starting pH and preparing another sample of the
eluant at a desired ending pH. In certain embodiments, the desired
starting pH is less than 7.0; less than 6.5; less than 6.0; less
than 5.5; less than 5.0; less than 4.5; less than 4.0; less than
3.5; or less than 3.0; or a pH values that is between any of the
preceding values. In certain embodiments, the desired ending pH is
more than 7.0; more than 7.5; more than 8.0; more than 8.5; more
than 9.0; more than 9.5; more than 10.0; more than 10.5; or more
than 11.0; more than 11.5; more than 12.0; or a pH values that is
between any of the preceding values.
[0205] In certain embodiments, difference between the calculated
isoelectric point of the first polypeptide and the calculated
isoelectric point of the second polypeptide of an MAI is a less
than 7.0 pH units; less than 6.5 pH units; less than 6.0 pH units;
less than 5.5 pH units; less than 5.0 pH units; less than 4.5 pH
units; less than 4.0 units; less than 3.5 pH units; less than 2.5
pH units; less than 2.0 pH units; less than 1.0 pH unit; less than
0.95 pH unit; less than 0.90 pH unit; less than 0.85 pH unit; less
than 0.80 pH unit; less than 0.75 p1-1 unit; less than 0.70 pH
unit; less than 0.65 pH unit; less than 0.60 pH unit; less than
0.55 pH unit; less than 0.50 pH unit; less than 0.45 pH unit; less
than 0.40 pH unit; less than 0.35 pH unit; less than 0.30 pH unit;
less than 0.25 pH unit; less than 0.20 pH unit; less than 0.15 pH
unit; less than 0.10 pH unit; 0.05 pH unit; less than 0.025 pH
unit; or pH values that are between any of the preceding
values.
[0206] In certain embodiments, difference between: the calculated
isoelectric point of a first antibody, such as a first
immunoglobulin, first IgG, or first parental homodimeric antibody
species; and the calculated isoelectric point of a second antibody,
such as a second immunoglobulin, second IgG, or second homodimeric
antibody species; is less than 7.0 pH units; less than 6.5 pH
units; less than 6.0 pH units; less than 5.5 pH units; less than
5.0 pH units; less than 4.5 pH units; less than 4.0 units; less
than 3.5 pH units; less than 2.5 pH units; less than 2.0 pH units;
less than 1.0 pH unit; less than 0.95 pH unit; less than 0.90 pH
unit; less than 0.85 pH unit; less than 0.80 pH unit; less than
0.75 pH unit; less than 0.70 pH unit; less than 0.65 pH unit; less
than 0.60 pH unit; less than 0.55 pH unit; less than 0.50 pH unit;
less than 0.45 pH unit; less than 0.40 pH unit; less than 0.35 pH
unit; less than 0.30 pH unit; less than 0.25 pH unit; less than
0.20 pH unit; less than 0.15 pH unit; less than 0.10 pH unit; 0.05
pH unit; less than 0.025 pH unit; or pH values that are between any
of the preceding values.
[0207] In accordance with the herein disclosed and claimed methods,
the eluant is flowed through the chromatographic
material-composition complex in order to elute the MAI and/or
parental homodimeric antibody species from the chromatographic
material. In certain embodiments, the eluted species are eluted as
individual solutions of essentially homogeneous samples, wherein
each sample contains one species, such as an MAI, and is
essentially devoid of appreciable amounts of the other species,
such as a parental homodimeric antibody species. In other
embodiments the species are eluted from the chromatographic
material such that one species, such as an MAI, is eluted in a
series of solution volumes, some of which comprise essentially
homogeneous samples of an MAI, and some of which comprise as the
major species the MAI, along with varying minor amounts of one or
more parental homodimeric antibody species. In such embodiments,
the artisan may routinely select to retain those volumes that
comprise the essentially homogeneous sample of the MAI and discard
other volumes.
[0208] Accordingly, as the artisan will understand, the inventive
methods allow for the MAI and parental homodimeric antibody species
to elute from chromatographic material such that these species are
essentially distinguishable from one another. As used herein and
throughout, "essentially distinguishable" means that such species
are sufficiently separated chromatographically such that samples of
each species may be collected essentially free from other species.
Such separation may be visualized in chromatographic traces which
allow for visualization of other means of monitoring, for example,
the concentration of proteinaceous material that elutes from a
column as a function of time, eluant volume, and the like. Such
distinguishable separation may comprise elutions in which
essentially all of each species are separated from one another, or
elutions in which a certain amount of overlap between two or more
species elution volumes occurs. In embodiments in which some
overlap occurs, as the artisan will understand, as described above,
one may collect eluant volumes that are observed to comprise no or
essentially no overlap, and thus achieve separation in accordance
with the claimed methods.
[0209] As used herein and throughout, "flowing" (and alternatively,
"flowed") means applying and/or passing a sufficient amount of an
eluant through a chromatographic material and/or chromatographic
material-composition complex, such that the material and/or complex
is contacted with eluant. As the art may understand, one may flow
several or multiple column volumes' worth of such a fluid/solution
in order to equilibrate the material or matrix prior to the elution
step, as well as multiple volumes' worth when performing the
elution step. This can be varied in order to increase or decrease
the slope of the pH gradient and thus the total elution volume
required to elute the various species adsorbed onto the column.
[0210] Advantageously, however, it has additionally been discovered
that one may prepare eluants comprising a large number of buffering
agents at appropriate concentrations as disclosed herein, such that
the eluant may be used to prepare pH gradients comprising: a linear
pH gradient phase; at least one step pH gradient phase prior to a
linear pH gradient phase; at least one step pH gradient phase
subsequent to a linear pH gradient phase; a linear pH gradient
phase only; an essentially linear pH gradient phase; and the like,
throughout the majority of the pH scale as the artisan may desire
and as described herein and throughout, such that a majority of
MAIs may be purified from compositions comprising such MAIs and
parental homodimeric antibody species without regard to the pI of
the heavy chain polypeptides or the pI difference. For example, one
exemplary eluant that has been found to elute certain model
proteins in single-protein mixtures (see Kroner et al, J.
Chromatog., Vol. 1285, pages 78-87 (2013)), effectively buffers
from approximately pH 3 through approximately pH 11, such that an
essentially linear pH gradient may be generated throughout this
range, contains Ncyclohexyl-3-aminopropanesulfonic acid (CAPS),
N-Cyclohexyl-2-aminoethanesulfonic acid (CHES),
N-Tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS),
N-(2-Hydroxyethyl)piperazine-N'-(2-hydroxypropanesulfonic acid)
(HEPPSO), 3-morpholino-2-hydroxypropanesulfonic acid sodium salt,
3-(N-morpholinyl)-2-hydroxypropanesulfonic acid (MOPSO),
2-(N-morpholino)ethanesulfonic acid (MES), acetic acid, formic
acid, and NaCl. An additional eluant that has been surprisingly
discovered to be particularly amenable to certain embodiments of
the disclosed and claimed methods comprises methyl amine,
1,2-ethanediamine, 1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt. It
has been discovered, as disclosed herein and throughout, that these
eluants are also effective in purifying a variety of MAIs from
compositions comprising the MAI and parental homodimeric antibody
species as provided in the disclosed and claimed methods
throughout. As these eluants are effective at generating
essentially linear pH gradients through a pH range of approximately
3 through approximately 11, the invention provides in certain
embodiments, methods for purifying an MAI from a composition
comprising the MAI and parental homodimeric antibody species
compositions without regard, or prior knowledge of, the pI of the
first and second heavy chain polypeptides of the MAI (and thus of
the heavy chains in the corresponding parental homodimeric antibody
species).
[0211] As used herein and throughout, a "linear pH gradient phase",
or a "linear pH gradient", used interchangeably throughout, means a
pH gradient that exhibits a largely, or essentially, a smooth,
constant rate of change per unit volume of eluate that flows or is
flowed through a chromatographic material and/or chromatographic
material-composition complex over a relatively large eluant volume
or a relatively large number of contiguous column eluant
fractions.
[0212] As used herein and throughout, a "step pH gradient phase",
or a "step pH gradient", used interchangeably throughout, means a
pH gradient that exhibits an relatively abrupt change pH such that
a large pH change in the eluant occurs as it flows or is flowed
through a chromatographic material and/or chromatographic
material-composition complex over in a relatively small volume of
the eluant or a relatively small number of contiguous column eluant
fractions. Although such step pH gradient phases, as a practical
matter, do exhibit an observable rate of change per unit eluant
volume, such step pH gradient phases are nonetheless
distinguishable from linear pH gradient phases as used herein and
throughout. In certain embodiments, such step pH gradient phases
are considered to exhibit essentially instantaneous rates of change
of pH per unit eluant volume relative to linear pH gradient
phases.
[0213] Additionally, however, it has been surprisingly discovered
that step pH gradient phases may also be employed using the eluants
described herein and throughout in circumstances in which such step
pH gradient phases may be desirable and useful for inclusion in a
chromatographic procedure aimed at separating certain MAIs from
MAI-parental homodimeric parental species mixtures.
[0214] In certain embodiments, the eluant does not include the
following agents: imidazole piperazine,
tris(hydroxymethyl)aminomethane (TRIS).
[0215] In certain embodiments, the eluant consists essentially of:
CAPS; CHES; TAPS; HEPPSO; MOPSO; MES; acetic acid; and formic acid;
and optionally at least one salt.
[0216] In other embodiments, the eluant consists of CAPS; CHES;
TAPS; HEPPSO; MOPSO; MES; acetic acid; and formic acid; and at
least one salt.
[0217] The inventive methods afford the ability to modify or
manipulate the ionic strength of the eluant as may be desired by
selecting a variety of salt concentrations. Accordingly, in certain
embodiments, a salt concentration may be selected from the group
consisting of: 0 mM to about 100 mM; 0 mM to about 60 mM; 0 mM to
about 50 mM; 0 mM to about 40 mM; 0 mM to about 30 mM; 0 mM to
about 20 mM; 0 mM to about 10 mM; 0 mM to about 5 mM; about 10 mM
to about 200 mM; about 10 mM to about 100 mM; about 10 mM to about
50 mM; about 10 mM to about 40 mM; about 10 mM to about 30 mM;
about 10 mM to about 20 mM; about 20 mM to about 200 mM; about 20
mM to about 100 mM; about 20 mM to about 50 mM; about 20 mM to
about 30 mM; about 30 mM to about 200 mM; about 30 mM to about 100
mM; and about 30 mM to about 50 mM; and about 5 mM to about 15
mM.
[0218] In certain embodiments, the eluant comprises at least one
salt selected from the group consisting of: NaCl, KCl, and
Na.sub.2SO.sub.4.
[0219] In certain embodiments, the eluant NaCl at a concentration
of approximately 10 mM.
[0220] In accordance with the inventive methods disclosed and
claimed herein and throughout, Applicants have further discovered
both loading buffer and eluant compositions that facilitate the
facile purification of MAIs from such compositions, and have
further discovered that one may conveniently employ the same buffer
composition (herein and throughout termed an "eluant") as both a
loading buffer and an elution buffer--one need only to prepare a
first sample of the buffer composition at a first pH (the "loading
pH") and a second sample of the buffer composition at a second pH
(the "eluting pH"), in which the loading pH and eluting pH are
chosen by the artisan order to generate an essentially linear pH
gradient through the elution step of the inventive methods. The
determination of the desired pH range through which the essentially
liner pH gradient should be applied may be arrived at based on, for
example, a calculation of the expected pis of each heavy chain to
be included in the MAI. Similarly, the determination of the slope
of the gradient to be applied may be informed by determining the
difference in pI units (.DELTA.pI) between each heavy chain to be
included in the MAI.
[0221] As disclosed herein and throughout, the inventive methods
afford the purification of MAIs, and reagents, such as buffering
agents, eluants, and the like, for performing the methods.
[0222] The term "antibody" is used herein in the broadest sense and
specifically encompasses at least monoclonal antibodies, polyclonal
antibodies, multi-specific antibodies (e.g., bispecific
antibodies), chimeric antibodies, humanized antibodies, human
antibodies, and antibody fragments. An antibody is a protein
comprising one or more polypeptides substantially or partially
encoded by immunoglobulin genes or fragments of immunoglobulin
genes. The recognized immunoglobulin genes include the kappa,
lambda, alpha, gamma, delta, epsilon and mu constant region genes,
as well as myriad immunoglobulin variable region genes.
[0223] An "antibody" also refers to an immunoglobulin molecule, a
fragment of an immunoglobulin molecule, or a derivative thereof,
which has the ability to specifically bind to an antigen, which may
be, for example: a protein; a polypeptide; peptide; a hormone; a
cytokine; a chemokine; a growth factor; a neurotransmitter; a
carbohydrate-containing biological molecule; a lipid or fatty
acid-containing biological molecule; or other biological molecule;
via an epitope present on such antigen.
[0224] "Antibodies" as used herein and throughout also refer to
polypeptides comprising one or more variable regions or variable
domains of an antibody, wherein such variable regions(s) or
variable domain(s) are capable of engaging and binding to one or
more epitopes of one or more antigens.
[0225] By "polypeptide" or "protein as used herein is meant at
least two covalently attached amino acids, which includes proteins,
polypeptides, oligopeptides and peptides. The protein may be made
up of naturally occurring amino acids and peptide bonds, or
synthetic peptidomimetic structures, i.e. "analogs", such as
peptides.
[0226] Antibodies (used interchangeably with "immunoglobulins", or
"immunoglobulin molecules") can be monomeric, dimeric, trimeric,
tetrameric, pentameric, etc., and may comprise a class of
structurally related proteins consisting of two pairs of
polypeptide chains: one pair of light chains (LC) and one pair of
heavy chains (HC), all of which are inter-connected by disulfide
bonds. The structure of immunoglobulins has been well
characterized. See for instance Fundamental Immunology Ch. 7 (Paul,
W., ed., 2nd ed. Raven Press, N.Y. (1989)).
[0227] Traditional natural antibody structural units typically
comprise a tetramer. Each tetramer is typically composed of two
identical pairs of polypeptide chains, each pair having one "light"
(typically having a molecular weight of about 25 kDa) and one
"heavy" chain (typically having a molecular weight of about 50-70
kDa). Human light chains are classified as kappa and lambda light
chains. Heavy chains are classified as mu, delta, gamma, alpha, or
epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA,
and IgE, respectively. IgG has several subclasses, including, but
not limited to IgG1, IgG2, IgG3, and IgG4. IgM has subclasses,
including, but not limited to, IgM1 and IgM2. IgA has several
subclasses, including but not limited to IgA1 and IgA2. Thus,
"isotype" as used herein is meant any of the classes and subclasses
of immunoglobulins defined by the chemical and antigenic
characteristics of their constant regions. The known human
immunoglobulin isotypes are IgG1, IgG2, IgG3, IgG4, IgA1, IgA2,
IgM1, IgM2, IgD, and IgE. The distinguishing features between these
antibody classes are their constant regions, although subtler
differences may exist in the variable region.
[0228] Each of the light and heavy chains is made up of two
distinct regions, referred to as the variable and constant regions.
The IgG heavy chain is composed of four immunoglobulin domains
linked from N- to C-terminus in the order VH-CH1-CH2-CH3, referring
to the "variable heavy domain" (also referred to as a "heavy chain
variable domain", used interchangeably throughout), heavy chain
constant domain 1, heavy chain constant domain 2, and heavy chain
constant domain 3 respectively (also referred to as
VH-C.gamma.1-C.gamma.2-C.gamma.3, referring to the variable heavy
domain, constant gamma 1 domain, constant gamma 2 domain, and
constant gamma 3 domain respectively). The IgG light chain is
composed of two immunoglobulin domains linked from N- to C-terminus
in the order VL-CL, referring to the "variable light domain" (also
referred to as a "light chain variable domain", used
interchangeably throughout) and the light chain constant domain
respectively. The constant regions show less sequence diversity,
and are responsible for binding a number of natural proteins to
elicit important biochemical events. The structure that constitutes
the natural biological form of an antibody, including the variable
and constant regions, is referred to herein as a "full length
antibody". In most mammals, including humans and mice, the full
length antibody of the IgG isotype is a tetramer and consists of
two identical pairs of two immunoglobulin chains, each pair having
one light chain and one heavy chain, each light chain comprising a
VL and a CL, and each heavy chain comprising a VH, CH1, a CH2, and
a CH3. In some mammals, for example in camels and llamas, IgG
antibodies may consist of only two heavy chains, each heavy chain
comprising a variable domain attached to the Fc region.
[0229] The heavy chain constant region typically is comprised of
three domains, CH1, CH2, and CH3, and the CH1 and CH2 domains are
connected by a hinge region. Each light chain typically is
comprised of a light chain variable domain (abbreviated herein as
"V.sub.L" or "VL") and a light chain constant domain. The V.sub.H
and V.sub.L domains may be further subdivided into regions of
hypervariability (or hypervariable regions which may be
hypervariable in sequence and/or form of structurally defined
loops), also termed complementarity determining regions (CDRs),
interspersed with regions that are more conserved, termed framework
regions (FRs). Each V.sub.H and V.sub.L is typically composed of
three CDRs and four FRs, arranged from amino-terminus to
carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3,
CDR3, FR4. Typically, the numbering of amino acid residues in this
region is performed by the method described in Kabat (see, e.g.,
Kabat et al, in "Sequences of Proteins of Immunological Interest,"
5.sup.th Edition, U.S. Department of Health and Human Services,
1992). Using this numbering system, the actual linear amino acid
sequence of a peptide may contain fewer or additional amino acids
corresponding to a shortening of, or insertion into, a FR or CDR of
the variable domain. For example, a heavy chain variable domain may
include a single amino acid insert (residue 52a according to Kabat)
after residue 52 of V.sub.H CDR2 and inserted residues (for
instance residues 82a, 82b, and 82c, etc. according to Kabat) after
heavy chain FR residue 82. The Kabat numbering of residues may be
determined for a given antibody by alignment at regions of homology
of the sequence of the antibody with a "standard" Kabat numbered
sequence.
[0230] The term "variable", "variable domain", or "variable region"
each interchangeably refers to the portions of the immunoglobulin
domains that exhibit variability in their sequence and that are
involved in determining the specificity and binding affinity of a
particular antibody (i.e., the "variable domain(s)"). Variability
is not evenly distributed throughout the variable domains of
antibodies; it is concentrated in sub-domains of each of the heavy
and light chain variable regions. These sub-domains are called
"hypervariable" regions or "complementarity determining regions"
(CDRs). The more conserved (i.e., non-hypervariable) portions of
the variable domains are called the "framework" regions (FRM). The
variable domains of naturally occurring heavy and light chains each
comprise four FRM regions, largely adopting a .beta.-sheet
configuration, connected by three hypervariable regions, which form
loops connecting, and in some cases forming part of, the
.beta.-sheet structure. The hypervariable regions in each chain are
held together in close proximity by the FRM and, with the
hypervariable regions from the other chain, contribute to the
formation of the antigen-binding site (see Kabat et al. Sequences
of Proteins of Immunological Interest, 5th Ed. Public Health
Service, National Institutes of Health, Bethesda, Md., 1991,
incorporated by reference in its entirety). The constant domains
are not directly involved in antigen binding, but exhibit various
effector functions, such as, for example, antibody-dependent,
cell-mediated cytotoxicity and complement activation.
[0231] The term "framework region" refers to the art-recognized
portions of an antibody variable region that exist between the more
divergent (i.e., hypervariable) CDRs. Such framework regions are
typically referred to as frameworks 1 through 4 (FRM1, FRM2, FRM3,
and FRM4) and provide a scaffold for the presentation of the six
CDRs (three from the heavy chain and three from the light chain) in
three dimensional space, to form an antigen-binding surface. The
term "canonical structure" refers to the main chain conformation
that is adopted by the antigen binding (CDR) loops. From
comparative structural studies, it has been found that five of the
six antigen binding loops have only a limited repertoire of
available conformations. Each canonical structure can be
characterized by the torsion angles of the polypeptide backbone.
Correspondent loops between antibodies may, therefore, have very
similar three dimensional structures, despite high amino acid
sequence variability in most parts of the loops (Chothia and Lesk,
J. Mol. Biol., 1987, 196: 901; Chothia et al, Nature, 1989, 342:
877; Martin and Thornton, J. Mol. Biol, 1996, 263: 800.
Furthermore, there is a relationship between the adopted loop
structure and the amino acid sequences surrounding it. The
conformation of a particular canonical class is determined by the
length of the loop and the amino acid residues residing at key
positions within the loop, as well as within the conserved
framework (i.e., outside of the loop). Assignment to a particular
canonical class can therefore be made based on the presence of
these key amino acid residues.
[0232] By "position" as used herein is meant a location in the
sequence of a protein or nucleic acid. Protein positions may be
numbered sequentially, or according to an established format, for
example the Kabat index for antibody variable regions or the EU
index for antibody constant regions. For example, position 297 is a
position in the human antibody IgG1. Corresponding positions are
determined as outlined above, generally through alignment with
other parent sequences.
[0233] By "residue" as used herein is meant a position in a protein
and its associated amino acid identity. For example, Asparagine 297
(also referred to as Asn297, also referred to as N297) is a residue
in the human antibody IgG1. In some embodiments it can also refer
to nucleic acid bases.
[0234] The term "canonical structure" may also include
considerations as to the linear sequence of the antibody, for
example, as catalogued by Kabat (Kabat et al, in "Sequences of
Proteins of Immunological Interest," 5.sup.th Edition, U.S.
Department of Health and Human Services, 1992). The Kabat numbering
scheme is a widely adopted standard for numbering the amino acid
residues of an antibody variable domain in a consistent manner.
Additional structural considerations can also be used to determine
the canonical structure of an antibody. For example, those
differences not fully reflected by Kabat numbering can be described
by the numbering system of Chothia et al and/or revealed by other
techniques, for example, crystallography and two or
three-dimensional computational modeling. Accordingly, a given
antibody sequence may be placed into a canonical class which allows
for, among other things, identifying appropriate chassis sequences
(e.g., based on a desire to include a variety of canonical
structures in a library). Kabat numbering of antibody amino acid
sequences and structural considerations as described by Chothia et
al., and their implications for construing canonical aspects of
antibody structure, are described in the literature.
[0235] By "Fc" or "Fc region", as used herein is meant the
polypeptide comprising the constant region of an antibody excluding
the first constant region immunoglobulin domain. Thus "Fc region"
refers to the last two constant region immunoglobulin domains of
IgA, IgD, and IgG, and the last three constant region
immunoglobulin domains of IgE and IgM, and the flexible hinge
N-terminal to these domains. For IgA and IgM, Fc may include the J
chain. For IgG, Fc comprises immunoglobulin domains Cgamma2 and
Cgamma3 (C.gamma.2 and C.gamma.3) and the hinge between Cgamma1
(C.gamma.1) and Cgamma2 (C.gamma.2). Accordingly, and without
departing from the above, "Fc region" may also be defined as
comprising a "CH2 domain or a variant thereof" and a "CH3 domain or
a variant thereof". Although the boundaries of the Fc region may
vary, the human IgG heavy chain Fc region is usually defined to
comprise residues C226 or P230 to its carboxyl-terminus, wherein
the numbering is according to the EU index as in Kabat. Fc may
refer to this region in isolation, or this region in the context of
an Fc polypeptide, for example an antibody. By "Fc polypeptide" as
used herein is meant a polypeptide that comprises all or part of an
Fc region. Fc polypeptides include antibodies, Fc fusions, isolated
Fcs, and Fc fragments.
[0236] A variable light chain (VL) and corresponding variable heavy
domain (VH) of the inventive multivalent antibody analogs comprise
a binding domain, also referred to interchangeably throughout as an
"antigen binding site" that interacts with an antigen. Thus, a
"first variable light domain" and a "first variable heavy domain"
of the inventive multivalent antibody analogs together form a
"first antigen binding site". Similarly, a "second variable light
domain" and a "second variable heavy domain" of the inventive
multivalent antibody analogs together form a "second antigen
binding site". A "third variable light domain" and a "third
variable heavy domain" of the inventive multivalent antibody
analogs together form a "third antigen binding site", and so
on.
[0237] The antigen binding sites for use in accordance with the
invention, including the VHs, VLs, and/or CDRs that comprise such,
may be obtained or derived from any source of such, as will be
understood by the artisan. Accordingly, such antigen binding sites,
VHs, VLs, and/or CDRs may be obtained or derived from hybridoma
cells that express antibodies against a target recognized by such;
from B cells from immunized donors, which express antibodies
against a target recognized by such; from B-cells that have been
stimulated to express antibodies against a target recognized by
such; and or from identification of antibodies or antibody
fragments that have been identified by screening a library
comprising a plurality of polynucleotides or polypeptides for
antigen binding antibodies (or antigen binding fragments
thereof).
[0238] "Antibody fragments" comprise a portion of an intact
antibody, for example, one or more portions of the antigen-binding
region thereof. Examples of antibody fragments include Fab, Fab',
F(ab')2, and Fv fragments, scFvs, diabodies, linear antibodies,
single-chain antibodies, and multi-specific antibodies formed from
intact antibodies and antibody fragments.
[0239] By "scFv" as used herein is meant a polypeptide consisting
of two variable regions connected by a linker sequence; e.g.,
"Linkers" (also referred to a "linker moieties", used
interchangeably throughout), are described in more detail
below.
[0240] By "Fab" or "Fab region" as used herein is meant the
polypeptides that comprise the VH, CH1, VL, and CL immunoglobulin
domains. Typically, the VH and CH1 domains comprise one polypeptide
and the VL and CL domains comprise another polypeptide, wherein the
two polypeptides are linked to one another via at least one
inter-polypeptide disulfide bond. Fab may refer to this region in
isolation, or this region in the context of a full length antibody
or antibody fragment.
[0241] "Humanized antibodies" generally refer to non-human
antibodies that have had the variable-domain framework regions
swapped for sequences found in human antibodies. Generally in a
humanized antibody the entire antibody, except the CDRs, is encoded
by a polynucleotide of human origin or is identical to such an
antibody except within its CDRs. The CDRs, one, some, or all of
which are encoded by nucleic acids originating in a non-human
organism, are grafted into the framework of a human antibody
variable region to create an antibody, the specificity of which is
determined by the engrafted CDRs. The creation of such antibodies
is described in, e.g., WO 92/11018, Jones, 1986, Nature
321:522-525, Verhoeyen et al., 1988, Science 239:1534-1536. "Back
mutation" of selected acceptor framework residues to the
corresponding donor residues is often required to regain affinity
that is lost in the initial grafted construct (see, e.g., U.S. Pat.
No. 5,693,762). The humanized antibody optimally also will comprise
at least a portion of an immunoglobulin constant region, typically
that of a human immunoglobulin, and thus will typically comprise a
human Fc region. A variety of techniques and methods for
humanizing, reshaping, and resurfacing non-human antibodies are
well known in the art (See Tsurushita & Vasquez, 2004,
Humanization of Monoclonal Antibodies, Molecular Biology of B
Cells, 533-545, Elsevier Science (USA), and references cited
therein). In certain variations, the immunogenicity of the antibody
is reduced using a method described in Lazar et al., 2007, Mol
Immunol 44:1986-1998 and U.S. Ser. No. 11/004,590, entitled
"Methods of Generating Variant Proteins with Increased Host String
Content and Compositions Thereof", filed on Dec. 3, 2004.
[0242] An "intact antibody" is one comprising full-length heavy-
and light-chains and an Fc region. An intact antibody is also
referred to as a "full-length, heterodimeric" antibody or
immunoglobulin.
[0243] The term "variable" refers to the portions of the
immunoglobulin domains that exhibit variability in their sequence
and that are involved in determining the specificity and binding
affinity of a particular antibody (i.e., the "variable domain(s)").
Variability is not evenly distributed throughout the variable
domains of antibodies; it is concentrated in sub-domains of each of
the heavy and light chain variable regions. These sub-domains are
called "hypervariable" regions or "complementarity determining
regions" (CDRs). The more conserved (i.e., non-hypervariable)
portions of the variable domains are called the "framework" regions
(FRM). The variable domains of naturally occurring heavy and light
chains each comprise four FRM regions, largely adopting a
.beta.-sheet configuration, connected by three hypervariable
regions, which form loops connecting, and in some cases forming
part of, the .beta.-sheet structure. The hypervariable regions in
each chain are held together in close proximity by the FRM and,
with the hypervariable regions from the other chain, contribute to
the formation of the antigen-binding site (see Kabat et al.
Sequences of Proteins of Immunological Interest, 5th Ed. Public
Health Service, National Institutes of Health, Bethesda, Md., 1991,
incorporated by reference in its entirety). The constant domains
are not directly involved in antigen binding, but exhibit various
effector functions, such as, for example, antibody-dependent,
cell-mediated cytotoxicity and complement activation
[0244] The "chassis" of the invention represent a portion of the
antibody heavy chain variable (IGHV) or light chain variable (IGLV)
domains that are not part of CDRH3 or CDRL3, respectively. The
chassis of the invention is defined as the portion of the variable
region of an antibody beginning with the first amino acid of FRM1
and ending with the last amino acid of FRM3. In the case of the
heavy chain, the chassis includes the amino acids including from
about Kabat position 1 to about Kabat position 94. In the case of
the light chains (kappa and lambda), the chassis are defined as
including from about Kabat position 1 to about Kabat position 88.
The chassis of the invention may contain certain modifications
relative to the corresponding germline variable domain sequences
presented herein or available in public databases. These
modifications may be engineered (e.g., to remove N-linked
glycosylation sites) or naturally occurring (e.g., to account for
allelic variation). For example, it is known in the art that the
immunoglobulin gene repertoire is polymorphic (Wang et al.,
Immunol. Cell. Biol, 2008, 86: 111; Collins et al, Immunogenetics,
2008, DOI 10.1007/s00251-008-0325-z, published online, each
incorporated by reference in its entirety); chassis, CDRs (e.g.,
CDRH3) and constant regions representative of these allelic
variants are also encompassed by the invention. In some
embodiments, the allelic variant(s) used in a particular embodiment
of the invention may be selected based on the allelic variation
present in different patient populations, for example, to identify
antibodies that are non-immunogenic in these patient populations.
In certain embodiments, the immunogenicity of an antibody of the
invention may depend on allelic variation in the major
histocompatibility complex (MHC) genes of a patient population.
Such allelic variation may also be considered in the design of
libraries of the invention. In certain embodiments of the
invention, the chassis and constant regions are contained on a
vector, and a CDR3 region is introduced between them via homologous
recombination. In some embodiments, one, two or three nucleotides
may follow the heavy chain chassis, forming either a partial (if
one or two) or a complete (if three) codon. When a full codon is
present, these nucleotides encode an amino acid residue that is
referred to as the "tail," and occupies position 95.
[0245] In certain embodiments, one or more of: the first heavy
chain variable region; the second heavy chain variable region; the
first light chain variable region; the second light chain variable
region; one or more CDRs contained in a variable region; the first
polypeptide; the second polypeptide; the third polypeptide; the
fourth polypeptide; one or more parental homodimeric antibody
species; and/or the MAI are obtained by performing one or more
selections against a one or more antigens from one or more
libraries comprising unique members of any of the aforementioned
antibody components or regions.
[0246] In certain embodiments, either the first heavy chain
variable region or the second heavy chain variable region of an
antibody, such as an MAI, is obtained by performing a first
selection against a first antigen from a first library comprising
unique heavy chain variable regions.
[0247] In certain embodiments, the first heavy chain variable
region and the second heavy chain variable region of an antibody,
such as an MAI, is obtained by performing a first selection against
a first antigen from a first library comprising unique heavy chain
variable regions.
[0248] In certain embodiments, the first heavy chain variable
region of an antibody, such as an MAI, is obtained by performing a
first selection against a first antigen from a first library
comprising unique heavy chain variable regions and the second heavy
chain variable region is obtained by performing a second selection
against a second antigen from a second library comprising unique
heavy chain variable regions.
[0249] In certain embodiments, the first heavy chain variable
region of an antibody, such as an MAI, is obtained by performing a
first selection against a first antigen from a first library
comprising unique heavy chain variable regions and the second heavy
chain variable region is obtained by performing a second selection
against a second antigen from a second library comprising unique
heavy chain variable regions.
[0250] In certain embodiments, at least one of the libraries
further comprises at least one light chain.
[0251] As will be appreciated by the artisan, the terms "library"
and "plurality" (and "libraries" and "pluralities") may be readily
used interchangeably. However, in the context of the inventions
disclosed throughout, whereas a "plurality" of items, such as
antibodies, nucleic acid encoding antibodies, or host cells, may
comprise many or most members that are essentially identical, a
"library" of items, such as antibodies, nucleic acid encoding
antibodies, or host cells comprise members many or most members
that are unique.
[0252] In certain embodiments, one or more naive libraries are
employed in selections in accordance with the claimed methods. A
"naive library" refers to a library of polynucleotides (or
polypeptides encoded by such polynucleotides) that has not been
interrogated for the presence of antibodies having specificity a
particular antigen. A "naive library" also refers to a library that
is not restricted to, or otherwise biased or enriched for, antibody
sequences having specificity for any group of antigens, or for a
particular antigen. A naive library is thus distinct from a
"restricted library" and "maturation library" (such as, for
example, an "affinity maturation library"), both of which are
described below.
[0253] A naive library may also comprise a "preimmune" library,
which refers to a library that has sequence diversity and length
diversity similar to naturally occurring antibody sequences, such
as human antibody sequences, before such naturally occurring
sequences have undergone negative selection and/or somatic
hypermutation. Such preimmune libraries may be designed and
prepared so as to reflect or mimic the pre-immune repertoire,
and/or may be designed and prepared based on rational design
informed by the collection of human V, D, and J genes, and other
large databases of human heavy and light chain sequences (e.g.,
publicly known germline sequences; sequences from Jackson et al, J.
Immunol Methods, 2007, 324: 26, incorporated by reference in its
entirety; sequences from Lee et al., Immunogenetics, 2006, 57: 917,
incorporated by reference in its entirety; and sequences compiled
for rearranged VK and V.lamda.. Additional information may be
found, for example, in Scaviner et al., Exp. Clin. Immunogenet.,
1999, 16: 234; Tomlinson et al, J. Mol. Biol, 1992, 227: 799; and
Matsuda et al, J. Exp. Med., 1998, 188: 2151 each incorporated by
reference in its entirety. In certain embodiments of the invention,
cassettes representing the possible V, D, and J diversity found in
the human repertoire, as well as junctional diversity (i.e., N1 and
N2), are synthesized de novo as single or double-stranded DNA
oligonucleotides. Exemplary such preimmune libraries, and the
design and composition of polynucleotide sequences (and polypeptide
sequences encoded by them) comprising them, are further described
in, for example, Lee et al. (Immunogenetics, 2006, 57: 917); Martin
et al., Proteins, 1996, 25:130; WO 2009/036379; and WO
2012/09568.
[0254] In the context of antibodies that are employed in practicing
the disclosed inventions, a library (or plurality) of such
antibodies will comprise many or most members that each possess a
unique primary acid sequence; however, such libraries (or
pluralities) may also include members that have identical amino
acid sequences. In certain embodiments, the variable regions of
such members will comprise many of the differences in amino acid
sequence between such members.
[0255] In the context of host cells that are employed in practicing
the disclosed inventions, a plurality (or library) of such host
cells will comprise host cell members, many of which that each
express a unique antibody; however, such host cell pluralities (or
libraries) may also include members that express identical antibody
sequences. In certain embodiments, such host cells will also harbor
nucleic acid that collectively encodes the antibody libraries that
are collectively expressed by the host cells.
[0256] As will be understood by the artisan and as disclosed
throughout, "diversity" refers to a variety or a noticeable
heterogeneity. The term "sequence diversity" refers to a variety of
sequences which are collectively representative of several
possibilities of sequences, for example, those found in natural
human antibodies. For example, heavy chain CDR3 (CDRH3) sequence
diversity may refer to a variety of possibilities of combining the
known human DH and H3-JH segments, including the N1 and N2 regions,
to form heavy chain CDR3 sequences. The light chain CDR3 (CDRL3)
sequence diversity may refer to a variety of possibilities of
combining the naturally occurring light chain variable region
contributing to CDRL3 (i.e., L3-VL) and joining (i.e., L3-JL)
segments, to form light chain CDR3 sequences. As used herein, H3-JH
refers to the portion of the IGHJ gene contributing to CDRH3. As
used herein, L3-VL and L3-JL refer to the portions of the IGLV and
IGLJ genes (kappa or lambda) contributing to CDRL3,
respectively.
[0257] As used herein, the term "expression" includes any step
involved in the production of a polypeptide including, but not
limited to, transcription, post-transcriptional modification,
translation, post-translational modification, and secretion.
[0258] In certain embodiments of the invention, antibody libraries
are designed to be small enough to chemically synthesize and
physically realize, but large enough to encode antibodies with the
potential to recognize any antigen. In certain embodiments, an
antibody library comprises about 10.sup.7 to about 10.sup.20
different antibodies and/or polynucleotide sequences encoding the
antibodies of the library. In some embodiments, the libraries are
designed to include 10.sup.3, 10.sup.4, 10.sup.5, 10.sup.6,
10.sup.7, 10.sup.8, 10.sup.9, 10.sup.10, 10.sup.11, 10.sup.12,
10.sup.13, 10.sup.14, 10.sup.15, 10.sup.16, 10.sup.17, 10.sup.18,
10.sup.19, or 10.sup.20 different antibodies and/or polynucleotide
sequences encoding the antibodies. In certain embodiments, the
libraries may comprise or encode about 10.sup.3 to about 10.sup.5,
about 10.sup.5 to about 10.sup.7, about 10.sup.7 to about 10.sup.9,
about 10.sup.9 to about 10.sup.11, about 10.sup.11 to about
10.sup.13, about 10.sup.13 to about 10.sup.15, about 10.sup.15 to
about 10.sup.17, or about 10.sup.17 to about 10.sup.20 different
antibodies. In certain embodiments, the diversity of the libraries
may be characterized as being greater than or less than one or more
of the diversities enumerated above, for example greater than about
10.sup.3, 10.sup.4, 10.sup.5, 10.sup.6, 10.sup.7, 10.sup.8,
10.sup.9, 10.sup.10, 10.sup.11, 10.sup.12, 10.sup.13, 10.sup.14,
10.sup.15, 10.sup.16, 10.sup.17, 10.sup.18, 10.sup.19, or 10.sup.20
or less than about 10.sup.3, 10.sup.4, 10.sup.5, 10.sup.6,
10.sup.7, 10.sup.8, 10.sup.9, 10.sup.10, 10.sup.11, 10.sup.12,
10.sup.13, 10.sup.14, 10.sup.15, 10.sup.16, 10.sup.17, 10.sup.18,
10.sup.19, or 10.sup.20. In certain other embodiments of the
invention, the probability of an antibody of interest being present
in a physical realization of a library with a size as enumerated
above is at least about 0.0001%, 0.001%, 0.01%, 0.1%, 1%, 5%, 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, 99.5%, or
99.9% (see Library Sampling, in the Detailed Description, for more
information on the probability of a particular sequence being
present in a physical realization of a library).
[0259] As will be understood by the artisan and as disclosed
throughout antibody libraries suitable for use in accordance with
the disclosed methods may be designed and prepared by any method
available in the art as disclosed, for example, in WO2009036379;
WO2012009568; WO2010105256; U.S. Pat. Nos. 8,258,082; 6,300,064;
6,696,248; 6,165,718; 6,500,644; 6,291,158; 6,291,159; 6,096,551;
6,368,805; 6,500,644; and the like.
[0260] For instance, libraries may be designed and prepared so as
to reflect or mimic the pre-immune repertoire, and/or may be
designed and prepared based on rational design informed by the
collection of human V, D, and J genes, and other large databases of
human heavy and light chain sequences (e.g., publicly known
germline sequences; sequences from Jackson et al, J. Immunol
Methods, 2007, 324: 26, incorporated by reference in its entirety;
sequences from Lee et al., Immunogenetics, 2006, 57: 917,
incorporated by reference in its entirety; and sequences compiled
for rearranged VK and V.lamda.--see Appendices A and B filed
herewith). Additional information may be found, for example, in
Scaviner et al., Exp. Clin. Immunogenet., 1999, 16: 234; Tomlinson
et al, J. Mol. Biol, 1992, 227: 799; and Matsuda et al, J. Exp.
Med., 1998, 188: 2151 each incorporated by reference in its
entirety. In certain embodiments of the invention, cassettes
representing the possible V, D, and J diversity found in the human
repertoire, as well as junctional diversity (i.e., N1 and N2), are
synthesized de novo as single or double-stranded DNA
oligonucleotides. In certain embodiments of the invention,
oligonucleotide cassettes encoding CDR sequences are introduced
into yeast along with one or more acceptor vectors containing heavy
or light chain chassis sequences. No primer-based PCR amplification
or template-directed cloning steps from mammalian cDNA or mRNA are
employed. Through standard homologous recombination, the recipient
yeast recombines the cassettes (e.g., CDR3s) with the acceptor
vector(s) containing the chassis sequence(s) and constant regions,
to create a properly ordered synthetic, full-length human heavy
chain and/or light chain immunoglobulin library that can be
genetically propagated, expressed, displayed, and screened. One of
ordinary skill in the art will readily recognize that the chassis
contained in the acceptor vector can be designed so as to produce
constructs other than full-length human heavy chains and/or light
chains. For example, in certain embodiments of the invention, the
chassis may be designed to encode portions of a polypeptide
encoding an antibody fragment or subunit of an antibody fragment,
so that a sequence encoding an antibody fragment, or subunit
thereof, is produced when the oligonucleotide cassette containing
the CDR is recombined with the acceptor vector. In certain
embodiments, the invention provides a synthetic, preimmune human
antibody repertoire comprising about 10.sup.7 to about 10.sup.20
antibody members, wherein the repertoire comprises: [0261] (a)
selected human antibody heavy chain chassis (i.e., amino acids 1 to
94 of the heavy chain variable region, using Kabat's definition);
(b) a CDRH3 repertoire, designed based on the human IGHD and IGHJ
germline sequences, the CDRH3 repertoire comprising the following:
[0262] (i) optionally, one or more tail regions; [0263] (ii) one or
more N1 regions, comprising about 0 to about 10 amino acids
selected from the group consisting of fewer than 20 of the amino
acid types preferentially encoded by the action of terminal
deoxynucleotidyl transferase (TdT) and functionally expressed by
human B cells; [0264] (iii) one or DH segments, based on one or
more selected IGHD segments, and one or more N- or C-terminal
truncations thereof; [0265] (iv) one or more N2 regions, comprising
about 0 to about 10 amino acids selected from the group consisting
of fewer than 20 of the amino acids preferentially encoded by the
activity of TdT and functionally expressed by human B cells; and
[0266] (v) one or more H3-JH segments, based on one or more IGHJ
segments, and one or more N-terminal truncations thereof (e.g.,
down to XXWG); (c) one or more selected human antibody kappa and/or
lambda light chain chassis; and [0267] (b) a CDRL3 repertoire
designed based on the human IGLV and IGLJ germline sequences,
wherein "L" may be a kappa or lambda light chain. The means and
methods for preparing such libraries are disclosed, for example, in
WO2009036379; WO2012009568; WO2010105256.
[0268] As will be understood by the artisan and as disclosed
throughout, "specificity" refers to the property of an antibody
which enables to react with one or more antigenic determinants,
such as one or more epitopes, of an antigen of interest, and not
with other epitopes of the antigen of interest or with other
antigens of interest. As understood in the art, antibody
specificity is dependent on chemical composition, physical forces,
energetic favorability, steric hindrance, and molecular structure
or topology of the binding site of the epitope and/or the
antibody.
[0269] As will be understood by the artisan and as disclosed
throughout, "affinity" refers to the strength, or stability of an
antibody-epitope interaction. Antibodies with better affinity for
an epitope bind relatively tightly and/or stably with the epitope,
whereas antibodies with poorer affinity for an epitope bind
relatively weakly and or less stably.
[0270] As will be understood by the artisan and as disclosed
throughout, "collecting" or "collected" antibodies having
specificity for (an) epitope(s) of an antigen of interest refers to
distinguishing (or distinguished) antibodies that have such
specificity from those antibodies that do not have such
specificity. Collecting antibodies or collected antibodies having
specificity for (an) epitope(s) of an antigen of interest need not
require physical separation of antibodies from those antibodies
that do not have such specificity in order for them to be
distinguished. However, in certain embodiments, collecting
antibodies having specificity for (an) epitope(s) of an antigen of
interest comprises physically separating such antibodies from those
antibodies that do not have such specificity. Exemplary methods and
means for collecting antibodies are known in the art, and include,
for example, flow cytometry, florescence activated cell sorting
(FACS), magnetic activated cell sorting (MACS), enzyme-linked
immunosorbent assay (ELISA), and the like, and combinations
thereof.
[0271] Any means for determining such specificity in the art may be
employed for determining such specificity in accordance with the
methods disclosed throughout, and include, for example, labelling
such antibodies with a detectable label; detecting a detectable
label; detecting a functional consequence of antibody binding to
(an) epitope of an antigen, such as competition with another
antibody known to have specificity for such epitope(s); modulation
of protein-protein or protein-ligand interaction between the
antigen of interest and a known protein interaction partner or
ligand.
[0272] It is often desirable to include one more maturation library
selections as part of an antibody discovery process. Such
maturation library selections, such as affinity maturation library
selections, may be advantageously incorporated into the methods
disclosed herein.
[0273] A "maturation library" refers to a library that is designed
to enhance or improve at least one characteristic of an antibody
sequence that is identified upon interrogation of a library, such
as a naive library or a preimmune library, for the presence of
antibody sequences having specificity for the antigen. Such
maturation libraries may be generated by incorporating nucleic acid
sequences corresponding to: one or more CDRs; one or more antigen
binding regions; one or more VH or VL regions; and/or one or more
heavy chains or light chains; obtained from or identified in an
interrogation of a naive library (herein referred to as "antibody
leads") into libraries designed to further mutagenize in vitro or
in vivo to generate libraries with diversity introduced in the
context of the initial antibody leads. Such maturation libraries
and methods of making them are provided in, for example, WO
2009/036379 (for example, at pages 75 through 77); and WO
2012/09568 (for example pages 69 to 72), and include: maturation
libraries in which variegation is performed in which a CDRH3 of
interest remains unaltered, and heavy chain framework regions,
CHRH1, and/or CHDH2 regions are variegated; libraries in which a
CDRL3 of interest remains unaltered, and light chain framework
regions, CHRL1, and/or CHDL2 regions are variegated; libraries in
which premade, diverse, light chains are combined with one or more
heavy chains of interest.
[0274] A "restricted library" refers to a library that comprises:
one or more unique heavy chains, one or more unique light chains,
or one or more unique heavy chains and one or more unique light
chains; that have been obtained or identified by performing a
selection from, for example, a naive library for antigen binding
regions having specificity for one antigen of interest; and is used
to obtain or identify antigen binding regions having specificity
for another antigen of interest. Such restricted libraries
typically comprise a number of either heavy chains or light chains
that is in far excess of the number of light chains or heavy
chains, respectively. In certain embodiments, the number of unique
heavy chains is at least 10.sup.5, at least 10.sup.6, at least
10.sup.7, 10.sup.8, or at least 10.sup.9 or greater and the number
of unique light chains is one, two, three, four, five, ten, 15, 20,
50, 100, 200, 500, or 1000. In certain embodiments, the number of
unique heavy chains is between 10.sup.7 and 108, and the number of
unique light chains is less than 10, preferably approximately
5.
[0275] In certain embodiments, the methods disclosed throughout may
comprise the use of pluralities of host cells, members of which
collectively harbor nucleic acids that collectively encode the
libraries of antibodies, wherein such host cells collectively
express the libraries of antibodies that are interrogated for
binders to the antigen of interest. When such pluralities of host
cells are prepared and employed in accordance with the methods
disclosed throughout, either: those host cells that express
antibodies with specificity toward an antigen of interest are be
collected from amongst the plurality of host cells host cells that
are interrogated; or the antibodies that are encoded by such host
cells may be collected. In certain embodiments, the antibodies are
collected after the host cells express and secrete them.
[0276] In accordance with the use of host cells in the methods
disclosed throughout libraries of polynucleotides generated by any
of the techniques described herein, or other suitable techniques,
may be introduced into such host cells and thereby expressed and
screened to identify antibodies having desired structure and/or
activity. Expression of the antibodies can be carried out, for
example, using cell-free extracts (and e.g., ribosome display),
phage display, prokaryotic host cells (e.g., bacterial display), or
eukaryotic host cells (e.g., yeast display, mammalian cell
display). In certain embodiments of the invention, the antibody
libraries are expressed and/or encoded by yeast. In certain
embodiments, the yeast are Saccharomyces cerevisiae. In other
embodiments, the yeast are Pichia pastoris.
[0277] In other embodiments, the polynucleotides are engineered to
serve as templates that can be expressed in a cell-free extract.
Vectors and extracts as described, for example in U.S. Pat. Nos.
5,324,637; 5,492,817; 5,665,563, (each incorporated by reference in
its entirety) can be used and many are commercially available.
Ribosome display and other cell-free techniques for linking a
polynucleotide (i.e., a genotype) to a polypeptide (i.e., a
phenotype) can be used, e.g., Profusion.TM. (see, e.g., U.S. Pat.
Nos. 6,348,315; 6,261,804; 6,258,558; and 6,214,553, each
incorporated by reference in its entirety).
[0278] Alternatively, the polynucleotides of the invention can be
expressed in an E. coli expression system, such as that described
by Pluckthun and Skerra. (Meth. Enzymol., 1989, 178: 476;
Biotechnology, 1991, 9: 273, each incorporated by reference in its
entirety). The mutant proteins can be expressed for secretion in
the medium and/or in the cytoplasm of the bacteria, as described by
Better and Horwitz, Meth. Enzymol., 1989, 178: 476, incorporated by
reference in its entirety. In some embodiments, the single domains
encoding VH and VL are each attached to the 3' end of a sequence
encoding a signal sequence, such as the ompA, phoA or pelB signal
sequence (Lei et al, J. Bacteriol, 1987, 169: 4379, incorporated by
reference in its entirety). These gene fusions are assembled in a
dicistronic construct, so that they can be expressed from a single
vector, and secreted into the periplasmic space of E. coli where
they will refold and can be recovered in active form. (Skerra et
al, Biotechnology, 1991, 9: 273, incorporated by reference in its
entirety). For example, antibody heavy chain genes can be
concurrently expressed with antibody light chain genes to produce
antibodies or antibody fragments.
[0279] In other embodiments of the invention, the antibody
sequences are expressed on the membrane surface of a prokaryote,
e.g., E. coli, using a secretion signal and lipidation moiety as
described, e.g., in US20040072740; US20030100023; and US20030036092
(each incorporated by reference in its entirety).
[0280] Higher eukaryotic cells, such as mammalian cells, for
example myeloma cells (e.g., NS/0 cells), hybridoma cells, Chinese
hamster ovary (CHO), and human embryonic kidney (HEK) cells, can
also be used for expression of the antibodies of the invention.
Typically, antibodies expressed in mammalian cells are designed to
be secreted into the culture medium, or expressed on the surface of
the cell. The antibody or antibody fragments can be produced, for
example, as intact antibody molecules or as individual VH and VL
fragments, Fab fragments, single domains, or as single chains
(scFv) (Huston et al, PNAS, 1988, 85: 5879, incorporated by
reference in its entirety).
[0281] Alternatively, antibodies can be expressed and screened by
anchored periplasmic expression (APEx 2-hybrid surface display), as
described, for example, in Jeong et al, PNAS, 2007, 104: 8247
(incorporated by reference in its entirety) or by other anchoring
methods as described, for example, in Mazor et al., Nature
Biotechnology, 2007, 25: 563 (incorporated by reference in its
entirety).
[0282] In other embodiments of the invention, antibodies can be
selected using mammalian cell display (Ho et al, PNAS, 2006, 103:
9637, incorporated by reference in its entirety).
[0283] The screening of the antibodies derived from the libraries
of the invention can be carried out by any appropriate means. For
example, binding activity can be evaluated by standard immunoassay
and/or affinity chromatography. Screening of the antibodies of the
invention for catalytic function, e.g., proteolytic function can be
accomplished using a standard assays, e.g., the hemoglobin plaque
assay as described in U.S. Pat. No. 5,798,208 (incorporated by
reference in its entirety). Determining the ability of candidate
antibodies to bind therapeutic targets can be assayed in vitro
using, e.g., a BIACORE.TM. instrument, which measures binding rates
of an antibody to a given target or antigen based on surface
plasmon resonance. In vivo assays can be conducted using any of a
number of animal models and then subsequently tested, as
appropriate, in humans. Cell-based biological assays are also
contemplated.
[0284] As mentioned above, the inventive methods do not require the
design or engineering of heterodimerization motifs in order to
obtain meaningful quantities and purities of the desired MAI.
However, the inventive methods are amenable to the inclusion of
such motifs. Interaction between heterodimeric pairs or disclosed
multispecific antibody analogs comprising such heterodimeric pairs
may be promoted at the heterodimeric pair interface by the
formation of protuberance-into-cavity complementary regions at such
interfaces; the formation of non-naturally occurring disulfide
bonds at such interfaces; leucine zipper at such interfaces;
hydrophobic regions at such interfaces; and/or hydrophilic regions
at such interfaces. "Protuberances" are constructed by replacing
small amino acid side chains from the interface of the first
polypeptide with larger side chains (e.g. tyrosine or tryptophan).
Compensatory "cavities" of identical or similar size to the
protuberances are optionally created on the interface of the second
polypeptide by replacing large amino acid side chains with smaller
ones (e.g. alanine or threonine). Where a suitably positioned and
dimensioned protuberance or cavity exists at the interface of
either the first or second polypeptide, it is only necessary to
engineer a corresponding cavity or protuberance, respectively, at
the adjacent interface. Non-naturally occurring disulfide bonds are
constructed by replacing on the first polypeptide a naturally
occurring amino acid with a free thiol-containing residue, such as
cysteine, such that the free thiol interacts with another free
thiol-containing residue on the second polypeptide such that a
disulfide bond is formed between the first and second polypeptides
Exemplary heterodimerization pairs and methods for making such in
accordance with the present invention are available in the art, and
are disclosed, for example, in US 2011/0054151; US 2007/0098712;
and the like.
[0285] In certain embodiments, the heterodimeric pairs are
contained within the Fc region of the inventive multi specific
antibody analogs. Fc regions that contain such heterodimeric pairs
are referred to as "heterodimeric Fc regions".
[0286] Accordingly, in certain embodiments, multispecific antibody
analogs comprise a CH2 and/or a CH3 domain variant, wherein either:
a) the CH2 domain variant and the CH3 domain variant each
independently comprises a at least one protuberance in either the
CH2 domain or the CH3 domain of the first polypeptide and at least
one corresponding cavity in the CH2 domain or the CH3 domain of the
second; or the CH2 domain variant and the CH3 domain variant each
independently comprises at least one cavity in either the CH2
domain or the CH3 domain of the first polypeptide and at least one
corresponding protuberance in the CH2 domain or the CH3 domain of
the second polypeptide. In certain other embodiments, the
multispecific antibody analogs comprise a CH2 and/or a CH3 domain
variant, wherein either: a) the CH2 domain variant and the CH3
domain variant each independently comprises at least one
substituted negatively-charged amino acid in either the CH2 domain
or the CH3 domain of the first polypeptide and at least one
corresponding positively-charged amino acid in either the CH2
domain or the CH3 domain of the second polypeptide; orb) the CH2
domain variant and the CH3 domain variant each independently
comprises at least one substituted positively-charged amino acid in
either the CH2 domain or the CH3 domain of the first polypeptide
and at least one corresponding substituted negatively-charged
substituted amino acid in either the CH2 domain or the CH3 domain
of the second polypeptide.
[0287] With regard to Fc function in "natural" antibodies (i.e.,
those antibodies generated in vivo via native biological antibody
synthesis by native B-cells), the Fc region of an antibody
interacts with a number of Fc receptors and ligands, imparting an
array of important functional capabilities referred to as effector
functions. For IgG the Fc region, Fc comprises Ig domains C.gamma.2
and C.gamma.3 and the N-terminal hinge leading into C.gamma.2. An
important family of Fc receptors for the IgG class is the Fc gamma
receptors (Fc.gamma.Rs). These receptors mediate communication
between antibodies and the cellular arm of the immune system
(Raghavan et al., 1996, Annu Rev Cell Dev Biol 12:181-220; Ravetch
et al., 2001, Annu Rev Immunol 19:275-290). In humans this protein
family includes Fc.gamma.RI (CD64), including isoforms
Fc.gamma.RIa, Fc.gamma.RIb, and Fc.gamma.RIc; Fc.gamma.RII (CD32),
including isoforms Fc.gamma.RIIa (including allotypes H131 and
R131), Fc.gamma.RIIb (including Fc.gamma.RIIb-1 and
Fc.gamma.RIIb-2), and Fc.gamma.RIIc; and Fc.gamma.RIII (CD16),
including isoforms Fc.gamma.RIIIa (including allotypes V158 and
F158) and Fc.gamma.RIIIb (including allotypes Fc.gamma.RIIIb-NA1
and Fc.gamma.RIIIb-NA2) (Jefferis et al., 2002, Immunol Lett
82:57-65). These receptors typically have an extracellular domain
that mediates binding to Fc, a membrane spanning region, and an
intracellular domain that may mediate some signaling event within
the cell. These receptors are expressed in a variety of immune
cells including monocytes, macrophages, neutrophils, dendritic
cells, eosinophils, mast cells, platelets, B cells, large granular
lymphocytes, Langerhans' cells, natural killer (NK) cells, and
.gamma..delta. T cells. Formation of the Fc/Fc.gamma.R complex
recruits these effector cells to sites of bound antigen, typically
resulting in signaling events within the cells and important
subsequent immune responses such as release of inflammation
mediators, B cell activation, endocytosis, phagocytosis, and
cytotoxic attack. The ability to mediate cytotoxic and phagocytic
effector functions is a potential mechanism by which antibodies
destroy targeted cells. The cell-mediated reaction wherein
nonspecific cytotoxic cells that express Fc.gamma.Rs recognize
bound antibody on a target cell and subsequently cause lysis of the
target cell is referred to as antibody dependent cell-mediated
cytotoxicity (ADCC) (Raghavan et al., 1996, Annu Rev Cell Dev Biol
12:181-220; Ghetie et al., 2000, Annu Rev Immunol 18:739-766;
Ravetch et al., 2001, Annu Rev Immunol 19:275-290). The
cell-mediated reaction wherein nonspecific cytotoxic cells that
express Fc.gamma.Rs recognize bound antibody on a target cell and
subsequently cause phagocytosis of the target cell is referred to
as antibody dependent cell-mediated phagocytosis (ADCP).
[0288] A particular feature of the Fc region of "natural"
antibodies is the conserved N-linked glycosylation that occurs at
N297. This carbohydrate, or oligosaccharide as it is sometimes
referred, plays a critical structural and functional role for the
antibody, and is one of the principle reasons that antibodies must
be produced using mammalian expression systems. Efficient Fc
binding to Fc.gamma.R and C1q requires this modification, and
alterations in the composition of the N297 carbohydrate or its
elimination affect binding to these proteins
[0289] In some embodiments, the inventive multispecific antibody
analogs disclosed herein comprise an Fc variant. An Fc variant
comprises one or more amino acid modifications relative to a parent
Fc polypeptide, wherein the amino acid modification(s) provide one
or more optimized properties. Fc variants further comprise either a
CH2 domain variant, a CH3 domain variant, or both a CH2 domain
variant and a CH3 domain variant. By "modification" herein is meant
an alteration in the physical, chemical, or sequence properties of
a protein, polypeptide, antibody, inventive multispecific antibody
analog, or immunoglobulin. An amino acid modification can be an
amino acid substitution, insertion, and/or deletion in a
polypeptide sequence. By "amino acid substitution" or
"substitution" herein is meant the replacement of an amino acid at
a particular position in a parent polypeptide sequence with another
amino acid. For example, the substitution Y349T refers to a variant
polypeptide, in this case a constant heavy chain variant, in which
the tyrosine at position 349 is replaced with threonine. By "amino
acid insertion" or "insertion" as used herein is meant the addition
of an amino acid at a particular position in a parent polypeptide
sequence. By "amino acid deletion" or "deletion" as used herein is
meant the removal of an amino acid at a particular position in a
parent polypeptide sequence.
[0290] An Fc variant disclosed herein differs in amino acid
sequence from its parent by virtue of at least one amino acid
modification. The inventive multispecific antibody analogs
disclosed herein may have more than one amino acid modification as
compared to the parent, for example from about one to fifty amino
acid modifications, e.g., from about one to ten amino acid
modifications, from about one to about five amino acid
modifications, etc. compared to the parent. Thus the sequences of
the Fc variants and those of the parent Fc polypeptide are
substantially homologous. For example, the variant Fc variant
sequences herein will possess about 80% homology with the parent Fc
variant sequence, e.g., at least about 90% homology, at least about
95% homology, at least about 98% homology, at least about 99%
homology, etc. Modifications disclosed herein also include
glycoform modifications. Modifications may be made genetically
using molecular biology, or may be made enzymatically or
chemically.
[0291] Fc variants disclosed herein are defined according to the
amino acid modifications that compose them. Thus, for example, the
substitution Y349T refers to a variant polypeptide, in this case a
constant heavy chain variant, in which the tyrosine at position 349
is replaced with threonine. Likewise, Y349T/T394F defines an Fc
variant with the substitutions Y349T and T394F relative to the
parent Fc polypeptide. The identity of the WT amino acid may be
unspecified, in which case the aforementioned variant is referred
to as 349T/394F. It is noted that the order in which substitutions
are provided is arbitrary, that is to say that, for example,
349T/394F is the same Fc variant as 394F/349T. Unless otherwise
noted, constant region and Fc positions discussed herein are
numbered according to the EU index or EU numbering scheme (Kabat et
al., 1991, Sequences of Proteins of Immunological Interest, 5th
Ed., United States Public Health Service, National Institutes of
Health, Bethesda). The EU index or EU index as in Kabat or EU
numbering scheme refers to the numbering of the EU antibody
(Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85).
[0292] In certain embodiments, the Fc variants disclosed herein are
based on human IgG sequences, and thus human IgG sequences are used
as the "base" sequences against which other sequences are compared,
including but not limited to sequences from other organisms, for
example rodent and primate sequences. Immunoglobulins may also
comprise sequences from other immunoglobulin classes such as IgA,
IgE, IgD, IgM, and the like. It is contemplated that, although the
Fc variants disclosed herein are engineered in the context of one
parent IgG, the variants may be engineered in or "transferred" to
the context of another, second parent IgG. This is done by
determining the "equivalent" or "corresponding" residues and
substitutions between the first and second IgG, typically based on
sequence or structural homology between the sequences of the first
and second IgGs. In order to establish homology, the amino acid
sequence of a first IgG outlined herein is directly compared to the
sequence of a second IgG. After aligning the sequences, using one
or more of the homology alignment programs known in the art (for
example using conserved residues as between species), allowing for
necessary insertions and deletions in order to maintain alignment
(i.e., avoiding the elimination of conserved residues through
arbitrary deletion and insertion), the residues equivalent to
particular amino acids in the primary sequence of the first
immunoglobulin are defined. Alignment of conserved residues may
conserve 100% of such residues. However, alignment of greater than
75% or as little as 50% of conserved residues is also adequate to
define equivalent residues. Equivalent residues may also be defined
by determining structural homology between a first and second IgG
that is at the level of tertiary structure for IgGs whose
structures have been determined. In this case, equivalent residues
are defined as those for which the atomic coordinates of two or
more of the main chain atoms of a particular amino acid residue of
the parent or precursor (N on N, CA on CA, C on C and O on O) are
within about 0.13 nm, after alignment. In another embodiment,
equivalent residues are within about 0.1 nm after alignment.
Alignment is achieved after the best model has been oriented and
positioned to give the maximum overlap of atomic coordinates of
non-hydrogen protein atoms of the proteins. Regardless of how
equivalent or corresponding residues are determined, and regardless
of the identity of the parent IgG in which the IgGs are made, what
is meant to be conveyed is that the Fc variants discovered as
disclosed herein may be engineered into any second parent IgG that
has significant sequence or structural homology with the Fc
variant. Thus for example, if a variant antibody is generated
wherein the parent antibody is human IgG1, by using the methods
described above or other methods for determining equivalent
residues, the variant antibody may be engineered in another IgG1
parent antibody that binds a different antigen, a human IgG2 parent
antibody, a human IgA parent antibody, a mouse IgG2a or IgG2b
parent antibody, and the like. Again, as described above, the
context of the parent Fc variant does not affect the ability to
transfer the Fc variants disclosed herein to other parent IgGs.
[0293] Fc variants that comprise or are CH3 domain variants as
described above may comprise at least one substitution at a
position in a CH3 domain selected from the group consisting of 349,
351, 354, 356, 357, 364, 366, 368, 370, 392, 394, 395, 396, 397,
399, 401, 405, 407, 409, 411, and 439, wherein numbering is
according to the EU index as in Kabat. In a preferred embodiment,
CH3 domain variants comprise at least one CH3 domain substitution
per heavy chain selected from the group consisting of 349A, 349C,
349E, 349I, 349K, 349S, 349T, 349W, 351 E, 351K, 354C, 356K, 357K,
364C, 364D, 364E, 364F, 364G, 364H, 364R, 364T, 364Y, 366D, 366K,
366S, 366W, 366Y, 368A, 368E, 368K, 368S, 370C, 370D, 370E, 370G,
370R, 370S, 370V, 392D, 392E, 394F, 394S, 394W, 394Y, 395T, 395V,
396T, 397E, 397S, 397T, 399K, 401 K, 405A, 405S, 407T, 407V, 409D,
409E, 411 D, 411 E, 411K, and 439D. Each of these variants can be
used individually or in any combination for each heavy chain Fc
region. As will be appreciated by those in the art, each heavy
chain can comprise different numbers of substitutions. For example,
both heavy chains that make up the Fc region may comprise a single
substitution, one chain may comprise a single substitution and the
other two substitutions, both can contain two substitutions
(although each chain will contain different substitutions),
etc.
[0294] In some embodiments, the CH2 and/or CH3 domain variants are
made in combinations, that is, two or more variants per heavy chain
Fc domain, selected from the group outlined above.
[0295] Other CH2 and/or CH3 domain variants that favor
heterodimerization that may be employed in the design and
preparation of the inventive multispecific antibody analogs of the
invention are provided in, for example, Ridgeway et al., 1996,
Protein Engineering 9[7]:617-621; U.S. Pat. No. 5,731,168; Xie et
al., 2005, J Immunol Methods 296:95-101; Davis et al., 2010,
Protein Engineering, Design & Selection 23[4]:195-202;
Gunasekaran et al., 2010, J Biol Chem 285[25]:1937-19646; and
PCT/US2009/000071 (published as WO 2009/089004).
[0296] The Fc variants disclosed herein may be optimized for
improved or reduced binding to Fc receptors or Fc ligands. By "Fc
receptor" or "Fc ligand" as used herein is meant a molecule,
preferably a polypeptide, from any organism that binds to the Fc
region of an antibody to form an Fc-ligand complex. Fc ligands
include but are not limited to Fc.gamma.Rs, (as described above,
including but not limited to Fc.gamma.RIIIa, Fc.gamma.RIIa,
Fc.gamma.RIIb, Fc.gamma.RI and FcRn), C1q, C3, mannan binding
lectin, mannose receptor, staphylococcal protein A, streptococcal
protein G, and viral Fc.gamma.R. Fc ligands also include Fc
receptor homologs (FcRH), which are a family of Fc receptors that
are homologous to the Fc.gamma.Rs. Fc ligands may include
undiscovered molecules that bind Fc.
[0297] The inventive multi specific antibody analogs may be
designed to optimize properties, including but are not limited to
enhanced or reduced affinity for an Fc receptor. By "greater
affinity" or "improved affinity" or "enhanced affinity" or "better
affinity" than a parent Fc polypeptide, as used herein, is meant
that an Fc variant binds to an Fc receptor with a significantly
higher equilibrium constant of association (KA or K.sub.a) or lower
equilibrium constant of dissociation (KD or K.sub.d) than the
parent Fc polypeptide when the amounts of variant and parent
polypeptide in the binding assay are essentially the same. For
example, the Fc variant with improved Fc receptor binding affinity
may display from about 5 fold to about 1000 fold, e.g. from about
10 fold to about 500 fold improvement in Fc receptor binding
affinity compared to the parent Fc polypeptide, where Fc receptor
binding affinity is determined, for example, by the binding methods
disclosed herein, including but not limited to Biacore, by one
skilled in the art. Accordingly, by "reduced affinity" as compared
to a parent Fc polypeptide as used herein is meant that an Fc
variant binds an Fc receptor with significantly lower KA or higher
KD than the parent Fc polypeptide. Greater or reduced affinity can
also be defined relative to an absolute level of affinity.
[0298] As would be understood by those of ordinary skill in the
art, the term "antibody" is used herein in the broadest sense and
specifically encompasses at least monoclonal antibodies, polyclonal
antibodies, multi-specific antibodies (e.g., bispecific
antibodies), chimeric antibodies, humanized antibodies, human
antibodies, antibody fragments, and derivatives thereof. An
antibody is a protein comprising one or more polypeptides
substantially or partially encoded by immunoglobulin genes or
fragments of immunoglobulin genes. The recognized immunoglobulin
genes include the kappa, lambda, alpha, gamma, delta, epsilon and
mu constant region genes, as well as myriad immunoglobulin variable
region genes. An "antibody" also refers to an immunoglobulin
molecule, a fragment of an immunoglobulin molecule, or a derivative
thereof, which has the ability to specifically bind to an antigen,
which may be, for example: a protein; a polypeptide; peptide; a
hormone; a cytokine; a chemokine; a growth factor; a
neurotransmitter; a carbohydrate-containing biological molecule; a
lipid or fatty acid-containing biological molecule; or other
biological molecule; via an epitope present on such antigen.
[0299] Antibodies (used interchangeably with "immunoglobulins", or
"immunoglobulin molecules") can be monomeric, dimeric, trimeric,
tetrameric, pentameric, etc., and comprise a class of structurally
related proteins consisting of two pairs of polypeptide chains: one
pair of light chains (LC) and one pair of heavy chains (HC), all of
which are inter-connected by disulfide bonds. The structure of
immunoglobulins has been well characterized. See for instance
Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press,
N.Y. (1989)).
[0300] Traditional natural antibody structural formats typically
comprise a tetramer. Each tetramer is typically composed of two
identical pairs of polypeptide chains, each pair having one "light"
(typically having a molecular weight of about 25 kDa) and one
"heavy" chain (typically having a molecular weight of about 50-70
kDa). Human light chains are classified as kappa and lambda light
chains. Heavy chains are classified as mu, delta, gamma, alpha, or
epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA,
and IgE, respectively. IgG has several subclasses, including, but
not limited to IgG1, IgG2, IgG3, and IgG4. IgM has subclasses,
including, but not limited to, IgM1 and IgM2. IgA has several
subclasses, including but not limited to IgA1 and IgA2. Thus,
"isotype" as used herein is meant any of the classes and subclasses
of immunoglobulins defined by the chemical and antigenic
characteristics of their constant regions. The known human
immunoglobulin isotypes are IgG1, IgG2, IgG3, IgG4, IgA1, IgA2,
IgM1, IgM2, IgD, and IgE. The distinguishing features between these
antibody classes are their constant regions, although subtler
differences may exist in the variable region.
[0301] Each of the light and heavy chains is made up of two
distinct regions, referred to as the variable and constant regions.
The IgG heavy chain is composed of four immunoglobulin domains
linked from N- to C-terminus in the order VH-CH1-CH2-CH3, referring
to the "variable heavy domain" (also referred to as a "heavy chain
variable domain", used interchangeably throughout), heavy chain
constant domain 1, heavy chain constant domain 2, and heavy chain
constant domain 3 respectively (also referred to as
VH-C.gamma.1-C.gamma.2-C.gamma.3, referring to the variable heavy
domain, constant gamma 1 domain, constant gamma 2 domain, and
constant gamma 3 domain respectively). The IgG light chain is
composed of two immunoglobulin domains linked from N- to C-terminus
in the order VL-CL, referring to the "variable light domain" (also
referred to as a "light chain variable domain", used
interchangeably throughout) and the light chain constant domain
respectively. The constant regions show less sequence diversity,
and are responsible for binding a number of natural proteins to
elicit important biochemical events. The structure that constitutes
the natural biological form of an antibody, including the variable
and constant regions, is referred to herein as a "full length
antibody". In most mammals, including humans and mice, the full
length antibody of the IgG isotype is a tetramer and consists of
two identical pairs of two immunoglobulin chains, each pair having
one light chain and one heavy chain, each light chain comprising a
VL and a CL, and each heavy chain comprising a VH, CH1, a CH2, and
a CH3. In some mammals, for example in camels and llamas, IgG
antibodies may consist of only two heavy chains, each heavy chain
comprising a variable domain attached to the Fc region.
[0302] The heavy chain constant region typically is comprised of
three domains, CH1, CH2, and CH3, and the CH1 and CH2 domains are
connected by a hinge region. Each light chain typically is
comprised of a light chain variable domain (abbreviated herein as
"V.sub.L" or "VL") and a light chain constant domain. The V.sub.H
and V.sub.L domains may be further subdivided into regions of
hypervariability (or hypervariable regions which may be
hypervariable in sequence and/or form of structurally defined
loops), also termed complementarity determining regions (CDRs),
interspersed with regions that are more conserved, termed framework
regions (FRs). Each V.sub.H and V.sub.L is typically composed of
three CDRs and four FRs, arranged from amino-terminus to
carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3,
CDR3, FR4. Typically, the numbering of amino acid residues in this
region is performed by the method described in Kabat (see, e.g.,
Kabat et al, in "Sequences of Proteins of Immunological Interest,"
5.sup.th Edition, U.S. Department of Health and Human Services,
1992). Using this numbering system, the actual linear amino acid
sequence of a peptide may contain fewer or additional amino acids
corresponding to a shortening of, or insertion into, a FR or CDR of
the variable domain. For example, a heavy chain variable domain may
include a single amino acid insert (residue 52a according to Kabat)
after residue 52 of V.sub.H CDR2 and inserted residues (for
instance residues 82a, 82b, and 82c, etc. according to Kabat) after
heavy chain FR residue 82. The Kabat numbering of residues may be
determined for a given antibody by alignment at regions of homology
of the sequence of the antibody with a "standard" Kabat numbered
sequence.
[0303] The term "variable", "variable domain", or "variable region"
each interchangeably refers to the portions of the immunoglobulin
domains that exhibit variability in their sequence and that are
involved in determining the specificity and binding affinity of a
particular antibody (i.e., the "variable domain(s)"). Variability
is not evenly distributed throughout the variable domains of
antibodies; it is concentrated in sub-domains of each of the heavy
and light chain variable regions. These sub-domains are called
"hypervariable" regions or "complementarity determining regions"
(CDRs). The more conserved (i.e., non-hypervariable) portions of
the variable domains are called the "framework" regions (FRM). The
variable domains of naturally occurring heavy and light chains each
comprise four FRM regions, largely adopting a .beta.-sheet
configuration, connected by three hypervariable regions, which form
loops connecting, and in some cases forming part of, the
.beta.-sheet structure. The hypervariable regions in each chain are
held together in close proximity by the FRM and, with the
hypervariable regions from the other chain, contribute to the
formation of the antigen-binding site (see Kabat et al. Sequences
of Proteins of Immunological Interest, 5th Ed. Public Health
Service, National Institutes of Health, Bethesda, Md., 1991,
incorporated by reference in its entirety). The constant domains
are not directly involved in antigen binding, but exhibit various
effector functions, such as, for example, antibody-dependent,
cell-mediated cytotoxicity and complement activation.
[0304] The term "framework region" refers to the art-recognized
portions of an antibody variable region that exist between the more
divergent (i.e., hypervariable) CDRs. Such framework regions are
typically referred to as frameworks 1 through 4 (FRM1, FRM2, FRM3,
and FRM4) and provide a scaffold for the presentation of the six
CDRs (three from the heavy chain and three from the light chain) in
three dimensional space, to form an antigen-binding surface. The
term "canonical structure" refers to the main chain conformation
that is adopted by the antigen binding (CDR) loops. From
comparative structural studies, it has been found that five of the
six antigen binding loops have only a limited repertoire of
available conformations. Each canonical structure can be
characterized by the torsion angles of the polypeptide backbone.
Correspondent loops between antibodies may, therefore, have very
similar three dimensional structures, despite high amino acid
sequence variability in most parts of the loops (Chothia and Lesk,
J. Mol. Biol., 1987, 196: 901; Chothia et al, Nature, 1989, 342:
877; Martin and Thornton, J. Mol. Biol, 1996, 263: 800.
Furthermore, there is a relationship between the adopted loop
structure and the amino acid sequences surrounding it. The
conformation of a particular canonical class is determined by the
length of the loop and the amino acid residues residing at key
positions within the loop, as well as within the conserved
framework (i.e., outside of the loop). Assignment to a particular
canonical class can therefore be made based on the presence of
these key amino acid residues.
[0305] The term "canonical structure" may also include
considerations as to the linear sequence of the antibody, for
example, as catalogued by Kabat (Kabat et al, in "Sequences of
Proteins of Immunological Interest," 5.sup.th Edition, U.S.
Department of Health and Human Services, 1992). The Kabat numbering
scheme is a widely adopted standard for numbering the amino acid
residues of an antibody variable domain in a consistent manner.
Additional structural considerations can also be used to determine
the canonical structure of an antibody. For example, those
differences not fully reflected by Kabat numbering can be described
by the numbering system of Chothia et al and/or revealed by other
techniques, for example, crystallography and two or
three-dimensional computational modeling. Accordingly, a given
antibody sequence may be placed into a canonical class which allows
for, among other things, identifying appropriate chassis sequences
(e.g., based on a desire to include a variety of canonical
structures in a library). Kabat numbering of antibody amino acid
sequences and structural considerations as described by Chothia et
al., and their implications for construing canonical aspects of
antibody structure, are described in the literature.
[0306] By "Fc" or "Fc region", as used herein is meant the
polypeptide comprising the constant region of an antibody excluding
the first constant region immunoglobulin domain. Thus "Fc region"
refers to the last two constant region immunoglobulin domains of
IgA, IgD, and IgG, and the last three constant region
immunoglobulin domains of IgE and IgM, and the flexible hinge
N-terminal to these domains. For IgA and IgM, Fc may include the J
chain. For IgG, Fc comprises immunoglobulin domains Cgamma2 and
Cgamma3 (C.gamma.2 and C.gamma.3) and the hinge between Cgamma1
(C.gamma.1) and Cgamma2 (C.gamma.2). Accordingly, and without
departing from the above, "Fc region" may also be defined as
comprising a "CH2 domain or a variant thereof" and a "CH3 domain or
a variant thereof". Although the boundaries of the Fc region may
vary, the human IgG heavy chain Fc region is usually defined to
comprise residues C226 or P230 to its carboxyl-terminus, wherein
the numbering is according to the EU index as in Kabat. Fc may
refer to this region in isolation, or this region in the context of
an Fc polypeptide, for example an antibody. By "Fc polypeptide" as
used herein is meant a polypeptide that comprises all or part of an
Fc region. Fc polypeptides include antibodies, Fc fusions, isolated
Fcs, and Fc fragments.
[0307] A variable light chain (VL) and corresponding variable heavy
domain (VH) of the inventive multispecific antibodies of interest
comprise a binding domain, also referred to interchangeably
throughout as an "antigen binding site" that interacts with an
antigen. Thus, a "first variable light domain" and a "first
variable heavy domain" of the inventive multi specific antibody of
interest together form a "first antigen binding site". Similarly, a
"second variable light domain" and a "second variable heavy domain"
of the inventive multispecific antibody of interest together form a
"second antigen binding site". A "third variable light domain" and
a "third variable heavy domain" of the inventive multi specific
antibody of interest together form a "third antigen binding site",
and so on.
[0308] The antigen binding sites for use in accordance with the
invention, including the VHs, VLs, and/or CDRs that comprise such,
may be obtained or derived from any source of such, as will be
understood by the artisan. Accordingly, such antigen binding sites,
VHs, VLs, and/or CDRs may be obtained or derived from hybridoma
cells that express antibodies against a target recognized by such;
from B cells from immunized donors, which express antibodies
against a target recognized by such; from B-cells that have been
stimulated to express antibodies against a target recognized by
such; and or from identification of antibodies or antibody
fragments that have been identified by screening a library
comprising a plurality of polynucleotides or polypeptides for
antigen binding antibodies (or antigen binding fragments thereof).
With regard to the design, preparation, display, and implementation
of such libraries for use in identifying and obtaining antigen
binding sites for use in accordance with the invention, see, e.g.,
WO 2009/036379; WO2012009568; WO2010105256; U.S. Pat. Nos.
8,258,082; 6,300,064; 6,696,248; 6,165,718; 6,500,644; 6,291,158;
6,291,159; 6,096,551; 6,368,805; 6,500,644; and the like.
[0309] Any one or more of the antigen binding sites, VHs, VLs, or
CDRs, and combinations thereof, of the inventive multispecific
antibodies of interest, may comprise sequences from a variety of
species. In some embodiments, such antigen binding sites, VHs, VLs,
or CDRs, and combinations thereof may be obtained from a nonhuman
source, including but not limited to mice, rats, rabbits, camels,
llamas, and monkeys. In some embodiments, the scaffold and/or
framework regions can be a mixture from different species. As such,
a multispecific antibody of interest in accordance with the
invention may comprise a chimeric antibody and/or a humanized
antibody. In general, both "chimeric antibodies" and "humanized
antibodies" refer to antibodies in which regions from more than one
species have been combined. For example, "chimeric antibodies"
traditionally comprise variable region(s) from a mouse or other
nonhuman species and the constant region(s) from a human.
[0310] "Humanized antibodies" generally refer to non-human
antibodies that have had the variable-domain framework regions
swapped for sequences found in human antibodies. Generally in a
humanized antibody the entire antibody, except the CDRs, is encoded
by a polynucleotide of human origin or is identical to such an
antibody except within its CDRs. The CDRs, one, some, or all of
which are encoded by nucleic acids originating in a non-human
organism, are grafted into the framework of a human antibody
variable region to create an antibody, the specificity of which is
determined by the engrafted CDRs. The creation of such antibodies
is described in, e.g., WO 92/11018, Jones, 1986, Nature
321:522-525, Verhoeyen et al., 1988, Science 239:1534-1536.
"Backmutation" of selected acceptor framework residues to the
corresponding donor residues is often required to regain affinity
that is lost in the initial grafted construct (see, e.g., U.S. Pat.
No. 5,693,762). The humanized antibody optimally also will comprise
at least a portion of an immunoglobulin constant region, typically
that of a human immunoglobulin, and thus will typically comprise a
human Fc region. A variety of techniques and methods for
humanizing, reshaping, and resurfacing non-human antibodies are
well known in the art (See Tsurushita & Vasquez, 2004,
Humanization of Monoclonal Antibodies, Molecular Biology of B
Cells, 533-545, Elsevier Science (USA), and references cited
therein). In certain variations, the immunogenicity of the antibody
is reduced using a method described in Lazar et al., 2007, Mol
Immunol 44:1986-1998 and U.S. Ser. No. 11/004,590, entitled
"Methods of Generating Variant Proteins with Increased Host String
Content and Compositions Thereof", filed on Dec. 3, 2004.
[0311] Accordingly, any one or more of the antigen binding sites,
or one or more VHs, VLs, CDRs, or combinations thereof, which
comprise the inventive multispecific antibodies of interest
disclosed herein may be derived from a non-human species and/or
result from humanization of a non-human antibody or antibody
fragment. Such VHs, VLs, and/or CDRs obtained or derived from
non-human species, when included in the inventive multispecific
analogs disclosed herein, are referred to as "humanized" such
regions and/or domains.
[0312] The inventive antibody analogs disclosed herein preferably
comprise first and second polypeptides that each comprise a hinge
region, wherein each hinge region comprises at least one thiol
group that is capable of participating in an intermolecular
disulfide bond such that the first and the second polypeptide are
covalently linked as a result of formation of the disulfide bond.
As is understood in the art, chemical modification may be
introduced into (or onto) certain residues within such hinge
regions which effect the introduction of such thiol groups for
disulfide bond formation. Alternatively, the thiol groups may be
provided by a cysteine residue that is present within the hinge
region. Such cysteines may be provided by native hinge polypeptide
sequence, or may be introduced by mutagenesis into nucleic acid
encoding the hinge region. As used herein, whereas a "hinge" or a
"hinge region" of the inventive antibody analogs may comprise or
constitute a natural or native hinge region as found in, for
example, immunoglobulins such as IgGs, IgMs, IgAs, IgEs, and the
like, such a hinge or hinge region may also comprise or constitute
a substitutes form thereof. Further, such a hinge or hinge region
may, in certain embodiments comprise or constitute a "linker
moiety" as disclosed throughout. In other embodiments, a hinge or
hinge region may comprise both a natural or native hinge region as
disclosed above and a linker moiety as disclosed throughout.
[0313] In certain embodiments, the inventive antibody analogs
disclosed herein comprise one or more linkers or linker moieties.
Such linkers or linker moieties may comprise a peptidic linker
moiety or a non-peptidic linker moiety. The terms "linker" and
"linker moiety" and the like, means a divalent species (-L-)
covalently bonded in turn to a polypeptide having a valency
available for bonding and to an amino acid that comprises the
inventive multispecific antibody of interest, which amino acid has
a valency available for bonding. The available bonding site may
conveniently comprise a side chain of an amino acid (e.g., a
lysine, cysteine, or aspartic acid side chain, and homologs
thereof). In some embodiments, the available bonding site in the
analog is the side chain of a lysine or a cysteine residue. In some
embodiments, the available bonding site in the analog is the
N-terminal amine of a polypeptide comprising the analog. In some
embodiments, the available bonding site in the analog is the
C-terminal carboxyl of a polypeptide comprising the analog. In some
embodiments, the available bonding site in the analog is a backbone
atom (e.g., a c-alpha carbon atom) of a polypeptide comprising the
analog.
[0314] Preferably, a linker moiety is employed to covalently attach
a VH or a VL to the C-terminus of a CH3 domain of an antibody
analog. A linker moiety may also be employed to covalently attach a
first VH or a first VL to a second VH or a second VL, respectively.
A linker moiety may also be employed to covalently attach a first
VH or a first VL to a second VL or a second VH, respectively. A
linker moiety may also be employed to covalently attach a VH of a
single chain antigen binding site, such as an scFv, to the VL of
such a single chain antigen binding site, and vice versa. A linker
moiety may also be employed to attach the VH or the VL of such a
single chain antigen binding site, such as an scFv, to a C-terminus
of a CH3 domain or variant thereof. A linker moiety may also be
employed to attach a VH to the N-terminus of a CL domain or to the
N-terminus of a CH2. A linker moiety may also be employed to attach
a VL to the N-terminus of a CL domain or to the N-terminus of a CH2
domain. As will be appreciated, combinations and/or multiples of
the foregoing may be employed in order to prepare any of the
multispecific antibodies of interest disclosed herein, such that a
plurality of antigen binding sites may be included in such analogs,
optionally with a multiple of specificities. Accordingly, a
multispecific antibody of interest may be generated by employing
one or more linkers to covalently attach one, two, three, four,
five, six, seven, or more VLs, VHs, and/or single chain antigen
binding sites, such as scFvs to the first polypeptide, the second
polypeptide, a VH, or a VL attached to the first polypeptide or the
second polypeptide, and the like, so as to generate an antibody
analog having bi-, tri-, tetra-, pent-, hexa-, hepta-, or
octa-valency, and so on, and/or bi-, tri-, tetra-, pent-, hexa-,
hepta-, or octa-specificity, and so on.
[0315] Accordingly, in certain embodiments, the multispecific
antibody of interest comprises a first VL that is covalently
attached to the CH3 domain, or variant thereof, of the first heavy
chain of the analog via a linker moiety, forming the second antigen
binding site. In additional embodiments, the multispecific antibody
of interest comprises a first VH that is covalently attached to the
CH3 domain, or variant thereof, of the Fc region of the analog via
a linker moiety, thereby forming the second antigen binding
site.
[0316] In further embodiments, the multispecific antibody of
interest comprises a third antigen binding site, wherein the third
antigen binding site is covalently attached via a linker moiety to
either the first VL or the first VH. In still further embodiments,
the third antigen binding site comprises a single chain antigen
binding site, such single chain variable region (scFv), wherein the
scFv comprises a second VL that is covalently attached to a second
VH via a linker moiety or wherein the second VL is covalently
attached to the second VH via a linker moiety.
[0317] In further embodiments, the inventive multispecific
antibodies of interest further comprise additional binding sites,
such as a fourth antigen binding site, a fifth antigen binding
site, a sixth antigen binding site, and so on, wherein one or more
of which may comprise a single chain antigen binding site, such as
an scFv, which are attached via linker moieties to the other VLs
and/or VHs of the multispecific antibody of interest.
[0318] In certain embodiments the linker moieties comprise amino
acids that are selected from glycine, alanine, proline, asparagine,
glutamine, lysine, aspartate, and glutamate. In a further
embodiment the linker moiety is made up of a majority of amino
acids that are sterically unhindered, such as glycine, alanine
and/or serine. In certain embodiments the linker moiety is
comprises a sequence selected from the group [Gly-Ser].sub.n (SEQ
ID NO: 1); [Gly-Gly-Ser].sub.n (SEQ ID NO: 2);
[Gly-Gly-Gly-Ser].sub.n (SEQ ID NO: 3); [Gly-Gly-Gly-Gly-Ser].sub.n
(SEQ ID NO: 4); [Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n (SEQ ID
NO: 5);
[Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n
(SEQ ID NO: 6); [Gly-Gly-Gly-Gly-Ser
Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n (SEQ
ID NO: 7);
[Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly--
Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n (SEQ ID NO: 8);
[Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly--
Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n (SEQ ID NO: 9);
[Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly--
Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n(SEQ
ID NO: 10); and combinations thereof; where n is an integer
selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,
44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60,
61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, and 75.
[0319] Such linkers may comprise: an acidic linker, a basic linker,
and a structural motif, or combinations thereof; a polyglycine, a
polyalanine, poly(Gly-Ala), or poly(Gly-Ser); (Gly)3, (Gly)4 (SEQ
ID NO: 11), or (Gly)5 (SEQ ID NO: 12); (Gly).sub.3Lys(Gly).sub.4
(SEQ ID NO: 13), (Gly).sub.3AsnGlySer(Gly).sub.2 (SEQ ID NO: 14),
(Gly).sub.3Cys(Gly).sub.4 (SEQ ID NO: 15), or GlyProAsnGlyGly (SEQ
ID NO: 16), [Gly-Ser].sub.n (SEQ ID NO: 1), [Gly-Gly-Ser].sub.n
(SEQ ID NO: 2), [Gly-Gly-Gly-Ser].sub.n (SEQ ID NO: 3),
[Gly-Gly-Gly-Gly-Ser].sub.n (SEQ ID NO: 4),
[Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n (SEQ ID NO: 5),
[Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n
(SEQ ID NO: 6), [Gly-Gly-Gly-Gly-Ser
Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n (SEQ
ID NO: 7),
[Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly--
Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n (SEQ ID NO: 8),
[Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly--
Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n (SEQ ID NO: 9),
or
[Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly--
Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly].sub.n
(SEQ ID NO: 10); [Gly-Glu].sub.n (SEQ ID NO: 17),
[Gly-Gly-Glu].sub.n (SEQ ID NO: 18), [Gly-Gly-Gly-Glu].sub.n (SEQ
ID NO: 19), [Gly-Gly-Gly-Gly-Glu].sub.n (SEQ ID NO: 20), [Gly-Asp]n
(SEQ ID NO: 21); [Gly-Gly-Asp].sub.n (SEQ ID NO: 22),
[Gly-Gly-Gly-Asp].sub.n (SEQ ID NO: 23),
[Gly-Gly-Gly-Gly-Asp].sub.n (SEQ ID NO: 24); where n is an integer
selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,
44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60,
61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, and 75.
[0320] In certain embodiments, charged linker moieties are
employed. Such charges linker moieties may contain a significant
number of acidic residues (e.g., Asp, Glu, and the like), or may
contain a significant number of basis residues (e.g., Lys, Arg, and
the like), such that the linker moiety has a pi lower than 7 or
greater than 7, respectively. As understood by the artisan, and all
other things being equal, the greater the relative amount of acidic
or basic residues in a given linker moiety, the lower or higher,
respectively, the pI of the linker moiety will be. Such linker
moieties may impart advantages to the multispecific antibodies of
interest disclosed herein, such as improving solubility and/or
stability characteristics of such polypeptides at a particular pH,
such as a physiological pH (e.g., between H 7.2 and pH 7.6,
inclusive), or a pH of a pharmaceutical composition comprising such
analogs, as well as allowing for optimization of characteristics
such as rotational and translational flexibility of the domains
and/or regions of the analog that are attached via the linker
moiety. Such characteristics may advantageously be optimized and
tailored for any given multispecific analog by the artisan.
[0321] For example, an "acidic linker" is a linker moiety that has
a pI of less than 7; between 6 and 7, inclusive; between 5 and 6,
inclusive; between 4 and 5, inclusive; between 3 and 4, inclusive;
between 2 and 3, inclusive; or between 1 and 2, inclusive.
Similarly, a "basic linker" is a linker moiety that has a pi of
greater than 7; between 7 and 8, inclusive; between 8 and 9,
inclusive; between 9 and 10, inclusive; between 10 and 11,
inclusive; between 11 and 12 inclusive, or between 12 and 13,
inclusive. In certain embodiments, an acidic linker will contain a
sequence that is selected from the group consisting of
[Gly-Glu].sub.n (SEQ ID NO: 17); [Gly-Gly-Glu].sub.n (SEQ ID NO:
18); [Gly-Gly-Gly-Glu].sub.n (SEQ ID NO: 19);
[Gly-Gly-Gly-Gly-Glu].sub.n (SEQ ID NO: 20); [Gly-Asp]n (SEQ ID NO:
21); [Gly-Gly-Asp].sub.n (SEQ ID NO: 22); [Gly-Gly-Gly-Asp].sub.n
(SEQ ID NO: 23); [Gly-Gly-Gly-Gly-Asp].sub.n (SEQ ID NO: 24); and
combinations thereof; where n is an integer selected from the group
consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,
33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49,
50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66,
67, 68, 69, 70, 71, 72, 73, 74, and 75. In certain embodiments, a
basic linker will contain a sequence that is selected from the
group consisting of [Gly-Lys].sub.n (SEQ ID NO: 25);
[Gly-Gly-Lys].sub.n (SEQ ID NO: 26); [Gly-Gly-Gly-Lys].sub.n (SEQ
ID NO: 27); [Gly-Gly-Gly-Gly-Lys].sub.n (SEQ ID NO: 28).sub.;
[Gly-Arg].sub.n (SEQ ID NO: 29); [Gly-Gly-Arg].sub.n (SEQ ID NO:
30); [Gly-Gly-Gly-Arg].sub.n (SEQ ID NO: 31);
[Gly-Gly-Gly-Gly-Arg].sub.n (SEQ ID NO: 32).sub.; and combinations
thereof; where n is an integer selected from the group consisting
of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,
53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69,
70, 71, 72, 73, 74, and 75.
[0322] Additionally, linker moieties may be employed which possess
certain structural motifs or characteristics, such as an alpha
helix. For example, such a linker moiety may contain a sequence
that is selected from the group consisting of
[Glu-Ala-Ala-Ala-Lys].sub.n (SEQ ID NO: 33), where n is 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56,
57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,
74, and 75: for example, [Glu-Ala-Ala-Ala-Lys].sub.3 (SEQ ID NO:
34), [Glu-Ala-Ala-Ala-Lys].sub.4 (SEQ ID NO: 35), or
[Glu-Ala-Ala-Ala-Lys].sub.5 (SEQ ID NO: 36), and so on.
[0323] In still further embodiments the each linker moiety employed
in the disclosed multispecific antibody of interest independently
comprises: polyglycine, polyalanine, poly(Gly-Ala), or
poly(Gly-Ser), (Gly)3, (Gly)4 (SEQ ID NO: 11), and (Gly)5 (SEQ ID
NO: 12), (Gly).sub.3Lys(Gly).sub.4 (SEQ ID NO: 13),
(Gly).sub.3AsnGlySer(Gly).sub.2 (SEQ ID NO: 14),
(Gly).sub.3Cys(Gly).sub.4 (SEQ ID NO: 15), and GlyProAsnGlyGly (SEQ
ID NO: 16), a combination of Gly and Ala, a combination of Gly and
Ser, a combination of, Gly and Glu, a combination of Gly and Asp, a
combination of Gly and Lys, or combinations thereof.
[0324] In certain embodiments, the inventive multispecific antibody
of interest comprises, for example, a CH2 domain variant and/or a
CH3 domain variant, wherein such variants each independently
comprise at least one different amino acid substitution such that a
heterodimeric domain pair is generated such that heterodimerization
of the first and second polypeptides of the inventive multispecific
antibody of interest is favored over homodimerization.
[0325] With regard to a "variant" of a domain or region of a
multispecific antibody of interest as used herein throughout, such
a variant refers a polypeptide sequence that comprises such a
domain or region, and that differs from that of a parent
polypeptide sequence by virtue of at least one amino acid
modification. The parent polypeptide sequence may be a naturally
occurring or wild-type (WT) polypeptide sequence, or may be a
modified version of a WT sequence. Preferably, the variant has at
least one amino acid modification compared to the parent
polypeptide, region, or domain, e.g. from about one to about ten
amino acid modifications, and preferably from about one to about
five amino acid modifications compared to the parent. The variant
polypeptide sequence herein will preferably possess at least about
80% homology with a parent sequence, and most preferably at least
about 90% homology, more preferably at least about 95%
homology.
[0326] By "parent polypeptide", "parent polypeptide sequence",
"parent protein", "precursor polypeptide", or "precursor protein"
as used herein is meant an unmodified polypeptide or polypeptide
sequence that is subsequently modified to generate a variant
polypeptide or polypeptide sequence. Said parent polypeptide may be
a naturally occurring polypeptide, or a variant or engineered
version of a naturally occurring polypeptide. Parent polypeptide
may refer to the polypeptide itself, compositions that comprise the
parent polypeptide, or the amino acid sequence that encodes it.
[0327] By "Fc variant" or "variant Fc" as used herein is meant an
Fc sequence that differs from that of a parent Fc sequence by
virtue of at least one amino acid modification. An Fc variant may
only encompass an Fc region, or may exist in the context of an
antibody, Fc fusion, isolated Fc, Fc fragment, or other polypeptide
that is substantially encoded by Fc. Fc variant may refer to the Fc
polypeptide itself, compositions comprising the Fc variant
polypeptide, or the amino acid sequence that encodes it.
[0328] By "Fc polypeptide variant" or "variant Fc polypeptide" as
used herein is meant an Fc polypeptide that differs from a parent
Fc polypeptide by virtue of at least one amino acid modification.
By "Fc variant antibody" or "antibody Fc variant" as used herein is
meant an antibody that differs from a parent antibody by virtue of
at least one amino acid modification in the Fc region.
[0329] By "protein variant" or "variant protein" as used herein is
meant a protein that differs from a parent protein by virtue of at
least one amino acid modification. By "antibody variant" or
"variant antibody" as used herein is meant an antibody that differs
from a parent antibody by virtue of at least one amino acid
modification. By "IgG variant" or "variant IgG" as used herein is
meant an antibody that differs from a parent IgG by virtue of at
least one amino acid modification. By "immunoglobulin variant" or
"variant immunoglobulin" as used herein is meant an immunoglobulin
sequence that differs from that of a parent immunoglobulin sequence
by virtue of at least one amino acid modification.
[0330] Interaction between heterodimeric pairs or disclosed
multispecific antibodies of interest comprising such heterodimeric
pairs may be promoted at the heterodimeric pair interface by the
formation of protuberance-into-cavity complementary regions at such
interfaces; the formation of non-naturally occurring disulfide
bonds at such interfaces; leucine zipper at such interfaces;
hydrophobic regions at such interfaces; and/or hydrophilic regions
at such interfaces. "Protuberances" are constructed by replacing
small amino acid side chains from the interface of the first
polypeptide with larger side chains (e.g. tyrosine or tryptophan).
Compensatory "cavities" of identical or similar size to the
protuberances are optionally created on the interface of the second
polypeptide by replacing large amino acid side chains with smaller
ones (e.g. alanine or threonine). Where a suitably positioned and
dimensioned protuberance or cavity exists at the interface of
either the first or second polypeptide, it is only necessary to
engineer a corresponding cavity or protuberance, respectively, at
the adjacent interface. Non-naturally occurring disulfide bonds are
constructed by replacing on the first polypeptide a naturally
occurring amino acid with a free thiol-containing residue, such as
cysteine, such that the free thiol interacts with another free
thiol-containing residue on the second polypeptide such that a
disulfide bond is formed between the first and second polypeptides
Exemplary heterodimerization pairs and methods for making such in
accordance with the present invention are available in the art, and
are disclosed, for example, in US 2011/0054151; US 2007/0098712;
and the like.
[0331] In certain embodiments, the heterodimeric pairs are
contained within the Fc region of the inventive multi specific
antibody of interest. Fc regions that contain such heterodimeric
pairs are referred to as "heterodimeric Fc regions".
[0332] Accordingly, in certain embodiments, multispecific
antibodies of interest comprise a CH2 and/or a CH3 domain variant,
wherein either: a) the CH2 domain variant and the CH3 domain
variant each independently comprises a at least one protuberance in
either the CH2 domain or the CH3 domain of the first polypeptide
and at least one corresponding cavity in the CH2 domain or the CH3
domain of the second; or the CH2 domain variant and the CH3 domain
variant each independently comprises at least one cavity in either
the CH2 domain or the CH3 domain of the first polypeptide and at
least one corresponding protuberance in the CH2 domain or the CH3
domain of the second polypeptide. In certain other embodiments, the
multispecific antibodies of interest comprise a CH2 and/or a CH3
domain variant, wherein either: a) the CH2 domain variant and the
CH3 domain variant each independently comprises at least one
substituted negatively-charged amino acid in either the CH2 domain
or the CH3 domain of the first polypeptide and at least one
corresponding positively-charged amino acid in either the CH2
domain or the CH3 domain of the second polypeptide; or b) the CH2
domain variant and the CH3 domain variant each independently
comprises at least one substituted positively-charged amino acid in
either the CH2 domain or the CH3 domain of the first polypeptide
and at least one corresponding substituted negatively-charged
substituted amino acid in either the CH2 domain or the CH3 domain
of the second polypeptide.
[0333] With regard to Fc function in "natural" antibodies (i.e.,
those antibodies generated in vivo via native biological antibody
synthesis by native B-cells), the Fc region of an antibody
interacts with a number of Fc receptors and ligands, imparting an
array of important functional capabilities referred to as effector
functions. For IgG the Fc region, Fc comprises Ig domains C.gamma.2
and C.gamma.3 and the N-terminal hinge leading into C.gamma.2. An
important family of Fc receptors for the IgG class is the Fc gamma
receptors (Fc.gamma.Rs). These receptors mediate communication
between antibodies and the cellular arm of the immune system
(Raghavan et al., 1996, Annu Rev Cell Dev Biol 12:181-220; Ravetch
et al., 2001, Annu Rev Immunol 19:275-290). In humans this protein
family includes Fc.gamma.RI (CD64), including isoforms
Fc.gamma.RIa, Fc.gamma.RIb, and Fc.gamma.RIc; Fc.gamma.RII (CD32),
including isoforms Fc.gamma.RIIa (including allotypes H131 and
R131), Fc.gamma.RIIb (including Fc.gamma.RIIb-1 and
Fc.gamma.RIIb-2), and Fc.gamma.RIIc; and Fc.gamma.RIII (CD16),
including isoforms Fc.gamma.RIIIa (including allotypes V158 and
F158) and Fc.gamma.RIIIb (including allotypes Fc.gamma.RIIIb-NA1
and Fc.gamma.RIIIb-NA2) (Jefferis et al., 2002, Immunol Lett
82:57-65). These receptors typically have an extracellular domain
that mediates binding to Fc, a membrane spanning region, and an
intracellular domain that may mediate some signaling event within
the cell. These receptors are expressed in a variety of immune
cells including monocytes, macrophages, neutrophils, dendritic
cells, eosinophils, mast cells, platelets, B cells, large granular
lymphocytes, Langerhans' cells, natural killer (NK) cells, and
.gamma..delta. T cells. Formation of the Fc/Fc.gamma.R complex
recruits these effector cells to sites of bound antigen, typically
resulting in signaling events within the cells and important
subsequent immune responses such as release of inflammation
mediators, B cell activation, endocytosis, phagocytosis, and
cytotoxic attack. The ability to mediate cytotoxic and phagocytic
effector functions is a potential mechanism by which antibodies
destroy targeted cells. The cell-mediated reaction wherein
nonspecific cytotoxic cells that express Fc.gamma.Rs recognize
bound antibody on a target cell and subsequently cause lysis of the
target cell is referred to as antibody dependent cell-mediated
cytotoxicity (ADCC) (Raghavan et al., 1996, Annu Rev Cell Dev Biol
12:181-220; Ghetie et al., 2000, Annu Rev Immunol 18:739-766;
Ravetch et al., 2001, Annu Rev Immunol 19:275-290). The
cell-mediated reaction wherein nonspecific cytotoxic cells that
express Fc.gamma.Rs recognize bound antibody on a target cell and
subsequently cause phagocytosis of the target cell is referred to
as antibody dependent cell-mediated phagocytosis (ADCP).
[0334] The different IgG subclasses have different affinities for
the Fc.gamma.Rs, with IgG1 and IgG3 typically binding substantially
better to the receptors than IgG2 and IgG4 (Jefferis et al., 2002,
Immunol Lett 82:57-65). The Fc.gamma.Rs bind the IgG Fc region with
different affinities. The extracellular domains of Fc.gamma.RIIIa
and Fc.gamma.RIIIb are 96% identical; however Fc.gamma.RIIIb does
not have an intracellular signaling domain. Furthermore, whereas
Fc.gamma.RI, Fc.gamma.RIIa/c, and Fc.gamma.RIIIa are positive
regulators of immune complex-triggered activation, characterized by
having an intracellular domain that has an immunoreceptor
tyrosine-based activation motif (ITAM), Fc.gamma.RIIb has an
immunoreceptor tyrosine-based inhibition motif (ITIM) and is
therefore inhibitory. Thus the former are referred to as activation
receptors, and Fc.gamma.RIIb is referred to as an inhibitory
receptor. Despite these differences in affinities and activities,
all Fc.gamma.Rs bind the same region on Fc, at the N-terminal end
of the C.gamma.2 domain and the preceding hinge.
[0335] An overlapping but separate site on Fc serves as the
interface for the complement protein C1q. In the same way that
Fc/Fc.gamma.R binding mediates ADCC, Fc/C1q binding mediates
complement dependent cytotoxicity (CDC). A site on Fc between the
C.gamma.2 and C.gamma.3 domains mediates interaction with the
neonatal receptor FcRn, the binding of which recycles endocytosed
antibody from the endosome back to the bloodstream (Raghavan et
al., 1996, Annu Rev Cell Dev Biol 12:181-220; Ghetie et al., 2000,
Annu Rev Immunol 18:739-76). This process, coupled with preclusion
of kidney filtration due to the large size of the full length
molecule, results in favorable antibody serum half-lives ranging
from one to three weeks. Binding of Fc to FcRn also plays a key
role in antibody transport. The binding site for FcRn on Fc is also
the site at which the bacterial proteins A and G bind. The tight
binding by these proteins is typically exploited as a means to
purify antibodies by employing protein A or protein G affinity
chromatography during protein purification. The fidelity of these
regions, the complement and FcRn/protein A binding regions are
important for both the clinical properties of antibodies and their
development.
[0336] A particular feature of the Fc region of "natural"
antibodies is the conserved N-linked glycosylation that occurs at
N297. This carbohydrate, or oligosaccharide as it is sometimes
referred, plays a critical structural and functional role for the
antibody, and is one of the principle reasons that antibodies must
be produced using mammalian expression systems. Efficient Fc
binding to Fc.gamma.R and C1q requires this modification, and
alterations in the composition of the N297 carbohydrate or its
elimination affect binding to these proteins.
[0337] In some embodiments, the inventive multispecific antibodies
of interest disclosed herein comprise an Fc variant. An Fc variant
comprises one or more amino acid modifications relative to a parent
Fc polypeptide, wherein the amino acid modification(s) provide one
or more optimized properties. Fc variants further comprise either a
CH2 domain variant, a CH3 domain variant, or both a CH2 domain
variant and a CH3 domain variant. By "modification" herein is meant
an alteration in the physical, chemical, or sequence properties of
a protein, polypeptide, antibody, inventive multispecific antibody
of interest, or immunoglobulin. An amino acid modification can be
an amino acid substitution, insertion, and/or deletion in a
polypeptide sequence. By "amino acid substitution" or
"substitution" herein is meant the replacement of an amino acid at
a particular position in a parent polypeptide sequence with another
amino acid. For example, the substitution Y349T refers to a variant
polypeptide, in this case a constant heavy chain variant, in which
the tyrosine at position 349 is replaced with threonine. By "amino
acid insertion" or "insertion" as used herein is meant the addition
of an amino acid at a particular position in a parent polypeptide
sequence. By "amino acid deletion" or "deletion" as used herein is
meant the removal of an amino acid at a particular position in a
parent polypeptide sequence.
[0338] An Fc variant disclosed herein differs in amino acid
sequence from its parent by virtue of at least one amino acid
modification. The inventive multispecific antibodies of interest
disclosed herein may have more than one amino acid modification as
compared to the parent, for example from about one to fifty amino
acid modifications, e.g., from about one to ten amino acid
modifications, from about one to about five amino acid
modifications, etc. compared to the parent. Thus the sequences of
the Fc variants and those of the parent Fc polypeptide are
substantially homologous. For example, the variant Fc variant
sequences herein will possess about 80% homology with the parent Fc
variant sequence, e.g., at least about 90% homology, at least about
95% homology, at least about 98% homology, at least about 99%
homology, etc. Modifications disclosed herein also include
glycoform modifications. Modifications may be made genetically
using molecular biology, or may be made enzymatically or
chemically.
[0339] Fc variants disclosed herein are defined according to the
amino acid modifications that compose them. Thus, for example, the
substitution Y349T refers to a variant polypeptide, in this case a
constant heavy chain variant, in which the tyrosine at position 349
is replaced with threonine. Likewise, Y349T/T394F defines an Fc
variant with the substitutions Y349T and T394F relative to the
parent Fc polypeptide. The identity of the WT amino acid may be
unspecified, in which case the aforementioned variant is referred
to as 349T/394F. It is noted that the order in which substitutions
are provided is arbitrary, that is to say that, for example,
349T/394F is the same Fc variant as 394F/349T. Unless otherwise
noted, constant region and Fc positions discussed herein are
numbered according to the EU index or EU numbering scheme (Kabat et
al., 1991, Sequences of Proteins of Immunological Interest, 5th
Ed., United States Public Health Service, National Institutes of
Health, Bethesda). The EU index or EU index as in Kabat or EU
numbering scheme refers to the numbering of the EU antibody
(Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85).
[0340] In certain embodiments, the Fc variants disclosed herein are
based on human IgG sequences, and thus human IgG sequences are used
as the "base" sequences against which other sequences are compared,
including but not limited to sequences from other organisms, for
example rodent and primate sequences. Immunoglobulins may also
comprise sequences from other immunoglobulin classes such as IgA,
IgE, IgGD, IgGM, and the like. It is contemplated that, although
the Fc variants disclosed herein are engineered in the context of
one parent IgG, the variants may be engineered in or "transferred"
to the context of another, second parent IgG. This is done by
determining the "equivalent" or "corresponding" residues and
substitutions between the first and second IgG, typically based on
sequence or structural homology between the sequences of the first
and second IgGs. In order to establish homology, the amino acid
sequence of a first IgG outlined herein is directly compared to the
sequence of a second IgG. After aligning the sequences, using one
or more of the homology alignment programs known in the art (for
example using conserved residues as between species), allowing for
necessary insertions and deletions in order to maintain alignment
(i.e., avoiding the elimination of conserved residues through
arbitrary deletion and insertion), the residues equivalent to
particular amino acids in the primary sequence of the first
immunoglobulin are defined. Alignment of conserved residues may
conserve 100% of such residues. However, alignment of greater than
75% or as little as 50% of conserved residues is also adequate to
define equivalent residues. Equivalent residues may also be defined
by determining structural homology between a first and second IgG
that is at the level of tertiary structure for IgGs whose
structures have been determined. In this case, equivalent residues
are defined as those for which the atomic coordinates of two or
more of the main chain atoms of a particular amino acid residue of
the parent or precursor (N on N, CA on CA, C on C and O on O) are
within about 0.13 nm, after alignment. In another embodiment,
equivalent residues are within about 0.1 nm after alignment.
Alignment is achieved after the best model has been oriented and
positioned to give the maximum overlap of atomic coordinates of
non-hydrogen protein atoms of the proteins. Regardless of how
equivalent or corresponding residues are determined, and regardless
of the identity of the parent IgG in which the IgGs are made, what
is meant to be conveyed is that the Fc variants discovered as
disclosed herein may be engineered into any second parent IgG that
has significant sequence or structural homology with the Fc
variant. Thus for example, if a variant antibody is generated
wherein the parent antibody is human IgG1, by using the methods
described above or other methods for determining equivalent
residues, the variant antibody may be engineered in another IgG1
parent antibody that binds a different antigen, a human IgG2 parent
antibody, a human IgA parent antibody, a mouse IgG2a or IgG2b
parent antibody, and the like. Again, as described above, the
context of the parent Fc variant does not affect the ability to
transfer the Fc variants disclosed herein to other parent IgGs.
[0341] Fc variants that comprise or are CH3 domain variants as
described above may comprise at least one substitution at a
position in a CH3 domain selected from the group consisting of 349,
351, 354, 356, 357, 364, 366, 368, 370, 392, 394, 395, 396, 397,
399, 401, 405, 407, 409, 411, and 439, wherein numbering is
according to the EU index as in Kabat. In a preferred embodiment,
CH3 domain variants comprise at least one CH3 domain substitution
per heavy chain selected from the group consisting of 349A, 349C,
349E, 349I, 349K, 349S, 349T, 349W, 351 E, 351K, 354C, 356K, 357K,
364C, 364D, 364E, 364F, 364G, 364H, 364R, 364T, 364Y, 366D, 366K,
366S, 366W, 366Y, 368A, 368E, 368K, 368S, 370C, 370D, 370E, 370G,
370R, 370S, 370V, 392D, 392E, 394F, 394S, 394W, 394Y, 395T, 395V,
396T, 397E, 397S, 397T, 399K, 401 K, 405A, 405S, 407T, 407V, 409D,
409E, 411 D, 411 E, 411K, and 439D. Each of these variants can be
used individually or in any combination for each heavy chain Fc
region. As will be appreciated by those in the art, each heavy
chain can comprise different numbers of substitutions. For example,
both heavy chains that make up the Fc region may comprise a single
substitution, one chain may comprise a single substitution and the
other two substitutions, both can contain two substitutions
(although each chain will contain different substitutions),
etc.
[0342] In some embodiments, the CH2 and/or CH3 domain variants are
made in combinations, that is, two or more variants per heavy chain
Fc domain, selected from the group outlined above.
[0343] Other CH2 and/or CH3 domain variants that favor
heterodimerization that may be employed in the design and
preparation of the inventive multispecific antibodies of interest
of the invention are provided in, for example, Ridgeway et al.,
1996, Protein Engineering 9[7]:617-621; U.S. Pat. No. 5,731,168;
Xie et al., 2005, J Immunol Methods 296:95-101; Davis et al., 2010,
Protein Engineering, Design & Selection 23[4]:195-202;
Gunasekaran et al., 2010, J Biol Chem 285[25]:1937-19646; and
PCT/US2009/000071 (published as WO 2009/089004).
[0344] The Fc variants disclosed herein may be optimized for
improved or reduced binding to Fc receptors or Fc ligands. By "Fc
receptor" or "Fc ligand" as used herein is meant a molecule,
preferably a polypeptide, from any organism that binds to the Fc
region of an antibody to form an Fc-ligand complex. Fc ligands
include but are not limited to Fc.gamma.Rs, (as described above,
including but not limited to Fc.gamma.RIIIa, Fc.gamma.RIIa,
Fc.gamma.RIIb, Fc.gamma.RI and FcRn), C1q, C3, mannan binding
lectin, mannose receptor, staphylococcal protein A, streptococcal
protein G, and viral Fc.gamma.R. Fc ligands also include Fc
receptor homologs (FcRH), which are a family of Fc receptors that
are homologous to the Fc.gamma.Rs. Fc ligands may include
undiscovered molecules that bind Fc.
[0345] The inventive multispecific antibodies of interest may be
designed to optimize properties, including but are not limited to
enhanced or reduced affinity for an Fc receptor. By "greater
affinity" or "improved affinity" or "enhanced affinity" or "better
affinity" than a parent Fc polypeptide, as used herein, is meant
that an Fc variant binds to an Fc receptor with a significantly
higher equilibrium constant of association (KA or K.sub.a) or lower
equilibrium constant of dissociation (KD or K.sub.d) than the
parent Fc polypeptide when the amounts of variant and parent
polypeptide in the binding assay are essentially the same. For
example, the Fc variant with improved Fc receptor binding affinity
may display from about 5 fold to about 1000 fold, e.g. from about
10 fold to about 500 fold improvement in Fc receptor binding
affinity compared to the parent Fc polypeptide, where Fc receptor
binding affinity is determined, for example, by the binding methods
disclosed herein, including but not limited to Biacore, by one
skilled in the art. Accordingly, by "reduced affinity" as compared
to a parent Fc polypeptide as used herein is meant that an Fc
variant binds an Fc receptor with significantly lower KA or higher
KD than the parent Fc polypeptide. Greater or reduced affinity can
also be defined relative to an absolute level of affinity.
[0346] In one embodiment, particularly useful Fc modifications for
the present invention are variants that reduce or ablate binding to
one or more Fc.gamma.Rs and/or complement proteins, thereby
reducing or ablating Fc-mediated effector functions such as ADCC,
ADCP, and CDC. Such variants are also referred to herein as
"knockout variants" or "KO variants". Variants that reduce binding
to Fc.gamma.Rs and complement are useful for reducing unwanted
interactions mediated by the Fc region and for tuning the
selectivity of the inventive multi specific antibody of interest.
Preferred knockout variants are described in U.S. Ser. No.
11/981,606, filed Oct. 31, 2007, entitled "Fc Variants with
Optimized Properties". Preferred modifications include but are not
limited substitutions, insertions, and deletions at positions 234,
235, 236, 237, 267, 269, 325, and 328, wherein numbering is
according to the EU index. Preferred substitutions include but are
not limited to 234G, 235G, 236R, 237K, 267R, 269R, 325L, and 328R,
wherein numbering is according to the EU index. A preferred variant
comprises 236R/328R. Variants may be used in the context of any IgG
isotype or IgG isotype Fc region, including but not limited to
human IgG1, IgG2, IgG3, and/or IgG4 and combinations thereof.
Preferred IgG Fc regions for reducing Fc.gamma.R and complement
binding and reducing Fc-mediated effector functions are IgG2 and
IgG4 Fc regions. Hybrid isotypes may also be useful, for example
hybrid IgG1/IgG2 isotypes as described in US 2006-0134105. Other
modifications for reducing Fc.gamma.R and complement interactions
include but are not limited to substitutions 297A, 234A, 235A,
237A, 318A, 228P, 236E, 268Q, 309L, 330S, 331S, 220S, 226S, 229S,
238S, 233P, and 234V, as well as removal of the glycosylation at
position 297 by mutational or enzymatic means or by production in
organisms such as bacteria that do not glycosylate proteins. These
and other modifications are reviewed in Strohl, 2009, Current
Opinion in Biotechnology 20:685-691.
[0347] Fc modifications that improve binding to Fc.gamma.Rs and/or
complement are also amenable to incorporation in the design and
preparation of the inventive multispecific antibodies of interest
disclosed herein. Such Fc variants may enhance Fc-mediated effector
functions such as ADCC, ADCP, and/or CDC. Preferred modifications
for improving Fc.gamma.R and complement binding are described in,
e.g., U.S. Pat. No. 8,188,231 and US 2006-0235208. Preferred
modifications comprise a substitution at a position selected from
the group consisting of 236, 239, 268, 324, and 332, wherein
numbering is according to the EU index. Preferred substitutions
include but are not limited to 236A, 239D, 239E, 268D, 267E, 268E,
268F, 324T, 332D, and 332E. Preferred variants include but are not
limited to 239D/332E, 236A/332E, 236A/239D/332E, 268F/324T
267E/268F, 267E/324T, and 267E/268F/324T. Other modifications for
enhancing Fc.gamma.R and complement interactions include but are
not limited to substitutions 298A, 333A, 334A, 326A, 2471, 339D,
339Q, 280H, 290S, 298D, 298V, 243L, 292P, 300L, 396L, 3051, and
396L. These and other modifications are reviewed in Strohl, 2009,
ibid.
[0348] In one embodiment, the inventive multispecific antibodies of
interest disclosed herein may incorporate Fc variants that enhance
affinity for an inhibitory receptor Fc.gamma.RIIb. Such variants
may provide the inventive multispecific antibodies of interest
herein with immunomodulatory activities related to
Fc.gamma.RIIb.sup.+ cells, including for example B cells and
monocytes. In one embodiment, the Fc variants provide selectively
enhanced affinity to Fc.gamma.RIIb relative to one or more
activating receptors. Modifications for altering binding to
Fc.gamma.RIIb are described in U.S. Pat. No. 8,063,187, filed May
30, 2008, entitled "Methods and Compositions for Inhibiting CD32b
Expressing Cells". In particular, Fc variants that improve binding
to Fc.gamma.RIIb may include one or more modifications at a
position selected from the group consisting of 234, 235, 236, 237,
239, 266, 267, 268, 325, 326, 327, 328, and 332, according to the
EU index. Preferable substitutions for enhancing Fc.gamma.RIIb
affinity include but are not limited to 234D, 234E, 234W, 235D,
235F, 235R,235Y, 236D, 236N, 237D, 237N, 239D, 239E, 266M, 267D,
267E, 268D, 268E, 327D, 327E, 328F, 328W, 328Y, and 332E. More
preferably, substitutions include but are not limited to 235Y,
236D, 239D, 266M, 267E, 268D, 268E, 328F, 328W, and 328Y. Preferred
Fc variants for enhancing binding to Fc.gamma.RIIb include but are
not limited to 235Y/267E, 236D/267E, 239D/268D, 239D/267E,
267E/268D, 267E/268E, and 267E/328F.
[0349] In some embodiments, the inventive multispecific antibodies
of interest disclosed herein may incorporate Fc variants that
improve FcRn binding. Such variants may enhance the in vivo
pharmacokinetic properties of the inventive multispecific
antibodies of interest. Preferred variants that increase binding to
FcRn and/or improve pharmacokinetic properties include but are not
limited to substitutions at positions 259, 308, 428, and 434,
including but not limited to for example 2591, 308F, 428L, 428M,
434S, 434H, 434F, 434Y, 434M, 428L/434S, 2591/308F and
2591/308F/428L (and others described in U.S. Ser. No. 12/341,769,
filed Dec. 22, 2008, entitled "Fc Variants with Altered Binding to
FcRn"). Other variants that increase Fc binding to FcRn include but
are not limited to: 250E, 250Q, 428L, 428F, 250Q/428L (Hinton et
al., 2004, J. Biol. Chem. 279(8): 6213-6216, Hinton et al. 2006
Journal of Immunology 176:346-356), 256A, 272A, 286A, 305A, 307A,
307Q, 311A, 312A, 376A, 378Q, 380A, 382A, 434A (Shields et al,
Journal of Biological Chemistry, 2001, 276(9):6591-6604), 252F,
252T, 252Y, 252W, 254T, 256S, 256R, 256Q, 256E, 256D, 256T, 309P,
311S, 433R, 433S, 433I, 433P, 433Q, 434H, 434F, 434Y,
252Y/254T/256E, 433K/434F/436H, 308T/309P/311S (Dall'Acqua et al.
Journal of Immunology, 2002, 169:5171-5180, Dall'Acqua et al.,
2006, Journal of Biological Chemistry 281:23514-23524). Other
modifications for modulating FcRn binding are described in Yeung et
al., 2010, J Immunol, 182:7663-7671.
[0350] The inventive multispecific antibodies of interest disclosed
herein can incorporate Fc modifications in the context of any IgG
isotype or IgG isotype Fc region, including but not limited to
human IgG1, IgG2, IgG3, and/or IgG4. The IgG isotype may be
selected such as to alter Fc.gamma.R- and/or complement-mediated
effector function(s). Hybrid IgG isotypes may also be useful. For
example, US Patent Publication No. 2006-0134105 describes a number
of hybrid IgG1/IgG2 constant regions that may find use in the
particular invention. In some embodiments of the invention,
inventive multispecific antibodies of interest may comprise means
for isotypic modifications, that is, modifications in a parent IgG
to the amino acid type in an alternate IgG. For example, an
IgG1/IgG3 hybrid variant may be constructed by a substitutional
means for substituting IgG1 positions in the CH2 and/or CH3 region
with the amino acids from IgG3 at positions where the two isotypes
differ. Thus a hybrid variant IgG antibody may be constructed that
comprises one or more substitutional means, e.g., 274Q, 276K, 300F,
339T, 356E, 358M, 384S, 392N, 397M, 4221, 435R, and 436F. In other
embodiments of the invention, an IgG1/IgG2 hybrid variant may be
constructed by a substitutional means for substituting IgG2
positions in the CH2 and/or CH3 region with amino acids from IgG1
at positions where the two isotypes differ. Thus a hybrid variant
IgG antibody may be constructed that comprises one or more
substitutional means, e.g., one or more of the following amino acid
substations: 233E, 234L, 235L, -236G (referring to an insertion of
a glycine at position 236), and 327A.
[0351] All antibodies contain carbohydrate at conserved positions
in the constant regions of the heavy chain. Each antibody isotype
has a distinct variety of N-linked carbohydrate structures. Aside
from the carbohydrate attached to the heavy chain, up to 30% of
human IgGs have a glycosylated Fab region. IgG has a single
N-linked biantennary carbohydrate at Asn297 of the CH2 domain. For
IgG from either serum or produced ex vivo in hybridomas or
engineered cells, the IgG are heterogeneous with respect to the
Asn297 linked carbohydrate. For human IgG, the core oligosaccharide
normally consists of GlcNAc2Man3GlcNAc, with differing numbers of
outer residues.
[0352] The inventive multispecific antibodies of interest herein
may also comprise carbohydrate moieties, which moieties will be
described with reference to commonly used nomenclature for the
description of oligosaccharides. A review of carbohydrate chemistry
which uses this nomenclature is found in Hubbard et al. 1981, Ann.
Rev. Biochem. 50:555-583. This nomenclature includes, for instance,
Man, which represents mannose; GlcNAc, which represents
2-N-acetylglucosamine; Gal which represents galactose; Fuc for
fucose; and Glc, which represents glucose. Sialic acids are
described by the shorthand notation NeuNAc, for
5-N-acetylneuraminic acid, and NeuNGc for 5-glycolylneuraminic.
[0353] The term "glycosylation" means the attachment of
oligosaccharides (carbohydrates containing two or more simple
sugars linked together e.g. from two to about twelve simple sugars
linked together) to a glycoprotein. The oligosaccharide side chains
are typically linked to the backbone of the glycoprotein through
either N- or O-linkages. The oligosaccharides of inventive
multispecific antibodies of interest disclosed herein occur
generally are attached to a CH2 domain of an Fc region as N-linked
oligosaccharides. "N-linked glycosylation" refers to the attachment
of the carbohydrate moiety to an asparagine residue in a
glycoprotein chain. The skilled artisan will recognize that, for
example, each of murine IgG1, IgG2a, IgG2b and IgG3 as well as
human IgG1, IgG2, IgG3, IgG4, IgA and IgD CH2 domains have a single
site for N-linked glycosylation at residue 297.
[0354] For the purposes herein, a "mature core carbohydrate
structure" refers to a processed core carbohydrate structure
attached to an Fc region which generally consists of the following
carbohydrate structure GlcNAc(Fucose)-GlcNAc-Man-(Man-GlcNAc).sub.2
typical of biantennary oligosaccharides. The mature core
carbohydrate structure is attached to the Fc region of the
glycoprotein, generally via N-linkage to Asn297 of a CH2 domain of
the Fc region. A "bisecting GlcNAc" is a GlcNAc residue attached to
the .alpha.1,4 mannose of the mature core carbohydrate structure.
The bisecting GlcNAc can be enzymatically attached to the mature
core carbohydrate structure by a
.alpha.(1,4)-N-acetylglucosaminyltransferase III enzyme (GnTIII).
CHO cells do not normally express GnTIII (Stanley et al., 1984, J.
Biol. Chem. 261:13370-13378), but may be engineered to do so (Umana
et al., 1999, Nature Biotech. 17:176-180).
[0355] Described herein are multispecific antibodies of interest
that comprise modified glycoforms or engineered glycoforms. By
"modified glycoform" or "engineered glycoform" as used herein is
meant a carbohydrate composition that is covalently attached to a
protein, for example an antibody, wherein said carbohydrate
composition differs chemically from that of a parent protein.
Engineered glycoforms may be useful for a variety of purposes,
including but not limited to enhancing or reducing
Fc.gamma.R-mediated effector function. In one embodiment, the
inventive multispecific antibodies of interest disclosed herein are
modified to control the level of fucosylated and/or bisecting
oligosaccharides that are covalently attached to the Fc region.
[0356] A variety of methods are well known in the art for
generating modified glycoforms (Umana et al., 1999, Nat Biotechnol
17:176-180; Davies et al., 2001, Biotechnol Bioeng 74:288-294;
Shields et al., 2002, J Biol Chem 277:26733-26740; Shinkawa et al.,
2003, J Biol Chem 278:3466-3473; U.S. Ser. No. 12/434,533). These
techniques control the level of fucosylated and/or bisecting
oligosaccharides that are covalently attached to the Fc region, for
example by expressing an IgG in various organisms or cell lines,
engineered or otherwise (for example Lec-13 CHO cells or rat
hybridoma YB2/0 cells), by regulating enzymes involved in the
glycosylation pathway (for example FUT8
[.alpha.-1,6-fucosyltransferase] and/or
.beta.1-4-N-acetylglucosaminyltransferase III [GnTIII]), by
modifying carbohydrate(s) after the IgG has been expressed, or by
expressing antibody in the presence of fucose analogs as enzymatic
inhibitors. Other methods for modifying glycoforms of the inventive
multispecific antibodies of interest disclosed herein include using
glycoengineered strains of yeast (Li et al., 2006, Nature
Biotechnology 24(2):210-215), moss (Nechansky et al., 2007, Mol
Immunol 44(7):1826-8), and plants (Cox et al., 2006, Nat Biotechnol
24(12):1591-7). The use of a particular method to generate a
modified glycoform is not meant to constrain embodiments to that
method. Rather, embodiments disclosed herein encompass inventive
multispecific antibodies of interest with modified glycoforms
irrespective of how they are produced.
[0357] In one embodiment, the inventive multispecific antibodies of
interest disclosed herein are glycoengineered to alter the level of
sialylation. Higher levels of sialylated Fc glycans in
immunoglobulin G molecules can adversely impact functionality
(Scallon et al., 2007, Mol. Immunol. 44(7):1524-34), and
differences in levels of Fc sialylation can result in modified
anti-inflammatory activity (Kaneko et al., 2006, Science
313:670-673). Because antibodies may acquire anti-inflammatory
properties upon sialylation of Fc core polysaccharide, it may be
advantageous to glycoengineer the inventive multispecific
antibodies of interest disclosed herein for greater or reduced Fc
sialic acid content.
[0358] "Engineered glycoform" typically refers to the different
carbohydrate or oligosaccharide; thus for example an immunoglobulin
may comprise an engineered glycoform. In one embodiment, a
composition disclosed herein comprises a glycosylated inventive
multi specific antibody of interest having an Fc region, wherein
about 51-100% of the glycosylated antibody, e.g., 80-100%, 90-100%,
95-100%, etc. of the antibody in the composition comprises a mature
core carbohydrate structure which lacks fucose. In another
embodiment, the antibody in the composition both comprises a mature
core carbohydrate structure that lacks fucose and additionally
comprises at least one amino acid modification in the Fc region. In
an alternative embodiment, a composition comprises a glycosylated
inventive multispecific antibody of interest having an Fc region,
wherein about 51-100% of the glycosylated antibody, 80-100%, or
90-100%, of the antibody in the composition comprises a mature core
carbohydrate structure which lacks sialic acid. In another
embodiment, the antibody in the composition both comprises a mature
core carbohydrate structure that lacks sialic acid and additionally
comprises at least one amino acid modification in the Fc region. In
yet another embodiment, a composition comprises a glycosylated
inventive multispecific antibody of interest having an Fc region,
wherein about 51-100% of the glycosylated antibody, 80-100%, or
90-100%, of the antibody in the composition comprises a mature core
carbohydrate structure which contains sialic acid. In another
embodiment, the antibody in the composition both comprises a mature
core carbohydrate structure that contains sialic acid and
additionally comprises at least one amino acid modification in the
Fc region. In another embodiment, the combination of engineered
glycoform and amino acid modification provides optimal Fc receptor
binding properties to the antibody.
[0359] The inventive multispecific antibodies of interest disclosed
herein may comprise one or more modifications that provide
additional optimized properties. Said modifications may be amino
acid modifications, or may be modifications that are made
enzymatically or chemically. Such modification(s) likely provide
some improvement in the inventive multispecific antibody of
interest, for example an enhancement in its stability, solubility,
function, or clinical use. Disclosed herein are a variety of
improvements that may be made by coupling the inventive
multispecific antibodies of interest disclosed herein with
additional modifications.
[0360] In one embodiment, at least one variable region of
multispecific antibody of interest disclosed herein may be affinity
matured, that is to say that amino acid modifications have been
made in the VH and/or VL domains to enhance binding of the antibody
to its target antigen. Such types of modifications may improve the
association and/or the dissociation kinetics for binding to the
target antigen. Other modifications include those that improve
selectivity for target antigen vs. alternative targets. These
include modifications that improve selectivity for antigen
expressed on target vs. non-target cells. Inventive multispecific
antibodies of interest disclosed herein may comprise one or more
modifications that provide reduced or enhanced internalization of
an inventive multispecific antibody of interest.
[0361] In other embodiments, modifications are made to improve
biophysical properties of the inventive multispecific antibodies of
interest disclosed herein, including but not limited to stability,
solubility, and oligomeric state. Modifications can include, for
example, substitutions that provide more favorable intramolecular
interactions in the inventive multispecific antibody of interest
such as to provide greater stability, or substitution of exposed
nonpolar amino acids with polar amino acids for higher solubility.
Other modifications to the inventive multispecific antibodies of
interest disclosed herein include those that enable the specific
formation or homodimeric or homomultimeric molecules. Such
modifications include but are not limited to engineered disulfides,
as well as chemical modifications or aggregation methods.
[0362] In further embodiments, the inventive multispecific
antibodies of interest disclosed herein comprise modifications that
remove proteolytic degradation sites. These may include, for
example, protease sites that reduce production yields, as well as
protease sites that degrade the administered protein in vivo. In
one embodiment, additional modifications are made to remove
covalent degradation sites such as deamidation (i.e. deamidation of
glutaminyl and asparaginyl residues to the corresponding glutamyl
and aspartyl residues), oxidation, and proteolytic degradation
sites. Deamidation sites that are particular useful to remove are
those that have enhance propensity for deamidation, including, but
not limited to asparaginyl and glutamyl residues followed by
glycines (NG and QG motifs, respectively). In such cases,
substitution of either residue can significantly reduce the
tendency for deamidation. Common oxidation sites include methionine
and cysteine residues. Other covalent modifications, that can
either be introduced or removed, include hydroxylation of proline
and lysine, phosphorylation of hydroxyl groups of seryl or threonyl
residues, methylation of the "-amino groups of lysine, arginine,
and histidine side chains, acetylation of the N-terminal amine, and
amidation of any C-terminal carboxyl group. Additional
modifications also may include but are not limited to
posttranslational modifications such as N-linked or O-linked
glycosylation and phosphorylation.
[0363] Modifications may include those that improve expression
and/or purification yields from hosts or host cells commonly used
for production of biologics. These include, but are not limited to
various mammalian cell lines (e.g. CHO, HEK, COS, NIH LT3, Saos,
and the like), yeast cells, bacterial cells, and plant cells.
Additional modifications include modifications that remove or
reduce the ability of heavy chains to form inter-chain disulfide
linkages. Additional modifications include modifications that
remove or reduce the ability of heavy chains to form intra-chain
disulfide linkages.
[0364] The inventive multispecific antibodies of interest disclosed
herein may comprise modifications that include the use of unnatural
amino acids incorporated using, including but not limited to
methods described in Liu & Schultz, 2010, Annu Rev Biochem
79:413-444. In some embodiments, these modifications enable
manipulation of various functional, biophysical, immunological, or
manufacturing properties discussed above. In additional
embodiments, these modifications enable additional chemical
modification for other purposes.
[0365] Other modifications are contemplated herein. For example,
the inventive multispecific antibodies of interest may be linked to
one of a variety of nonproteinaceous polymers, e.g., polyethylene
glycol (PEG), polypropylene glycol, polyoxyalkylenes, or copolymers
of polyethylene glycol and polypropylene glycol. Additional amino
acid modifications may be made to enable specific or non-specific
chemical or posttranslational modification of the inventive
multispecific antibodies of interest. Such modifications, include,
but are not limited to PEGylation and glycosylation. Specific
substitutions that can be utilized to enable PEGylation include,
but are not limited to, introduction of novel cysteine residues or
unnatural amino acids such that efficient and specific coupling
chemistries can be used to attach a PEG or otherwise polymeric
moiety. Introduction of specific glycosylation sites can be
achieved by introducing novel N-X-T/S sequences into the inventive
multispecific antibodies of interest disclosed herein.
[0366] Modifications to reduce immunogenicity may include
modifications that reduce binding of processed peptides derived
from the parent sequence to MHC proteins. For example, amino acid
modifications would be engineered such that there are no or a
minimal number of immune epitopes that are predicted to bind, with
high affinity, to any prevalent MHC alleles. Several methods of
identifying MHC-binding epitopes in protein sequences are known in
the art and may be used to score epitopes in an antibody disclosed
herein.
[0367] Covalent modifications are included within the scope of
inventive multispecific antibodies of interest disclosed herein,
and are generally, but not always, done post-translationally. For
example, several types of covalent modifications can be introduced
into the molecule by reacting specific amino acid residues with an
organic derivatizing agent that is capable of reacting with
selected side chains or the N- or C-terminal residues. In some
embodiments, the covalent modification of the inventive
multispecific antibodies of interest disclosed herein comprises the
addition of one or more labels. The term "labeling group" means any
detectable label. In some embodiments, the labeling group is
coupled to the inventive multispecific antibody of interest via
spacer arms of various lengths to reduce potential steric
hindrance. Various methods for labeling proteins are known in the
art and may be used in generating inventive multispecific
antibodies of interest disclosed herein.
[0368] In certain embodiments, the inventive multispecific
antibodies of interest disclosed herein comprise "fusion proteins",
also referred to herein as "conjugates". The fusion partner or
conjugate partner can be proteinaceous or non-proteinaceous; the
latter generally being generated using functional groups on the
inventive multispecific antibody of interest and on the conjugate
partner. Conjugate and fusion partners may be any molecule,
including small molecule chemical compounds and polypeptides. For
example, a variety of conjugates and methods are described in Trail
et al., 1999, Curr. Opin. Immunol. 11:584-588. Possible conjugate
partners include but are not limited to cytokines, cytotoxic
agents, toxins, radioisotopes, chemotherapeutic agent,
anti-angiogenic agents, a tyrosine kinase inhibitors, and other
therapeutically active agents. In some embodiments, conjugate
partners may be thought of more as payloads, that is to say that
the goal of a conjugate is targeted delivery of the conjugate
partner to a targeted cell, for example a cancer cell or immune
cell, by the multispecific antibodies of interest. Thus, for
example, the conjugation of a toxin to a multispecific antibody of
interest targets the delivery of said toxin to cells expressing the
target antigen. As will be appreciated by one skilled in the art,
in reality the concepts and definitions of fusion and conjugate are
overlapping. The designation of a fusion or conjugate is not meant
to constrain it to any particular embodiment disclosed herein.
Rather, these terms are used to convey the broad concept that any
multispecific antibody of interest disclosed herein may be linked
genetically, chemically, or otherwise, to one or more polypeptides
or molecules to provide some desirable property.
[0369] Suitable conjugates include, but are not limited to, labels
as described below, drugs and cytotoxic agents including, but not
limited to, cytotoxic drugs (e.g., chemotherapeutic agents) or
toxins or active fragments of such toxins. Suitable toxins and
their corresponding fragments include diphtheria A chain, exotoxin
A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin,
enomycin and the like. Cytotoxic agents also include radiochemicals
made by conjugating radioisotopes to inventive multi specific
antibody of interest, or binding of a radionuclide to a chelating
agent that has been covalently attached to the inventive
multispecific antibody of interest. Additional embodiments utilize
calicheamicin, auristatins, geldanamycin, maytansine, and
duocarmycins and analogs. Antibody-drug conjugates are described in
Alley et al., 2010, Curr Opin Chem Biol 14[4]:529-37.
[0370] In certain embodiments, the inventive multispecific
antibodies of interest disclosed herein are fused or conjugated to
a cytokine. By "cytokine" as used herein is meant a generic term
for proteins released by one cell population that act on another
cell as intercellular mediators. For example, as described in
Penichet et al., 2001, J. Immunol. Methods 248:91-101, cytokines
may be fused to an inventive multispecific antibody of interest to
provide an array of desirable properties. Examples of such
cytokines are lymphokines, monokines, and traditional polypeptide
hormones. Included among the cytokines are growth hormone such as
human growth hormone, N-methionyl human growth hormone, and bovine
growth hormone; parathyroid hormone; thyroxine; insulin;
proinsulin; relaxin; prorelaxin; glycoprotein hormones such as
follicle stimulating hormone (FSH), thyroid stimulating hormone
(TSH), and luteinizing hormone (LH); hepatic growth factor;
fibroblast growth factor; prolactin; placental lactogen; tumor
necrosis factor-alpha and -beta; mullerian-inhibiting substance;
mouse gonadotropin-associated peptide; inhibin; activin; vascular
endothelial growth factor; integrin; thrombopoietin (TPO); nerve
growth factors such as NGF-beta; platelet-growth factor;
transforming growth factors (TGFs) such as TGF-alpha and TGF-beta;
insulin-like growth factor-I and -II; erythropoietin (EPO);
osteoinductive factors; interferons such as interferon-alpha, beta,
and -gamma; colony stimulating factors (CSFs) such as
macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and
granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1,
IL-1alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10,
IL-11, IL-12; IL-15, a tumor necrosis factor such as TNF-alpha or
TNF-beta; C5a; and other polypeptide factors including LIF and kit
ligand (KL). As used herein, the term cytokine includes proteins
from natural sources or from recombinant cell culture, and
biologically active equivalents of the native sequence
cytokines.
[0371] In further embodiments, the inventive multispecific
antibodies of interest disclosed herein may be conjugated to a
"receptor" (such streptavidin) for utilization in tumor
pretargeting wherein the analog-receptor conjugate is administered
to the patient, followed by removal of unbound conjugate from the
circulation using a clearing agent and then administration of a
"ligand" (e.g. avidin) which is conjugated to a cytotoxic agent
(e.g. a radionucleotide). In an alternate embodiment, the inventive
multispecific antibody of interest is conjugated or operably linked
to an enzyme in order to employ Antibody Dependent Enzyme Mediated
Prodrug Therapy (ADEPT). ADEPT may be used by conjugating or
operably linking the inventive multispecific antibody of interest
to a prodrug-activating enzyme that converts a prodrug (e.g. a
peptidyl chemotherapeutic agent.
[0372] Also disclosed herein are methods for producing and
experimentally testing the inventive multi specific antibodies of
interest. The disclosed methods are not meant to constrain
embodiments to any particular application or theory of operation.
Rather, the provided methods are meant to illustrate generally that
one or more multispecific antibodies of interest of the invention
may be produced and experimentally tested to obtain inventive
multispecific antibodies of interest. General methods for antibody
molecular biology, expression, purification, and screening are
described in Antibody Engineering, edited by Kontermann &
Dubel, Springer, Heidelberg, 2001; and Hayhurst & Georgiou,
2001, Curr Opin Chem Biol 5:683-689; Maynard & Georgiou, 2000,
Annu Rev Biomed Eng 2:339-76.
[0373] In one embodiment disclosed herein, nucleic acids are
created that encode the inventive multispecific antibodies of
interest, and that may then be cloned into host cells, such as
yeast cells or mammalian cells, expressed and assayed, if desired.
Thus, nucleic acids, and particularly DNA, may be made that encode
each protein sequence. These practices are carried out using
well-known procedures. For example, a variety of methods that may
find use in generating inventive multi specific antibodies of
interest disclosed herein are described in Molecular Cloning--A
Laboratory Manual, 3rd Ed. (Maniatis, Cold Spring Harbor Laboratory
Press, New York, 2001), and Current Protocols in Molecular Biology
(John Wiley & Sons). There are a variety of techniques that may
be used to efficiently generate DNA encoding inventive
multispecific antibodies of interest disclosed herein. Such methods
include but are not limited to gene assembly methods, PCR-based
method and methods which use variations of PCR, ligase chain
reaction-based methods, pooled oligo methods such as those used in
synthetic shuffling, error-prone amplification methods and methods
which use oligos with random mutations, classical site-directed
mutagenesis methods, cassette mutagenesis, and other amplification
and gene synthesis methods. As is known in the art, there are a
variety of commercially available kits and methods for gene
assembly, mutagenesis, vector subcloning, and the like, and such
commercial products find use in for generating nucleic acids that
encode inventive multispecific antibodies of interest.
[0374] The inventive multi specific antibodies of interest
disclosed herein may be produced by culturing a host cell
transformed with nucleic acid, e.g., expression vectors containing
nucleic acid encoding the first and second polypeptides of
inventive multispecific antibodies of interest, under the
appropriate conditions to induce or cause expression of the
polypeptides. The conditions appropriate for expression will vary
with the choice of the expression vector and the host cell, and
will be easily ascertained by one skilled in the art through
routine experimentation. A wide variety of appropriate host cells
may be used, including but not limited to mammalian cells,
bacteria, insect cells, yeast cells, and plant cells. For example,
a variety of cell lines that may find use in generating inventive
multispecific antibodies of interest disclosed herein are described
in the ATCC.RTM. cell line catalog, available from the American
Type Culture Collection.
[0375] In certain embodiments, the inventive multispecific
antibodies of interest are expressed in mammalian expression
systems, including systems in which the expression constructs are
introduced into the mammalian cells using virus such as retrovirus
or adenovirus. Any mammalian cells may be used, e.g., human, mouse,
rat, hamster, and primate cells. Suitable cells also include known
research cells, including but not limited to Jurkat T cells,
NIH3T3, CHO, BHK, COS, HEK293, PER C.6, HeLa, Sp2/0, NS0 cells and
variants thereof. In an alternative embodiment, library proteins
are expressed in bacterial cells. Bacterial expression systems are
well known in the art, and include Escherichia coli (E. coli),
Bacillus subtilis, Streptococcus cremoris, and Streptococcus
lividans. In alternate embodiments, inventive multi specific
antibodies of interest are produced in insect cells (e.g. Sf21/Sf9,
Trichoplusia ni Bti-Tn5b1-4) or yeast cells (e.g. S. cerevisiae,
Pichia, etc.). In an alternate embodiment, inventive multispecific
antibodies of interest are expressed in vitro using cell free
translation systems. In vitro translation systems derived from both
prokaryotic (e.g. E. coli) and eukaryotic (e.g. wheat germ, rabbit
reticulocytes) cells are available and may be chosen based on the
expression levels and functional properties of the protein of
interest. For example, as appreciated by those skilled in the art,
in vitro translation is required for some display technologies, for
example ribosome display. In addition, the inventive multispecific
antibodies of interest may be produced by chemical synthesis
methods. Also transgenic expression systems both animal (e.g. cow,
sheep or goat milk, embryonated hen's eggs, whole insect larvae,
etc.) and plant (e.g. corn, tobacco, duckweed, etc.)
[0376] The nucleic acids that encode the first and second
polypeptides of inventive multispecific antibodies of interest
disclosed herein may be incorporated into one or more expression
vectors, as appropriate, in order to express the encoded
polypeptides. A variety of expression vectors may be utilized for
protein expression. Expression vectors may comprise
self-replicating extra-chromosomal vectors or vectors which
integrate into a host genome. Expression vectors are constructed to
be compatible with the host cell type. Thus expression vectors
which find use in generating inventive multispecific antibodies of
interest disclosed herein include but are not limited to those
which enable protein expression in mammalian cells, bacteria,
insect cells, yeast cells, and in vitro systems. As is known in the
art, a variety of expression vectors are available, commercially or
otherwise, that may find use for expressing inventive multispecific
antibodies of interest disclosed herein.
[0377] Expression vectors typically comprise a protein or
polypeptide to be expressed, which is operably linked with control
or regulatory sequences, selectable markers, any fusion partners,
and/or additional elements. By "operably linked" herein is meant
that the nucleic acid is placed into a functional relationship with
another nucleic acid sequence. Generally, these expression vectors
include transcriptional and translational regulatory nucleic acid
operably linked to the nucleic acid encoding the inventive
multispecific antibody of interest, and are typically appropriate
to the host cell used to express the protein. In general, the
transcriptional and translational regulatory sequences may include
promoter sequences, ribosomal binding sites, transcriptional start
and stop sequences, translational start and stop sequences, and
enhancer or activator sequences. As is also known in the art,
expression vectors typically contain a selection gene or marker to
allow the selection of transformed host cells containing the
expression vector. Selection genes are well known in the art and
will vary with the host cell used.
[0378] The first and second polypeptides of the invention may each
be independently operably linked to a fusion partner to enable
targeting of the expressed polypeptide and/or multispecific
antibody of interest, purification, screening, display, and the
like. Fusion partners may be linked to the inventive multispecific
antibody of interest sequence via a linker sequences. The linker
sequence will generally comprise a small number of amino acids,
typically less than ten, although longer linkers may also be used.
Typically, linker sequences are selected to be flexible and
resistant to degradation. As will be appreciated by those skilled
in the art, any of a wide variety of sequences may be used as
linkers. For example, a common linker sequence comprises the amino
acid sequence GGGGS (SEQ ID NO: 37). A fusion partner may be a
targeting or signal sequence that directs inventive multispecific
antibody of interest and any associated fusion partners to a
desired cellular location or to the extracellular media. As is
known in the art, certain signaling sequences may target a protein
to be either secreted into the growth media, or into the
periplasmic space, located between the inner and outer membrane of
the cell. A fusion partner may also be a sequence that encodes a
peptide or protein that enables purification and/or screening. Such
fusion partners include but are not limited to polyhistidine tags
(His-tags) (for example H6 (SEQ ID NO: 38) and H10 (SEQ ID NO: 39)
or other tags for use with Immobilized Metal Affinity
Chromatography (IMAC) systems (e.g. Ni+2 affinity columns)), GST
fusions, MBP fusions, Strep-tag, the BSP biotinylation target
sequence of the bacterial enzyme BirA, and epitope tags which are
targeted by antibodies (for example c-myc tags, flag-tags, and the
like). As will be appreciated by those skilled in the art, such
tags may be useful for purification, for screening, or both. For
example, an inventive multispecific antibody of interest may be
purified using a His-tag by immobilizing it to a Ni+2 affinity
column, and then after purification the same His-tag may be used to
immobilize the antibody to a Ni+2 coated plate to perform an ELISA
or other binding assay (as described below). A fusion partner may
enable the use of a selection method to screen inventive
multispecific antibodies of interest (see below). Fusion partners
that enable a variety of selection methods are well-known in the
art.
[0379] For example, by fusing the members of an inventive
multispecific antibody of interest library to the gene III protein,
phage display can be employed. Fusion partners may enable inventive
multispecific antibodies of interest to be labeled. Alternatively,
a fusion partner may bind to a specific sequence on the expression
vector, enabling the fusion partner and associated inventive multi
specific antibody of interest to be linked covalently or
noncovalently with the nucleic acid that encodes them. The methods
of introducing exogenous nucleic acid into host cells are well
known in the art, and will vary with the host cell used. Techniques
include but are not limited to dextran-mediated transfection,
calcium phosphate precipitation, calcium chloride treatment,
polybrene mediated transfection, protoplast fusion,
electroporation, viral or phage infection, encapsulation of the
polynucleotide(s) in liposomes, and direct microinjection of the
DNA into nuclei. In the case of mammalian cells, transfection may
be either transient or stable.
Additional Non-Limiting, Exemplary Embodiments are as Follows
[0380] Embodiment 1. A method of purifying a multispecific antibody
of interest (MAI), wherein the MAI comprises a heterodimer
comprising a first heavy chain polypeptide comprising a first heavy
chain (HC) variable region and a second heavy chain polypeptide
comprising a second HC variable region, wherein the first and the
second variable regions have different antigen specificities and
different isoelectric points, the method comprising: [0381] i)
obtaining a composition comprising the MAI, a first parental
homodimeric antibody species comprising either at least one copy of
the first heavy chain polypeptide or at least two copies of the
first heavy chain polypeptide, and a second parental homodimeric
antibody species comprising either at least one copy of the second
heavy chain polypeptide or at least two copies of the second heavy
chain polypeptide; and [0382] ii) performing chromatography whereby
the MAI is separated from the first and the second parental
homodimeric antibody species; [0383] thereby purifying the MAI.
[0384] Embodiment 2. The method of Embodiment 1, wherein the
performing step ii) comprises: [0385] contacting the composition
with a chromatographic material forming a
composition-chromatographic material complex; and [0386] performing
an elution step wherein the chromatographic material-composition
complex is contacted with a sample of eluant that is capable of
eluting the MAI and parental homodimeric antibody species in a
pH-dependent manner.
[0387] Embodiment 3. The method of Embodiment 2, wherein the eluant
comprises at least two buffering agents that each have a different
negative log acid dissociation constant (pKa).
[0388] Embodiment 4. The method according to Embodiment 2 or
Embodiment 3, further comprising preparing or equilibrating either:
[0389] the composition; or [0390] the composition-chromatographic
material complex; [0391] in a first sample of the eluant at a
desired starting pH prior performing the elution step.
[0392] Embodiment 5. The method according to any one of Embodiments
2 through 4, further comprising flowing a volume of a second sample
of the eluant that is prepared at a desired ending pH through the
chromatographic material-composition complex.
[0393] Embodiment 6. The method according to any one of Embodiments
2 through 5, wherein a pH gradient is generated as the eluant flows
through the chromatographic material-composition complex.
[0394] Embodiment 7. The method according to any one of Embodiments
2 through 6, wherein a pH gradient is generated as the eluant flows
through the chromatographic material-composition complex, and
wherein the pH gradient comprises: [0395] (i) a step pH gradient
phase prior to a linear pH gradient phase; [0396] (ii) a step pH
gradient subsequent to a linear gradient phase; [0397] (iii) a
linear pH gradient phase with no step pH gradient phase at least
one linear pH gradient phase; or [0398] (iv) an essentially linear
pH gradient phase.
[0399] Embodiment 8 The method according to any one of Embodiments
2 through 7, wherein the MAI, the first parental homodimeric
antibody species, and the second parental homodimeric antibody
species elute from the chromatographic material in essentially
distinguishable elution volumes.
[0400] Embodiment 9. The method according to any one of Embodiments
2 through 8, wherein the eluant comprises either: [0401] at least
two; [0402] at least three; [0403] at least four; [0404] at least
five; [0405] at least six; [0406] at least seven; or [0407] eight;
[0408] of the following buffering agents:
Ncyclohexyl-3-aminopropanesulfonic acid (CAPS),
N-Cyclohexyl-2-aminoethanesulfonic acid (CHES),
N-Tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS),
N-(2-Hydroxyethyl)piperazine-N'-(2-hydroxypropanesulfonic acid)
(HEPPSO), 3-morpholino-2-hydroxypropanesulfonic acid sodium salt,
3-(N-morpholinyl)-2-hydroxypropanesulfonic acid (MOPSO),
2-(N-morpholino)ethanesulfonic acid (MES), acetic acid, and formic
acid; or [0409] at least two; [0410] at least three; [0411] at
least four; [0412] at least five; or [0413] at least six; of the
following buffering agents: methylamine, 1,2-ethanediamine,
1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine.
[0414] Embodiment 10. The method according to any one of
Embodiments 2 through 9, wherein the eluant comprises either:
[0415] (i) CAPS, CHES, TAPS, HEPPSO, MOPSO, MES, acetic acid, and
formic acid; or [0416] (ii) methylamine, 1,2-ethanediamine,
1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine.
[0417] Embodiment 11. The method according to any one of
Embodiments 2 through 10, wherein the eluant comprises: [0418] at
least two; [0419] at least three; [0420] at least four; [0421] at
least five; [0422] at least six; [0423] at least seven; or [0424]
eight; [0425] of the following buffering agents:
Ncyclohexyl-3-aminopropanesulfonic acid (CAPS),
N-Cyclohexyl-2-aminoethanesulfonic acid (CHES),
N-Tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS),
N-(2-Hydroxyethyl)piperazine-N'-(2-hydroxypropanesulfonic acid)
(HEPPSO), 3-morpholino-2-hydroxypropanesulfonic acid sodium salt,
3-(N-morpholinyl)-2-hydroxypropanesulfonic acid (MOPSO),
2-(N-morpholino)ethanesulfonic acid (MES), acetic acid, and formic
acid; [0426] with the proviso that the eluant does not include any
of the following: imidazole; piperazine,
tris(hydroxymethyl)aminomethane (TRIS).
[0427] Embodiment 12. The method according to any one of
Embodiments 2 through 11, wherein the eluant consists essentially
of: [0428] (i) CAPS; CHES; TAPS; HEPPSO; MOPSO; MES; acetic acid;
and formic acid; and optionally at least one salt; or [0429] (ii)
methylamine, 1,2-ethanediamine, 1-methylpiperazine,
1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt.
[0430] Embodiment 13. The method according to any one of
Embodiments 2 through 12, wherein the eluant consists of: [0431]
(i) CAPS; CHES; TAPS; HEPPSO; MOPSO; MES; acetic acid; and formic
acid; and at least one salt; or [0432] (ii) methylamine,
1,2-ethanediamine, 1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt and
optionally at least one salt.
[0433] Embodiment 14. The method according to any one of
Embodiments 2 through 13, wherein the eluant comprises at least one
salt selected from the group consisting of: NaCl, KCl, and
Na.sub.2SO.sub.4.
[0434] Embodiment 15. The method according to any one of
Embodiments 2 through 14, wherein each sample of the eluant
comprises at least one salt at a concentration range selected from
the group consisting of: 0 mM to about 100 mM; 0 mM to about 60 mM;
0 mM to about 50 mM; 0 mM to about 40 mM; 0 mM to about 30 mM; 0 mM
to about 20 mM; 0 mM to about 10 mM; 0 mM to about 5 mM; about 10
mM to about 200 mM; about 10 mM to about 100 mM; about 10 mM to
about 50 mM; about 10 mM to about 40 mM; about 10 mM to about 30
mM; about 10 mM to about 20 mM; about 20 mM to about 200 mM; about
20 mM to about 100 mM; about 20 mM to about 50 mM; about 20 mM to
about 30 mM; about 30 mM to about 200 mM; about 30 mM to about 100
mM; and about 30 mM to about 50 mM; and about 5 mM to about 15
mM.
[0435] Embodiment 16. The method according to any one of
Embodiments 2 through 15, wherein each sample of the eluant
comprises at least one salt at a concentration of about 10 mM.
[0436] Embodiment 17. The method according to any one of
Embodiments 2 through 16, wherein each sample of the eluant
comprises NaCl at a concentration of about 10 mM.
[0437] Embodiment 18. The method according to any one of
Embodiments 1 through 17, wherein either: [0438] a. the difference
in the actual isoelectric point of the first heavy chain
polypeptide and the actual isoelectric point of the second heavy
chain polypeptide is less than 7.0 pH units; less than 6.5 pH
units; less than 6.0 pH units; less than 5.5 pH units; less than
5.0 pH units; less than 4.5 pH units; less than 4.0 units; less
than 3.5 pH units; less than 2.5 pH units; less than 2.4 pH units;
less than 2.3 pH units; less than 2.2 pH units; less than 2.1 pH
units; less than 2.0 pH units; less than 1.9 pH units; less than
1.8 pH units; less than 1.7 pH units; less than 1.6 pH units; less
than 1.5 pH units; less than 1.4 pH units; less than 1.3 pH units,
less than 1.2 pH units; less than 1.1 pH units; less than 1.0 pH
unit; less than 0.95 pH unit; less than 0.90 pH unit; less than
0.85 pH unit; less than 0.80 pH unit; less than 0.75 pH unit; less
than 0.70 pH unit; less than 0.65 pH unit; less than 0.60 pH unit;
less than 0.55 pH unit; less than 0.50 pH unit; less than 0.45 pH
unit; less than 0.40 pH unit; less than 0.35 pH unit; less than
0.30 pH unit; less than 0.25 pH unit; less than 0.20 pH unit; less
than 0.15 pH unit; less than 0.14 pH unit; less than 0.13 pH unit;
less than 0.12 pH unit; less than 0.11 pH unit; less than 0.10 pH
unit; less than 0.09 pH unit; less than 0.08 pH unit; less than
0.07 pH unit; less than 0.06 pH unit less than 0.04 pH unit; less
than 0.03 pH unit; less than 0.025 pH unit; less than 0.02 pH unit;
or pH values that are between any of the preceding values; [0439]
b. the difference in the actual isoelectric point of the first
parental homodimeric species and the actual isoelectric point of
the second parental homodimeric species is less than 7.0 pH units;
less than 6.5 pH units; less than 6.0 pH units; less than 5.5 pH
units; less than 5.0 pH units; less than 4.5 pH units; less than
4.0 units; less than 3.5 pH units; less than 2.5 pH units; less
than 2.4 pH units; less than 2.3 pH units; less than 2.2 pH units;
less than 2.1 pH units; less than 2.0 pH units; less than 1.9 pH
units; less than 1.8 pH units; less than 1.7 pH units; less than
1.6 pH units; less than 1.5 pH units; less than 1.4 pH units; less
than 1.3 pH units, less than 1.2 pH units; less than 1.1 pH units;
less than 1.0 pH unit; less than 0.95 pH unit; less than 0.90 pH
unit; less than 0.85 pH unit; less than 0.80 pH unit; less than
0.75 pH unit; less than 0.70 pH unit; less than 0.65 pH unit; less
than 0.60 pH unit; less than 0.55 pH unit; less than 0.50 pH unit;
less than 0.45 pH unit; less than 0.40 pH unit; less than 0.35 pH
unit; less than 0.30 pH unit; less than 0.25 pH unit; less than
0.20 pH unit; less than 0.15 pH unit; less than 0.14 pH unit; less
than 0.13 pH unit; less than 0.12 pH unit; less than 0.11 pH unit;
less than 0.10 pH unit; less than 0.09 pH unit; less than 0.08 pH
unit; less than 0.07 pH unit; less than 0.06 pH unit less than 0.04
pH unit; less than 0.03 pH unit; less than 0.025 pH unit; less than
0.02 pH unit; or pH values that are between any of the preceding
values; [0440] c. the difference in the calculated isoelectric
point of the first heavy chain polypeptide and the calculated
isoelectric point of the second heavy chain polypeptide is less
than 7.0 pH units; less than 6.5 pH units; less than 6.0 pH units;
less than 5.5 pH units; less than 5.0 pH units; less than 4.5 pH
units; less than 4.0 units; less than 3.5 pH units; less than 2.5
pH units; less than 2.4 pH units; less than 2.3 pH units; less than
2.2 pH units; less than 2.1 pH units; less than 2.0 pH units; less
than 1.9 pH units; less than 1.8 pH units; less than 1.7 pH units;
less than 1.6 pH units; less than 1.5 pH units; less than 1.4 pH
units; less than 1.3 pH units, less than 1.2 pH units; less than
1.1 pH units; less than 1.0 pH unit; less than 0.95 pH unit; less
than 0.90 pH unit; less than 0.85 pH unit; less than 0.80 pH unit;
less than 0.75 pH unit; less than 0.70 pH unit; less than 0.65 pH
unit; less than 0.60 pH unit; less than 0.55 pH unit; less than
0.50 pH unit; less than 0.45 pH unit; less than 0.40 pH unit; less
than 0.35 pH unit; less than 0.30 pH unit; less than 0.25 pH unit;
less than 0.20 pH unit; less than 0.15 pH unit; less than 0.14 pH
unit; less than 0.13 pH unit; less than 0.12 pH unit; less than
0.11 pH unit; less than 0.10 pH unit; less than 0.09 pH unit; less
than 0.08 pH unit; less than 0.07 pH unit; less than 0.06 pH unit
less than 0.04 pH unit; less than 0.03 pH unit; less than 0.025 pH
unit; less than 0.02 pH unit; or pH values that are between any of
the preceding values; or [0441] d. the difference in the calculated
isoelectric point of the first parental homodimeric species and the
calculated isoelectric point of the second parental homodimeric
species is less than 7.0 pH units; less than 6.5 pH units; less
than 6.0 pH units; less than 5.5 pH units; less than 5.0 pH units;
less than 4.5 pH units; less than 4.0 units; less than 3.5 pH
units; less than 2.5 pH units; less than 2.4 pH units; less than
2.3 pH units; less than 2.2 pH units; less than 2.1 pH units; less
than 2.0 pH units; less than 1.9 pH units; less than 1.8 pH units;
less than 1.7 pH units; less than 1.6 pH units; less than 1.5 pH
units; less than 1.4 pH units; less than 1.3 pH units, less than
1.2 pH units; less than 1.1 pH units; less than 1.0 pH unit; less
than 0.95 pH unit; less than 0.90 pH unit; less than 0.85 pH unit;
less than 0.80 pH unit; less than 0.75 pH unit; less than 0.70 pH
unit; less than 0.65 pH unit; less than 0.60 pH unit; less than
0.55 pH unit; less than 0.50 pH unit; less than 0.45 pH unit; less
than 0.40 pH unit; less than 0.35 pH unit; less than 0.30 pH unit;
less than 0.25 pH unit; less than 0.20 pH unit; less than 0.15 pH
unit; less than 0.14 pH unit; less than 0.13 pH unit; less than
0.12 pH unit; less than 0.11 pH unit; less than 0.10 pH unit; less
than 0.09 pH unit; less than 0.08 pH unit; less than 0.07 pH unit;
less than 0.06 pH unit less than 0.04 pH unit; less than 0.03 pH
unit; less than 0.025 pH unit; less than 0.02 pH unit; or pH values
that are between any of the preceding values.
[0442] Embodiment 19. The method according to any one of
Embodiments 4 through 18, wherein the desired starting pH is less
than 9.0; less than 8.5; less than 8.0; less than 7.5; less than
7.0; less than 6.5; less than 6.0; less than 5.5; less than 5.0;
less than 4.5; less than 4.0; less than 3.5; or less than 3.0; or a
pH values that is between any of the preceding values.
[0443] Embodiment 20. The method according to any one of
Embodiments 5 through 19, wherein the desired ending pH is more
than 7.0; more than 7.5; more than 8.0; more than 8.5; more than
9.0; more than 9.5; more than 10.0; more than 10.5; or more than
11.0; more than 11.5; more than 12.0; more than 12.5; more than
13.0; more than 13.5; or a pH values that is between any of the
preceding values.
[0444] Embodiment 21. The method according to any one of
Embodiments 2 through 20, wherein the eluant comprises at least two
buffering agents and wherein the acid dissociation constant (pKa)
of each buffering agent is between about 3 and 11.
[0445] Embodiment 22. The method according to any one of
Embodiments 2 through 21, wherein the eluant comprises at least two
buffering agents wherein the acid dissociation constant (pKa) of
each buffering agent is in a range selected from the group
consisting of: about 3.25 to about 3.85; about 4.5 to about 4.85;
about 6.0 to about 6.45; about 6.60 to about 7.0; about 7.5 to
about 8.15; about 8.35 to about 8.55; about 9.25 to about 9.65; and
about 10.00 to about 11.5.
[0446] Embodiment 23. The method according to any one of
Embodiments 2 through 22, wherein the eluant comprises at least two
buffering agents wherein the acid dissociation constant (pKa) of
each buffering agent is in a different range that is selected from
the group consisting of: about 3.25 to about 3.85; about 4.5 to
about 4.85; about 6.0 to about 6.45; about 6.60 to about 7.0; about
7.5 to about 8.15; about 8.35 to about 8.55; about 9.25 to about
9.65; and about 10.00 to about 11.5.
[0447] Embodiment 24. The method according to any one of
Embodiments 2 through 23, wherein the eluant comprises at least two
buffering agents wherein the acid dissociation constant (pKa) of
each buffering agent is selected from the group consisting of about
3.75; about 4.76; about 6.10; about 6.90; about 8.04; about 8.44;
about 9.39; and about 10.50.
[0448] Embodiment 25. The method according to any one of
Embodiments 1 through 24, wherein the MAI further comprises a third
polypeptide comprising a first light chain variable region.
[0449] Embodiment 26. The method according to any one of
Embodiments 1 through 25, wherein the MAI further comprises a third
polypeptide and a fourth polypeptide, wherein each of the third
polypeptide and the fourth polypeptide comprises a second light
chain variable region.
[0450] Embodiment 27. The method according to Embodiment 26,
wherein the first light chain variable region and the second light
chain variable region are identical.
[0451] Embodiment 28. The method according to Embodiment 26 or
Embodiment 27, wherein the third polypeptide and the fourth
polypeptide are identical.
[0452] Embodiment 29. The method according to any one of
Embodiments 1 through 28, wherein the first polypeptide and the
second polypeptide each further comprise an Fc region.
[0453] Embodiment 30. The method according to any one of
Embodiments 1 through 29, wherein the first polypeptide and the
second polypeptide each further comprise a wild-type Fc region.
[0454] Embodiment 31. The method according to any one of
Embodiments 1 through 30, wherein the first polypeptide and the
second polypeptide each further comprise an IgG1 isotype Fc region,
an IgG3 isotype Fc region, an IgG3 isotype Fc region, or an IgG4
isotype Fc region.
[0455] Embodiment 32. The method according to any one of
Embodiments 1 through 31, wherein the first polypeptide and the
second polypeptide each further comprise an IgG1 isotype Fc
region.
[0456] Embodiment 33. The method according to any one of
Embodiments 1 through 32, wherein the first polypeptide and the
second polypeptide each further comprise an Fc region that has not
been engineered in order to alter the pI of the first parental
homodimeric antibody species, the second parental homodimeric
species, or the MAI.
[0457] Embodiment 34. The method according to any one of
Embodiments 1 through 33, wherein the first polypeptide and the
second polypeptide each further comprise an IgG1 isotype Fc region
that has not been engineered in order to alter the pI of the first
parental homodimeric antibody species, the second parental
homodimeric species, or the MAI.
[0458] Embodiment 35. The method according to any one of
Embodiments 1 through 34, wherein either: MAI is in a native
antibody format; at least the first parental homodimeric antibody
species is in a native format; at least the second parental
homodimeric antibody species is in a native format; the first
parental homodimeric antibody species is in a native format and the
second parental homodimeric antibody species is in a native format;
or the MAI is in a native antibody format, the first parental
homodimeric antibody species is in a native format, and the second
parental homodimeric antibody species is in a native format.
[0459] Embodiment 36. The method according to any one of
Embodiments 1 through 35, wherein either: the MAI; the first
parental homodimeric antibody species; the second parental
homodimeric antibody species; the first parental homodimeric
antibody species and the second parental homodimeric antibody
species; or the MAI, the first parental homodimeric antibody
species and the second parental homodimeric antibody species; is in
an IgG1 format, and IgG2 format, and IgG3 format, or an IgG4
format, or a hybrid format.
[0460] Embodiment 37. The method according to any one of
Embodiments 1 through 36, wherein the chromatography performed at
essentially the same ionic strength.
[0461] Embodiment 38. The method according to any one of
Embodiments 2 through 37, wherein the ionic strength of the eluant
remains essentially the same throughout the elution step.
[0462] Embodiment 39. The method according to any one of
Embodiments 4 through 38, wherein first sample of the eluant and
the second sample of the eluant each have essentially the same
ionic strength.
[0463] Embodiment 40. The method according to any one of
Embodiments 1 through 39, wherein the chromatography is ion
exchange chromatography.
[0464] Embodiment 41. The method according to any one of
Embodiments 1 through 40, wherein the chromatography is selected
from the group consisting of: cation exchange chromatography; anion
exchange chromatography; multimodal chromatography; and mixed-mode
chromatography.
[0465] Embodiment 42. The method according to any one of
Embodiments 1 through 41, wherein the chromatography further
comprises using a chromatographic material selected from the group
consisting of Mustang S, Sartobind S, S03 Monolith, S Ceramic
HyperD, Poros XS, Poros HS50, Poros HS20, HS20, SPSFF, Porors
GoPure HS, Poros GoPure XS, SP-Sepharose XL (SPXL), CM Sepharose
Fast Flow, Capto Q ImpRes, Capto SP ImpRes, Capto S, Capto MN/IC,
Fractogel Se HiCap, Fractogel S03, Fractogel COO, Poros HQ 50,
Poros PI 50, Poros D, Mustang Q, Q Sepharose FF, SP Sepharose FF,
UNOshere S, Macro-Prep High S, DEAE, Mono S, Mono S 5/50 GL, Mono
Q, Mono Q 5/50 GL, Mono S 10/100 GL, SP Sepharose HP, Source 30S,
Poros XQ, Poros HQ, Q HP, and Source 30Q.
[0466] Embodiment 43. The method according to any one of
Embodiments 1 through 42, wherein the chromatography further
comprises using a chromatographic material selected from the group
consisting of Mono S, Mono S 5/50 GL, Mono Q, Mono Q 5/50 GL, SP
Sepharose HP, Source 30S, Poros XQ, Poros HQ, Q HP, and Source 30Q,
and Mono S 10/100 GL.
[0467] Embodiment 44. The method according to any one of
Embodiments 2 through 43, wherein the chromatographic material is
an ion exchange chromatographic material.
[0468] Embodiment 45. The method according to any one of
Embodiments 2 through 44, wherein the chromatographic material is
selected from the group consisting of: a cation exchange
chromatographic material; an anion exchange chromatographic
material; a multimodal chromatographic material; and a mixed-mode
chromatographic material.
[0469] Embodiment 46. The method according to any one of
Embodiments 2 through 45, wherein the ion exchange chromatographic
material is selected from the group consisting of Mustang S,
Sartobind S, S03 Monolith, S Ceramic HyperD, Poros XS, Poros HS50,
Poros HS20, HS20, SPSFF, Porors GoPure HS, Poros GoPure XS,
SP-Sepharose XL (SPXL), CM Sepharose Fast Flow, Capto Q ImpRes,
Capto SP ImpRes, Capto S, Capto MMC, Fractogel Se HiCap, Fractogel
S03, Fractogel COO, Poros HQ 50, Poros PI 50, Poros D, Mustang Q, Q
Sepharose FF, SP Sepharose FF, UNOshere S, Macro-Prep High S, DEAE,
Mono S, Mono S 5/50 GL, Mono Q, Mono Q 5/50 GL, Mono S 10/100 GL,
SP Sepharose HP, Source 30S, Poros XQ, Poros HQ, Q HP, and Source
30Q; or [0470] is selected from the group consisting of Mono S,
Mono S 5/50 GL, Mono Q, Mono Q 5/50 GL, SP Sepharose HP, Source
30S, Poros XQ, Poros HQ, Q HP, and Source 30Q, and Mono S 10/100
GL.
[0471] Embodiment 47. The method according to any one of
Embodiments 1 through 46, wherein either the first heavy chain
variable region or the second heavy chain variable region is
obtained by performing a first selection against a first antigen
from a first library comprising unique heavy chain variable
regions.
[0472] Embodiment 48. The method according to any one of
Embodiments 1 through 47, wherein the first heavy chain variable
region and the second heavy chain variable region is obtained by
performing a first selection against a first antigen from a first
library comprising unique heavy chain variable regions.
[0473] Embodiment 49. The method according to any one of
Embodiments 1 through 48, wherein the first heavy chain variable
region is obtained by performing a first selection against a first
antigen from a first library comprising unique heavy chain variable
regions and the second heavy chain variable region is obtained by
performing a second selection against a second antigen from a
second library comprising unique heavy chain variable regions.
[0474] Embodiment 50. The method according to any one of
Embodiments 1 through 49, wherein the first heavy chain variable
region is obtained by performing a first selection against a first
antigen from a first library comprising unique heavy chain variable
regions and the second heavy chain variable region is obtained by
performing a second selection against a second antigen from a
second library comprising unique heavy chain variable regions.
[0475] Embodiment 51. The method according to any one of
Embodiments 1 through 50, wherein at least one of the libraries
further comprises at least one light chain.
[0476] Embodiment 52. The method according to any one of
Embodiments 1 through 51, the composition is expressed by
prokaryotic host cells or eukaryotic host cells, into which nucleic
acid sequences encoding the first polypeptide and the second
polypeptide have each been introduced.
[0477] Embodiment 53. The method according to any one of
Embodiments 25 through 23, the composition is expressed by
prokaryotic host cells or eukaryotic host cells into which nucleic
acid sequences encoding the first polypeptide and the second
polypeptide have each been introduced.
[0478] Embodiment 54. The method according to any one of
Embodiments 26 through 53, the composition is expressed by
prokaryotic host cells or eukaryotic host cells into which nucleic
acid sequences encoding the first polypeptide, the second
polypeptide, the third polypeptide, and the fourth polypeptide have
each been introduced.
[0479] Embodiment 55. The method according to any one of
Embodiments 52 through 54, wherein each encoded polypeptide is
expressed by the host cells.
[0480] Embodiment 56. The method according to any one of
Embodiments 52 through 55, wherein the composition is expressed by
the host cells.
[0481] Embodiment 57. The method according to any one of
Embodiments 52 through 56, wherein essentially each host cell has
been transformed or transfected with the first polypeptide, the
second polypeptide, the third polypeptide, and the fourth
polypeptide.
[0482] Embodiment 58. The method according to any one of
Embodiments 52 through 57, wherein essentially each host cell
expresses the MAI, the first parental antibody species, and the
second parental antibody species.
[0483] Embodiment 59. The method to any one of Embodiments 52
through 58, wherein the host cells are selected from the group
consisting of: eukaryotic cells; fungal cells; yeast cells; insect
cells; mammalian cells; Saccharomyces cerevisiae cells; Pichia
pastoris cells; mammalian cells; COS cells; human embryonic kidney
(HEK) cells; and CHO cells.
[0484] Embodiment 60. An ion exchange eluant comprising either:
[0485] (i) CAPS, CHES, TAPS, HEPPSO, MOPSO, MES, acetic acid,
formic acid, and a salt; or [0486] (ii) methylamine,
1,2-ethanediamine, 1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt.
[0487] Embodiment 61. An ion exchange eluant comprising CAPS, CHES,
TAPS, HEPPSO, MOPSO, MES, acetic acid, formic acid, and NaCl.
[0488] Embodiment 62. The ion exchange eluant according to
Embodiment 60 or Embodiment 61, with the proviso that the eluant
does not include TRIS, piperazine, or imidazole.
[0489] Embodiment 63. An ion exchange eluant consisting essentially
of either: [0490] (i) CAPS, CHES, TAPS, HEPPSO, MOPSO, MES, acetic
acid, formic acid, and a salt; or [0491] (ii) methylamine,
1,2-ethanediamine, 1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt.
[0492] Embodiment 64. An ion exchange eluant consisting of either:
[0493] (i) CAPS, CHES, TAPS, HEPPSO, MOPSO, MES, acetic acid,
formic acid, and a salt; or [0494] (ii) methylamine,
1,2-ethanediamine, 1-methylpiperazine, 1,4-dimethylpiperazine,
2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol
(bis-tris), and hydroxylamine and optionally at least one salt.
[0495] Embodiment 65. The ion exchange eluant according to any one
of Embodiments 61 through 64, wherein the salt is selected from the
group consisting of NaCl, KCl, or Na.sub.2SO.sub.4.
[0496] Embodiment 66. The ion exchange eluant according to any one
of Embodiments 60 through 65, wherein the eluant is used for
purifying an MAI from a composition comprising the MAI and parental
homodimeric antibody species.
[0497] Embodiment 67. The ion exchange eluant according to any one
of Embodiments 61 through 66, wherein the eluant comprises at least
one salt at a concentration range selected from the group
consisting of: 0 mM to about 100 mM; 0 mM to about 60 mM; 0 mM to
about 50 mM; 0 mM to about 40 mM; 0 mM to about 30 mM; 0 mM to
about 20 mM; 0 mM to about 10 mM; 0 mM to about 5 mM; about 10 mM
to about 200 mM; about 10 mM to about 100 mM; about 10 mM to about
50 mM; about 10 mM to about 40 mM; about 10 mM to about 30 mM;
about 10 mM to about 20 mM; about 20 mM to about 200 mM; about 20
mM to about 100 mM; about 20 mM to about 50 mM; about 20 mM to
about 30 mM; about 30 mM to about 200 mM; about 30 mM to about 100
mM; and about 30 mM to about 50 mM; and about 5 mM to about 15
mM.
[0498] Embodiment 68. The ion exchange eluant according to any one
of Embodiments 61 through 67, wherein each sample of the eluant
comprises at least one salt at a concentration of about 10 mM.
[0499] Embodiment 69. The ion exchange eluant according to any one
of Embodiments 61 through 68, wherein the salt is NaCl.
[0500] Embodiment 70. The ionic exchange eluant according to any
one of Embodiments 61 through 69, wherein each sample of the eluant
comprises NaCl at a concentration of about 10 mM.
EXAMPLES
Materials and Methods
[0501] All chromatographic separations presented in the Examples
were carried out on a computer controlled AKTA avant 150
preparative chromatography system (GE Healthcare Life Sciences)
equipped with an integrated pH electrode, enabling in-line pH
monitoring during each chromatography experiment. The Mono S 5/50
GL, Mono Q 5/50 GL, and Mono S 10/100 GL columns were purchased
each purchased from GE Healthcare Life Sciences. All other columns
were purchased from the providers as listed in the column titled
"Resin" each of in FIGS. 26A and 26B. Acetic acid and sodium
chloride were from VWR, CAPS, MOPSO, and TAPS were from Sigma, CHES
and formic acid were from EMD, HEPPSO was from MP Biomedicals, and
MES was from Calbiochem. Methylamine (40% in H.sub.2O),
1,2-ethanediamine, 1-methylpiperazine, 1,4-dimethylpiperazine, and
hydroxylamine (50% in H.sub.2O) were purchased from Sigma, bis-tris
was purchased from Affymetrix, and sodium chloride was purchased
from VWR. The pH gradient-forming solutions were freshly prepared
before each experiment by dissolving the buffering agents in water
and dividing the solution into two equal parts. Unless otherwise
noted, the eluant composition was as listed in FIG. 1. One half was
then adjusted to pH 4 (buffer A) using sodium hydroxide, while the
other half was adjusted to pH 11 (buffer B) also using sodium
hydroxide.
[0502] Unless otherwise indicated, the following procedure was used
to perform all purifications described in the Examples.
Approximately 0.2 mg to 2 mg (for the Mono S 5/50 GL, Mono Q 5/50
GL, and all other similarly sized columns utilized in the Examples
below) or approximately 5 mg to 10 mg (for the Mono S 10/100 column
and all other similarly sized columns utilized in the Examples
below) of the MAI-parental homodimeric antibody species composition
to be separated were buffer exchanged into the starting pH buffer
and filtered through a 0.2 .mu.m filter. Before each separation,
the column was equilibrated with 10 column volumes of starting
buffer (either buffer A, buffer B, or the appropriate mixture of
buffer A and buffer B). The protein composition was then loaded
onto the column via a capillary loop, and the column was washed
with another 10 column volumes of starting buffer to remove the
unbound material. Subsequently a linear pH gradient of 20 column
volumes made up of the appropriate mixtures of buffer A and buffer
B was used for separation of the common light chain bispecific
antibody mixture. Alternatively, 15 column volumes of a step
elution were performed before a shallower gradient of buffers A and
B was used to elute.
[0503] Common-light-chain antibodies (i.e., parental homodimeric
antibody species) were isolated from a full-length human IgG1
antibody library using an in vitro yeast selection system and
associated methods (see, e.g., WO 2009/036379; WO 2010/105256; and
WO 2012/009568).Target-binding mAbs were enriched by incubating
biotin labeled antigens with antibody expressing yeast cells at
different concentrations followed by magnetic bead selection
(Miltenyi, Biotec) and fluorescence-activated cell sorting on a
FACSAria II cell sorter (BD Biosciences) employing streptavidin
secondary reagents in several successive selection rounds. After
the last round of enrichment, yeast cells were sorted and plated
onto agar plates, clones were analyzed by DNA sequencing and used
for IgG production. Optimization of antibodies for higher affinity
was performed in successive cycles of selection rounds using lower
concentrations of antigen baits with sub-libraries generated by
light chain shuffling, targeted mutagenesis of CDR1 and CDR2 of
heavy chains and ePCR of the variable region of the heavy or light
chain. For Examples in which an IgG isotype format other than the
IgG1 isotype format was employed, the variable domains isolated
from the libraries as described above were reformatted into the
indicated alternative IgG isotype format (e.g., IgG4, etc.).
[0504] The compositions comprising each antibody (heavy
chain-heterodimeric MAI and two parental heavy-chain homodimeric
species) described and tested in each the Examples were obtained
from mammalian host cells (HEK cells) harboring and transiently
expressing nucleic acid sequences encoding each of a first heavy
chain polypeptide, a second heavy chain polypeptide, and a third
light chain polypeptide. The transfected cells were cultured under
standard conditions known in the art, and the supernatants
comprising the antibodies were collected and subjected to Protein
A-based affinity purification in order to obtain compositions
comprising all antibody species present in the supernatant.
Depending on the isotype format of the antibodies encoded by the
nucleic acid for each Example as described below, such antibody
species (MAI and/or parental homodimeric antibodies) were either in
the IgG1 format (described in, e.g., Examples 1 through 9 and
Examples 14 and 15), IgG4 format (described in, e.g., Examples 10
through 13) or a hybrid IgG1/IgG4 isotype format (described in,
e.g., Example 11).
Compositions and Formats Tested in the Examples
[0505] The compositions tested in Examples 1 through 9 and Example
14 comprised the following antibody species:
[0506] Scheme A: [0507] an MAI in the native human IgG1 isotype
format, comprising a first heavy chain polypeptide in the IgG1
isotype format, a second heavy chain polypeptide in the IgG1
isotype format, and two copies of a light chain polypeptide that
were identical in amino acid sequence, wherein the variable regions
of the first heavy chain polypeptide and the second heavy chain
polypeptide had different amino acid sequences and different
antigen specificities (and thus the antigen binding regions formed
by each pairing of each of the first and the second heavy chain
polypeptide variable regions with one of the two copies of the
light chain polypeptide (i.e., "common light chain") had two
different antigen specificities); [0508] a first parental heavy
chain-homodimeric antibody species in the native human IgG1 isotype
format, comprising two copies of the first heavy chain polypeptide
and two copies of the light chain polypeptide as in 1) above,
wherein the antigen binding regions formed by pairing of one copy
of the first heavy chain polypeptide and one copy of the light
chain polypeptide has a single antigen specificity (and thus the
antigen binding regions formed by pairing of each copy of the heavy
chain polypeptide with each copy of the light chain polypeptide
each had the same single antigen specificity); and [0509] a second
parental heavy chain-homodimeric antibody species in the native
human IgG1 isotype format, comprising two copies of the second
heavy chain polypeptide and two copies of the light chain
polypeptide as in 1) above, wherein the antigen binding regions
formed by pairing of one copy of the second heavy chain polypeptide
and one copy of the light chain polypeptide has a single antigen
specificity (and thus the antigen binding regions formed by pairing
of each copy of the second heavy chain polypeptide with each copy
of the light chain polypeptide each had the same single antigen
specificity).
[0510] The compositions tested in Example 10 comprised the
following antibody species:
[0511] Scheme B: [0512] an MAI in the native human IgG4 isotype
format, comprising a first heavy chain polypeptide in the IgG4
isotype format, a second heavy chain polypeptide in the IgG4
isotype format, and two copies of a light chain polypeptide that
were identical in amino acid sequence, wherein the variable regions
of the first heavy chain polypeptide and the second heavy chain
polypeptide had different amino acid sequences and different
antigen specificities (and thus the antigen binding regions formed
by each pairing of each of the first and the second heavy chain
polypeptide variable regions with one of the two copies of the
light chain polypeptide (i.e., "common light chain") had two
different antigen specificities); [0513] a first parental heavy
chain-homodimeric antibody species in the native human IgG4 isotype
format, comprising two copies of the first heavy chain polypeptide
and two copies of the light chain polypeptide as in 1) above,
wherein the antigen binding regions formed by pairing of one copy
of the first heavy chain polypeptide and one copy of the light
chain polypeptide has a single antigen specificity (and thus the
antigen binding regions formed by pairing of each copy of the heavy
chain polypeptide with each copy of the light chain polypeptide
each had the same single antigen specificity); and [0514] a second
parental heavy chain-homodimeric antibody species in the native
human IgG4 isotype format, comprising two copies of the second
heavy chain polypeptide and two copies of the light chain
polypeptide as in 1) above, wherein the antigen binding regions
formed by pairing of one copy of the second heavy chain polypeptide
and one copy of the light chain polypeptide has a single antigen
specificity (and thus the antigen binding regions formed by pairing
of each copy of the second heavy chain polypeptide with each copy
of the light chain polypeptide each had the same single antigen
specificity).
[0515] The compositions tested in Example 11 comprised the
following antibody species:
[0516] Scheme C: [0517] an MAI in the hybrid IgG1/IgG4 isotype
format (native human IgG1 isotype format/human native IgG4 isotype
format), comprising a first heavy chain polypeptide in the IgG1
isotype format, a second heavy chain polypeptide in the IgG4
isotype format, and two copies of a light chain polypeptide that
were identical in amino acid sequence, wherein the variable regions
of the first heavy chain polypeptide and the second heavy chain
polypeptide had different amino acid sequences and different
antigen specificities (and thus the antigen binding regions formed
by each pairing of each of the first and the second heavy chain
polypeptide heavy chain variable regions with one of the two copies
of the light chain polypeptide (i.e., "common light chain") had two
different antigen specificities); [0518] a first parental heavy
chain-homodimeric antibody species in the native human IgG1 isotype
format, comprising two copies of the first heavy chain polypeptide
and two copies of the light chain polypeptide as in 1) above,
wherein the antigen binding regions formed by pairing of one copy
of the first heavy chain polypeptide and one copy of the light
chain polypeptide has a single antigen specificity (and thus the
antigen binding regions formed by pairing of each copy of the heavy
chain polypeptide with each copy of the light chain polypeptide
each had the same single antigen specificity); and [0519] a second
parental heavy chain-homodimeric antibody species in the native
human IgG4 isotype format, comprising two copies of the second
heavy chain polypeptide and two copies of the light chain
polypeptide as in 1) above, wherein the antigen binding regions
formed by pairing of one copy of the second heavy chain polypeptide
and one copy of the light chain polypeptide has a single antigen
specificity (and thus the antigen binding regions formed by pairing
of each copy of the second heavy chain polypeptide with each copy
of the light chain polypeptide each had the same single antigen
specificity).
[0520] The compositions tested in Example 12 and Example 13
comprised the following antibody species:
[0521] Scheme D: [0522] an MAI in the native human IgG4 isotype
format, comprising a first heavy chain polypeptide in the IgG4
isotype format, a second heavy chain polypeptide in the IgG4
isotype format, one copy of a first light chain polypeptide amino
acid sequence in which a first engineered heterodimerization motif
was introduced in order to help favor preferential dimerization
with the first heavy chain polypeptide relative to dimerization
with the second heavy chain polypeptide, and one copy of a second
light chain polypeptide amino acid sequence in which a second
engineered heterodimerization motif was introduced in order to help
favor preferential dimerization with the second heavy chain
polypeptide relative to dimerization with the first heavy chain
polypeptide, wherein the variable regions of the first heavy
polypeptide and the second heavy polypeptide had different amino
acid sequences and different antigen specificities (and thus the
antigen binding region formed by each pairing of the first heavy
chain polypeptide heavy chain variable region with the first light
chain polypeptide had a different specificity than the antigen
binding region formed by the pairing of the second heavy chain
polypeptide heavy chain variable region with the second light chain
polypeptide; [0523] a first parental heavy chain-homodimeric
antibody species in the native human IgG4 isotype format,
comprising two copies of the first heavy chain polypeptide and two
copies of the light chain polypeptide as in 1) above, wherein the
antigen binding regions formed by pairing of one copy of the heavy
chain polypeptide and one copy of the light chain polypeptide has a
single antigen specificity (and thus the antigen binding regions
formed by pairing of each copy of the heavy chain polypeptide with
each copy of the light chain polypeptide each had the same single
antigen specificity); and [0524] a second parental heavy
chain-homodimeric antibody species in the native human IgG4 isotype
format, comprising two copies of the second heavy chain polypeptide
and two copies of the light chain polypeptide as in 1) above,
wherein the antigen binding regions formed by pairing of one copy
of the second heavy chain polypeptide and one copy of the light
chain polypeptide has a single antigen specificity (and thus the
antigen binding regions formed by pairing of each copy of the
second heavy chain polypeptide with each copy of the light chain
polypeptide each had the same single antigen specificity).
Example 1
[0525] Linear pH gradient separation of a composition comprising
common-light-chain IgG1 bispecific heterodimer (the "MAI") and each
of two different parental homodimeric antibody species (formats as
described in Scheme A of Compositions and Formats tested in the
Examples, above) with a calculated difference in heavy chain pI of
0.68 pH unit (the calculated pI of HC1=9.73; calculated pI of
HC2=9.05; the calculated isoelectric points (pIs) of the two
corresponding parental homodimeric antibody species differed by
1.33 pH unit) using a linear pH gradient on a strong cation
exchanger Mono S 5/50 GL column. Starting buffer A: 15.6 mM CAPS,
9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES,
13 mM acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 4.0. Final
buffer B: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO,
8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic acid, 10
mM NaCl, pH 11.0 Flow rate 1 ml/min, length of linear gradient
formation from 0% B to 100% B 20 column volumes.
[0526] The results depicted in FIG. 2 demonstrate that despite the
relatively steep pH gradient and the small scale column, the
difference in pI of the two heavy chains (as well as the difference
in pl of the two corresponding parental homodimeric species from
which the two different heavy chains of the MAI were derived) is
sufficient to yield baseline resolution between the two homodimer
species and the desired heterodimer, and thus purification of the
heterodimer (the MAI) (FIG. 2).
Example 2
[0527] Linear pH gradient separation of a composition comprising
common-light-chain IgG1 bispecific heterodimer (the "MAI") and each
of two different parental homodimeric antibody species (formats as
described in Scheme A of Compositions and Formats tested in the
Examples, above) with a calculated difference in heavy chain pI of
0.25 pH unit (calculated pI of HC1=9.46; calculated pI of HC2=9.21;
the calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.59 pH unit)
using various linear pH gradients on a strong cation exchanger Mono
S 5/50 GL column or a strong cation exchanger Mono S 10/100 GL
column. FIG. 4A: separation of 0.228 mg of total material on a Mono
S 5/50 GL column (column volume: 1 mL): Starting buffer A: 15.6 mM
CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM
MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 4.0.
Final buffer: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM
HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic
acid, 10 mM NaCl, pH 11.0. Flow rate 1 ml/min, length of linear
gradient formation from 0% B to 100% B 20 column volumes. FIG. 4B:
separation of 1.57 mg of total material on a Mono S 5/50 GL column
(column size: 1 mL): Starting buffer A: 15.6 mM CAPS, 9.4 mM CHES,
4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic
acid, 9.9 mM formic acid, 10 mM NaCl, pH 4.0. Final buffer: 15.6 mM
CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM
MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 11.0.
Flow rate 1 ml/min, length of linear gradient formation from 32.5%
B to 55% B 20 column volumes. FIG. 4C: separation of 8.88 mg of
total material on a Mono S 10/100 GL column (column size: 8 ml):
Starting buffer A: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM
HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic
acid, 10 mM NaCl, pH 4.0. Final buffer: 15.6 mM CAPS, 9.4 mM CHES,
4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic
acid, 9.9 mM formic acid, 10 mM NaCl, pH 11.0. Flow rate 1 ml/min,
length of linear gradient formation from 32.5% B to 55% B 20 column
volumes.
[0528] The elution diagrams in FIGS. 4A through 4C demonstrate that
both making the linear gradient shallower (i.e., generating a pH
gradient range that encompasses a narrower pH range as illustrated
in FIGS. 4B and 4C) relative to that generated as illustrated in
FIG. 4A, as well as increasing the sample material mount (mass) and
with it the residence time of the sample on the column, lead to
increased resolution. Furthermore, the sample that showed only
partial resolution on the 1 ml Mono S 5/50 GL column with the full
gradient from 0% B to 100% B over 20 column volumes was resolved by
increasing the column volume to 8 ml for the Mono S 10/100 GL
column and making the gradient shallower (32.5% B to 55% B over 20
column volumes). Accordingly, the results demonstrate that MAIs
were purified from two different parental homodimeric antibody
species for which the calculated pI difference was approximately
0.59 pH unit. Additionally, the results demonstrate that MAIs were
purified from two different parental homodimeric antibody species
for which the calculated pI difference of the heavy chains of such
parental homodimeric species was approximately 0.25 pH unit.
Example 3
[0529] Linear pH gradient separation of a composition comprising
common-light-chain IgG1 bispecific heterodimer (the "MAI") and each
of two different parental homodimeric antibody species (formats as
described in Scheme A of Compositions and Formats tested in the
Examples, above) with varying calculated differences in heavy chain
pI using a strong cation exchanger Mono S 10/100 GL column and a
linear pH gradient with starting buffer A: 15.6 mM CAPS, 9.4 mM
CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM
acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 4.0 and final
buffer: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7
mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM
NaCl, pH 11.0. Flow rate 1 ml/min, length of linear gradient
formation from 32.5% B to 55% B 20 column volumes. FIG. 5A:
common-light-chain bispecific homodimers and heterodimer with
calculated differences in heavy chain pI of 0.68 unit (calculated
pI of HC1=9.73; calculated pI of HC2=9.05; the calculated
isoelectric points (pIs) of the two corresponding parental
homodimeric antibody species differed by 1.33 pH unit). FIG. 5B:
common-light-chain bispecific homodimers and heterodimer with
calculated differences in heavy chain pI of 0.43 pH unit
(calculated pI of HC1=9.43; calculated pI of HC2=9.00; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 1.33 pH unit).
FIG. 5C: common-light-chain bispecific homodimers and heterodimer
with calculated differences in heavy chain pI of 0.25 unit
(calculated 1 pI of HC1=9.46; calculated t pI of HC2=9.21; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.59 pH unit).
FIG. 5D: common-light-chain bispecific homodimers and heterodimer
with calculated differences in heavy chain pI of 0.24 (calculated
pI of HC1=9.43; calculated theoretical pI of HC2=9.18; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.26 pH unit).
FIG. 5E: common-light-chain bispecific homodimers and heterodimer
with calculated theoretical differences in heavy chain pI of 0.21
(calculated pI of HC1=9.54; calculated pI of HC2=9.33; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.38 pH unit).
Baseline resolution on the strong cation exchanger Mono S 10/100 GL
column and a relatively shallow linear pH gradient is achieved for
mixtures of common-light-chain bispecific homodimers and
heterodimer with differences the calculated isoelectric points
(pIs) of the two corresponding parental homodimeric antibody
species differed by 0.26 pH unit Accordingly, the results
demonstrate that MAIs were purified from two different parental
homodimeric antibody species for which the calculated pI difference
was approximately 1.33 to as small as approximately 0.26 pH unit.
Additionally the results demonstrate that MAIs were purified from
two different parental homodimeric antibody species for which the
calculated pI difference of the heavy chains of such parental
homodimeric species was from approximately 0.7 pH unit to as low as
approximately 0.26 pH unit.
Example 4
[0530] Linear pH gradient separation of a composition comprising
common-light-chain IgG1 bispecific heterodimer (the "MAI") and each
of two different parental homodimeric antibody species (formats as
described in Scheme A of Compositions and Formats tested in the
Examples, above) with a calculated difference in heavy chain pI of
0.09 (calculated pI of HC1=9.43; calculated 1 pI of HC2=9.33;
calculated isoelectric point (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.10 pH unit);
using various linear pH gradients on a strong cation exchanger Mono
S 5/50 GL column or a strong cation exchanger Mono S 10/100 GL
column. FIG. 8A: separation of 0.421 mg of total material on a Mono
S 5/50 GL column: Starting buffer A: 15.6 mM CAPS, 9.4 mM CHES, 4.6
mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid,
9.9 mM formic acid, 10 mM NaCl, pH 4.0. Final buffer: 15.6 mM CAPS,
9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES,
13 mM acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 11.0. Flow
rate 1 ml/min, length of linear gradient formation from 0% B to
100% B 20 column volumes. FIG. 8B: separation of 7.57 mg of total
material on a Mono S 10/100 GL column: Starting buffer A: 15.6 mM
CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM
MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 4.0.
Final buffer: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM
HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic
acid, 10 mM NaCl, pH 11.0. Flow rate 1 ml/min, length of linear
gradient formation from 35% B to 53% B 20 column volumes. FIG. 8C:
separation of 6.69 mg of total material on a Mono S 10/100 GL
column: Starting buffer A: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS,
9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM
formic acid, 10 mM NaCl, pH 4.0. Final buffer: 15.6 mM CAPS, 9.4 mM
CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM
acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 11.0. Flow rate 1
ml/min, length of linear gradient formation from 37% B to 43% B 20
column volumes. The recovery of MAI recovery observed in the
experiment illustrated in FIG. 8C was 64% increased relative to the
recovery observed in FIG. 8B.
[0531] The results demonstrate that MAIs were purified from two
different parental homodimeric antibody species for which the
calculated pI differences as low as approximately 0.10 pH unit to
an acceptable degree (i.e., such that fraction volumes can be
selected such that the MAI is purified essentially to homogeneity,
albeit with modest loss of yield). Additionally the results
demonstrate that MAIs were purified from two different parental
homodimeric antibody species for which the calculated pI difference
of the heavy chains of such parental homodimeric species was
approximately 0.9 pH unit. Furthermore, the results demonstrate
that employing a shallower pH gradient (ii., narrowing the pH range
of the pH gradient) as well as increasing the column volume (and
hence, the residence time of the protein composition that is
applied to the column) can increase both the degree of separation
of the MAI from the parental homodimeric species and increase the
percent recovery of the MAI.
Example 5
[0532] Linear pH gradient separations of compositions comprising
common-light-chain IgG1 bispecific heterodimers (the "MAIs") and
each of two different parental homodimeric antibody species
(formats as described in Scheme A of Compositions and Formats
tested in the Examples, above) were compared to separations of the
same compositions using linear salt gradients, using the Mono S
10/100 GL strong cation exchanger resin and the buffer compositions
as outlined in the table in the top portion of FIG. 3. Briefly,
starting buffer A: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM
HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic
acid, 10 mM NaCl, pH 4.0. Final buffer B: 15.6 mM CAPS, 9.4 mM
CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM
acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 11.0 Flow rate 1
ml/min, length of linear gradient formation from 0% B to 100% B 20
column volumes.
[0533] For both pH gradient experiments and salt gradient
experiments, common-light-chain bispecific homodimers and
heterodimer with the following calculated differences were
compared: calculated differences in heavy chain pI of 0.68 unit
(calculated pI of HC1=9.73; calculated pI of HC2=9.05; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 1.33 pH unit);
calculated differences in heavy chain pI of 0.24 unit (calculated
pI of HC1=9.43; calculated pI of HC2=9.18; the calculated
isoelectric points (pIs) of the two corresponding parental
homodimeric antibody species differed by 0.26 pH unit); the
calculated differences in heavy chain pI of 0.11 (calculated pI of
HC1=9.43; calculated pI of HC2=9.32; the calculated isoelectric
points (pIs) of the two corresponding parental homodimeric antibody
species differed by 0.11 pH unit); and the calculated differences
in heavy chain pI of 0.09 (calculated pI of HC1=9.43; calculated pI
of HC2=9.34; the calculated isoelectric points (pIs) of the two
corresponding parental homodimeric antibody species differed by 0.1
pH unit).
[0534] The results demonstrate that the MAIs were better separated
from the corresponding parental homodimeric antibody species tested
compositions when subjected to pH gradient elution when compared to
salt gradient elution.
Example 6
[0535] It was desirable to further explore the extent to which
differences in calculated pI of different parental homodimeric
antibody species affected the ability to separate MAIs from
compositions comprising the MAIs and the two different parental
homodimeric antibody species.
[0536] Linear pH gradient separation of a composition comprising
common-light-chain IgG1 bispecific heterodimer (the "MAI") and each
of two different parental homodimeric antibody species (formats as
described in Scheme A of Compositions and Formats tested in the
Examples, above) with varying calculated differences in heavy chain
pI using a strong cation exchanger Mono S 5/50 GL column and a
linear pH gradient with starting buffer A: 15.6 mM CAPS, 9.4 mM
CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM
acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 4.0 and final
buffer: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7
mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM
NaCl, pH 11.0. Flow rate 1 ml/min, length of linear gradient
formation from 0% B to 100% B 20 column volumes.
[0537] FIG. 6A: common-light-chain bispecific homodimers and
heterodimer with calculated differences in heavy chain pI of 0.68
unit (calculated pI of HC1=9.73; calculated pI of HC2=9.05; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 1.33 pH unit).
FIG. 6B: common-light-chain bispecific homodimers and heterodimer
with calculated differences in heavy chain pI of 0.43 pH unit
(calculated pI of HC1=9.43; calculated pI of HC2=9.00; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.48 pH unit).
FIG. 6C: common-light-chain bispecific homodimers and heterodimer
with calculated differences in heavy chain pI of 0.25 unit
(calculated pI of HC1=9.46; calculated pI of HC2=9.21; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.59 pH unit).
FIG. 6D: common-light-chain bispecific homodimers and heterodimer
with calculated differences in heavy chain pI of 0.21 (calculated
pI of HC1=9.54; calculated theoretical pI of HC2=9.33; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.38 pH unit).
FIG. 6E: common-light-chain bispecific homodimers and heterodimer
with calculated theoretical differences in heavy chain pI of 0.24
(calculated pI of HC1=9.43; calculated pI of HC2=9.18; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.26 pH unit).
FIG. 6F: common-light-chain bispecific homodimers and heterodimer
with calculated theoretical differences in heavy chain pI of 0.11
(calculated pI of HC1=9.43; calculated pI of HC2=9.32; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.11 pH unit).
FIG. 6G: common-light-chain bispecific homodimers and heterodimer
with calculated theoretical differences in heavy chain pI of 0.09
(calculated pI of HC1=9.43; calculated pI of HC2=9.33; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.10 pH
unit).
[0538] The results indicate that successful separation of each of
the MAIs contained in compositions comprising the MAI and its
parental homodimeric antibody species correlates well with
calculated difference in pI of the such parental homodimeric
antibody species, and correlates fairly well with calculated
difference in pI of the heavy chain polypeptides contained in the
parental homodimeric antibody species from which the heavy chain
polypeptides of the MAI are derived.
[0539] The results also demonstrate, as illustrated in FIG. 7, that
the methods performed herein are suitable to separate MAIs from
corresponding parental homodimeric antibody species at an
acceptable degree when the heavy chain sequences of the different
parental homodimeric species differ from one another by as little
as one amino acid.
Example 7
[0540] It was desirable to explore the ability of anion exchange
resins to effect separation of MAIs from compositions comprising
the MAIs and the two different parental homodimeric antibody
species. Accordingly, separations were performed as described
below, in which the performance of an exemplary cation exchange
resin was compared with the performance of an exemplary anion
exchange resin.
[0541] Linear pH gradient separation of a composition comprising
common-light-chain IgG1 bispecific heterodimer (the "MAI") and each
of two different parental homodimeric antibody species (formats as
described in Scheme A of Compositions and Formats tested in the
Examples, above) with varying calculated differences in heavy chain
pI using a strong cation exchanger Mono S 5/50 GL column and a
linear pH gradient with starting buffer A: 15.6 mM CAPS, 9.4 mM
CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM
acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 4.0 and final
buffer: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7
mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM
NaCl, pH 11.0, or using a strong anion exchanger Mono Q 5/50 GL
column and a linear pH gradient with starting buffer B: 15.6 mM
CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM
MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 11.0 and
final buffer: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM
HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic
acid, 10 mM NaCl, pH 4.0. FIG. 9A: common-light-chain bispecific
homodimers and heterodimer with calculated differences in heavy
chain pI of 0.68 (calculated pI of HC1=9.73; calculated theoretical
pI of HC2=9.05; the calculated isoelectric points (pIs) of the two
corresponding parental homodimeric antibody species differed by
1.33 pH unit) separated on MONO S 5/50 GL. FIG. 9B:
common-light-chain bispecific homodimers and heterodimer with
calculated theoretical differences in heavy chain pI of 0.24
(calculated pI of HC1=9.43; calculated pI of HC2=9.18; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 0.26 pH unit)
separated on MONO S 5/50 GL. FIG. 9C: common-light-chain bispecific
homodimers and heterodimer with calculated theoretical differences
in heavy chain pI of 0.11 (calculated pI of HC1=9.43; calculated pI
of HC2=9.32; the calculated isoelectric points (pIs) of the two
corresponding parental homodimeric antibody species differed by
0.11 pH unit) separated on MONO S 5/50 GL. FIG. 9D:
common-light-chain bispecific homodimers and heterodimer with
calculated differences in heavy chain pI of 0.68 (calculated
theoretical pI of HC1=9.73; calculated pI of HC2=9.05; the
calculated isoelectric points (pIs) of the two corresponding
parental homodimeric antibody species differed by 1.33 pH unit)
separated on MONO Q 5/50 GL. FIG. 9E: common-light-chain bispecific
homodimers and heterodimer with calculated differences in heavy
chain pI of 0.24 (calculated theoretical pI of HC1=9.43; calculated
pI of HC2=9.18; the calculated isoelectric points (pIs) of the two
corresponding parental homodimeric antibody species differed by
0.26 pH unit) separated on MONO Q 5/50 GL. FIG. 9F:
common-light-chain bispecific homodimers and heterodimer with
calculated differences in heavy chain pI of 0.11 (calculated pI of
HC1=9.43; calculated pI of HC2=9.32; the calculated isoelectric
points (pIs) of the two corresponding parental homodimeric antibody
species differed by 0.11 pH unit) separated on MONO Q 5/50 GL.
[0542] The results demonstrate that the strong anion exchanger Mono
Q 5/50 GL column was able to purify MAI from parental homodimeric
antibody species to an acceptable level (i.e., such that fraction
volumes can be selected such that the MAI is purified essentially
to homogeneity, albeit with modest loss of yield) in instances in
which the similarly sized strong cation exchanger Mono S 5/50 GL
column provided no resolution.
Example 8
[0543] It was desirable to further compare the performance of
cation exchange resins with anion exchange resins in the ability to
separate MAIs from compositions comprising a given MAI and its
parental homodimeric antibody species with a larger sample of
differences in calculated pI of the parental homodimeric antibody
species. In this case, however, the pH gradients were prepared as
described in the above examples, but were generated so as to be
more shallow (span a narrower pH range), as indicated in FIG. 10A
and FIG. 10B. Accordingly, 8 mL Mono S columns were used in FIG.
10A and 8 mL Mono Q columns were used in FIG. 10B, and the
MAI-parental homodimeric antibody species compositions in which the
difference in calculate pI of the parental homodimeric antibody
species was 1.33, 0.26, 0.11, and 0.1, respectively, prepared and
characterized as described in Example 6, were each tested using the
two resins.
[0544] The results, depicted in FIGS. 10A and 10B, demonstrate that
the MonoQ anion exchange resin effected the separation of each MAI
from its corresponding parental homodimeric antibody species to a
greater degree than the cation Mono S exchange resin for all
compositions tested.
Example 9
[0545] It was desirable to determine whether the disclosed methods
could be applied with process scale resins. Accordingly, in a first
phase experiment, a series of small scale (1 mL column) scouting
experiments were conducted in which a series of cation and anion
exchange resins were tested for their ability to effect separation
of compositions in which the difference in calculate pI of the
parental homodimeric antibody species was 1.33 and 0.26, using a
full pH gradient pH 4 to pH 11) respectively, prepared and
characterized as described in Example 6. In a second phase of
experiments, the three best performing anion exchange resins and
cation exchange resins from the first phase were then employed
using larger columns (8 mL and shallower gradients to assess the
ability of these best-performing resins to separate compositions in
which the difference in calculate pI of the parental homodimeric
antibody species was as low as approximately 0.1 pH unit.
[0546] The results of the first phase cation exchange experiments
for the compositions containing the 1.33 pH unit pI difference
between parental homodimeric antibody species, depicted in FIGS.
11A and 11B, indicated that the Mono S, Source 30S, and SP HP
cation exchange resins effected the best separation of the tested
composition (i.e., the "1.33" composition). The results of the
first phase anion exchange experiments for the compositions
containing the 1.33 pH unit pI difference and the 0.26 pH unit
difference, respectively, between parental homodimeric antibody
species, depicted in FIGS. 12A, 12B, 13A, and 13B indicated that
the Mono Q, Source 30Q, and Q HP anion exchange resins effected the
best separation of the tested compositions (i.e., the "1.33"
composition and the "0.26" composition). However, in order to
achieve better resolution using each of the best performing cation
resins and anion resins, a series of further scouting experiments
were performed, but using shallower pH gradients (i.e., narrower pH
range). As depicted in FIGS. 14A and 14B, the cation resins and
anion resins, respectively, were tested in small columns (1 mL)
with the depicted shallower gradients, for their ability to
separate MAIs from compositions containing the 1.33 pH unit pI
difference between parental homodimeric antibody species.
[0547] Thus, for the second phase of experiments, shallower
gradients were used with large columns (8 mL) and tested for their
ability to separate MAIs from compositions in which the difference
in calculated pI of the parental homodimeric antibody species was
0.26, 0.11, and 0.10 pH unit, respectively. As depicted in FIGS.
15A and 15B, the cation resins and anion resins, respectively, were
tested in large columns (8 mL) with the depicted shallower
gradients, for their ability to separate MAIs from compositions
containing the 0.26 pH unit pI difference between parental
homodimeric antibody species. As depicted in FIGS. 16A and 16B, the
cation resins and anion resins, respectively, were tested in large
columns (8 mL) with the depicted shallower gradients, for their
ability to separate MAIs from compositions containing the 0.11 pH
unit pI difference between parental homodimeric antibody species.
As depicted in FIGS. 17A and 17B, the cation resins and anion
resins, respectively, were tested in large columns (8 mL) with the
depicted shallower gradients, for their ability to separate MAIs
from compositions containing the 0.1 pH unit pI difference between
parental homodimeric antibody species.
[0548] The results demonstrate that both sets of the
best-performing cation and anion resins separate most of the
compositions to adequate to exceptional degrees, with better
separations occurring with greater parental homodimeric antibody
species pI differences. Generally, the anion exchange resins
achieved MAI separation that was better than that achieved by the
cation resins.
Example 10
[0549] Linear pH gradient separation of mixtures of
common-light-chain IgG4 bispecific heterodimer and parental
homodimeric antibody species (formats as described in Scheme B of
Compositions and Formats tested in the Examples, above) with
varying theoretical differences in heavy chain pI using a strong
cation exchanger Mono S 10/100 GL column and a linear pH gradient
with starting buffer A: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9
mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM
formic acid, 10 mM NaCl, pH 4.0 and final buffer: 15.6 mM CAPS, 9.4
mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM
acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 11.0. Flow rate 4
ml/min. FIG. 18A: common-light-chain bispecific homodimers and
heterodimer with calculated theoretical differences in heavy chain
pI of 1.68 (calculated theoretical pI HC1=7.05; calculated
theoretical pI HC2=8.73) were purified using a 15 column volume
step gradient of 32% B, followed by a 20 column volume linear
gradient from 32% B to 71% B, followed by a 15 column volume hold
of 71% B. FIG. 18B: common-fight-chain bispecific homodimers and
heterodimer with calculated theoretical differences in heavy chain
pI of 1.99 (calculated theoretical pI HC1=6.74; calculated
theoretical pI HC2=8.73) were purified using a 15 column volume
step gradient of 22% B, followed by a 20 column volume linear
gradient from 22% B to 75% B, followed by a 15 column volume hold
of 75% B. FIG. 18C: common-light-chain bispecific homodimers and
heterodimer with calculated theoretical differences in heavy chain
pI of 1.77 (calculated theoretical pI HC1=7.27; calculated
theoretical pI HC2=9.04) were purified using a 15 column volume
step gradient of 25% B, followed by a 20 column volume linear
gradient from 25% B to 83% B, followed by a 15 column volume hold
of 83% B. FIG. 18D: common-light-chain bispecific homodimers and
heterodimer with calculated theoretical differences in heavy chain
pI of 1.94 (calculated theoretical pI HC1=6.74; calculated
theoretical pI HC2=8.68) were purified using a 15 column volume
step gradient of 21% B, followed by a 20 column volume linear
gradient from 21% B to 75% B, followed by a 15 column volume hold
of 75% B.
[0550] The results demonstrate that MAIs of the IgG4 isotype format
were readily purified from parental homodimeric IgG4 isotype
species at all pI differences tested.
Example 11
[0551] Linear pH gradient separation of mixtures of
common-light-chain bispecific IgG1/IgG4 hybrid heterodimer, and
IgG1 and IgG4 homodimeric antibody species (formats as described in
Scheme C of Compositions and Formats tested in the Examples, above)
with varying theoretical differences in heavy chain pI using a
strong cation exchanger Mono S 10/100 GL column and a linear pH
gradient with starting buffer A: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM
TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid,
9.9 mM formic acid, 10 mM NaCl, pH 4.0 and final buffer: 15.6 mM
CAPS, 9,4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM
MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 11.0.
Flow rate 4 ml/min. FIG. 19A: common-light-chain bispecific IgG1
and IgG4 homodimers and IgG1/IgG4 heterodimer with calculated
theoretical differences in heavy chain pI of 2.2 (calculated
theoretical pI HC1 (IgG4)=7.05; calculated theoretical pI HC2
(IgG1)=9.22) were purified using a 15 column. volume step gradient
of 24.5% B, followed by a 20 column volume linear gradient from
24.5% B to 51% B, followed by a 15 column volume hold of 51% B.
FIG. 19B: common-light-chain bispecific IgG1 and IgG4 homodimers
and IgG1/IgG4 heterodimer with calculated theoretical differences
in heavy chain pI of 2.4 (calculated theoretical pI HC1
(IgG4)=7.05; calculated theoretical pI HC2 (IgG1)=9.46) were
purified using a 15 column volume step gradient of 24.5% B,
followed by a 20 column volume linear gradient from 24.5% B to 58%
B, followed by a 15 column volume hold of 58% B. The large
difference in pI between IgG1 and IgG4 backbones leads to excellent
separation of the IgG1 and IgG4 homodimers from the
heterodimer.
[0552] The results demonstrate that MAIs of the hybrid IgG1/IgG4
isotype format were readily purified from parental homodimeric IgG4
isotype species at all pI differences tested.
Example 12
[0553] In certain instances, very broad elution profiles had been
observed, as illustrated in FIGS. 20A and 20B, which depict the
elution profiles of each of two different mixtures of parental
homodimeric species and the corresponding MAI (formats as described
in Scheme D of Compositions and Formats tested in the Examples,
above). The gradients and eluant compositions were as described in
Examples 1 through 9. In the experiment depicted in FIG. 20A, two
different IgG4 homodimers (homodimeric parental species) with
calculated theoretical differences in full IgG pI of 1.81
(calculated theoretical pI of IgG4 homodimeric parental species
A=7.41; calculated theoretical pI of IgG4 homodimeric parental
species B=9.22) and the corresponding MAI with a calculated whole
IgG4 pI of 8.87, were subjected to cation exchange chromatography
using a strong cation exchanger Mono S 5/50 GL column and a linear
pH gradient with starting buffer A: 15.6 mM CAPS, 9.4 mM CHES, 4.6
mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid,
9.9 mM formic acid, 10 mM NaCl, pH 4.0 and final buffer: 15.6 mM
CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM
MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 11.0.
The observed pH at which each various species in the first mixture
eluted as in FIG. 20A was 7.30 (homodimeric parental species A),
9.73 (homodimeric parental species B), and 9.14 (the MAI
(heterodimeric parental species)). FIG. 20B depicts the results of
a similar experiment using different IgG4 homodimeric parental
species A and B (but which, coincidentally, had the same calculated
theoretical pIs as calculated for the parental species depicted in
FIG. 20A). The MAI depicted in FIG. 20B had a calculated pI=8.76.
The observed pH at which each various species in the first mixture
eluted as in FIG. 20B was 7.43 (homodimeric parental species A),
9.77 (homodimeric parental species B), and 9.18 (the MAI
(heterodimeric parental species)).
[0554] As in the previous Examples, all samples and columns used in
the studies depicted in FIGS. 20A and 20B were prepared and
equilibrated at pH 4. It was thus desirable to determine if certain
modified elution conditions and components might better resolve or
separate species in mixtures for which such broad elution profiles
are observed or anticipated based on the nature of the species in a
given mixture.
[0555] Accordingly, experiments were undertaken using the same
homodimeric parental species and MAIs used to generate the data
depicted in FIGS. 20A and 20B, except that a step pH gradient phase
was included in the elution portion, in which the pH of the eluant
was increased from about pH 4 to about pH 6.5 within a very small
eluant volume (i.e., within very few elution fraction).
Additionally, the sample mixture containing both homodimeric
parental species and the heterodimeric MAI (formats as described in
Scheme D of Compositions and Formats tested in the Examples, above)
was prepared and equilibrated on the column at pH 6 prior to
generating the step gradient, which eluted the lowest pI
homodimeric species. This then allowed for the resolving and
separation of the remaining MAI from the second homodimeric species
by using a shallow linear gradient phase (from pH 7.8 through pH
9.65 as in FIG. 21A, and from pH 7.94 through pH 9.68 as in FIG.
21B).
[0556] As depicted in FIGS. 22A and 22B the same two sample
mixtures used to generate the data in FIG. 21A and FIG. 21B were
employed in two similar dual phase (i.e., step pH gradient then
linear pH gradient schemes) elution experiments; one beginning at
pH 4, the other beginning at pH 6. The results, depicted in FIGS.
22A and 22B, demonstrate that elutions which begin at milder pH
(e.g., pH 6 versus pH 4), resolution, separation, and elution of
the MAIs from their respective corresponding homodimeric parental
species is enhanced relative to elutions beginning at more extreme
pH (i.e., beginning at pH 4 versus pH 6).
Example 13
[0557] It was desirable to next determine if employing milder
beginning pHs of sample mixtures (e.g., pH 6 versus lower pH's) and
shallow linear pH gradients (i.e., gradients applied over
relatively large eluant volumes (large numbers of
fractions/fraction volumes), would result in the resolution and
separation of MAIs from corresponding homodimeric parental species
that have calculated and/or experimental pIs that are very close in
value to one another.
[0558] Accordingly, a sample mixture containing both homodimeric
parental species and the heterodimeric MAI (formats as described in
Scheme D of Compositions and Formats tested in the Examples,
above), wherein calculated theoretical whole IgG4 pI of each
homodimeric parental species was 8.97 and 8.99, respectively, and
the calculated theoretical whole IgG4 pI of the MAI was 8.98, were
prepared and the column equilibrated at pH 6.0, and then subjected
to cation exchange chromatography using a strong cation exchanger
Mono S 10/100 GL column and a linear pH gradient with starting
buffer A: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO,
8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic acid, 10
mM NaCl, pH 8.34 and final buffer: 15.6 mM CAPS, 9.4 mM CHES, 4.6
mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid,
9.9 mM formic acid, 10 mM NaCl, pH 9.86. The observed pH at which
each various species in the first mixture eluted as in FIG. 20A was
7.30 (homodimeric parental species A), 9.73 (homodimeric parental
species B), and 9.14 (the MAI (heterodimeric parental species was
subjected to the elution conditions depicted in FIG. 23.
[0559] The results indicate that an MAI with a pI as little as 0.01
pH units different from each corresponding parental homodimeric
species can be resolved and separated from both such homodimeric
parental species using the disclosed methods.
Example 14
[0560] It had been observed that, for certain sample mixtures,
neither cation exchange nor anion exchange, alone, was sufficient
to separate certain MAIs from their homodimeric parental species to
satisfactory purity. It was then desirable to assess whether the
resolution and purification of such MAIs could be improved to
satisfaction by subjecting a set of pooled fractions corresponding
to the MAI-eluting peak of a cation exchange procedure to a
subsequent anion exchange procedure, each procedure as described
above in Examples 1-9 and as indicated in FIG. 24.
[0561] More specifically, two different 10 milligram sample
aliquots of an MAI/homodimeric parental species mixture of the
format as described in Scheme A of Compositions and Formats tested
in the Examples, above, were injected into the cation exchange
column in order to generate sufficient eluate for the subsequence
anion exchange procedure. The calculated theoretical whole IgG pI
of each homodimeric parental species was 9.19 and 9.09,
respectively, and the calculated theoretical whole IgG1 pI of the
MAI was 9.09. The sample mixture was prepared and the column
equilibrated at pH 6.0, and then subjected to cation exchange
chromatography using a strong cation exchanger Mono S 10/100 GL
column and a linear pH gradient with starting buffer A: 15.6 mM
CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM
MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 6.87 and
final buffer: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM
HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic
acid, 10 mM NaCl, pH 7.27. The pools containing the presumptive
heterodimer (MAI)-containing middle peak as depicted in the left
portion of FIG. 24 were collected, pooled, and then injected into
the anion exchange column and eluted using a linear pH gradient
with starting buffer A: 9.8 mM methylamine, 9.1 mM
1,2-ethanediamine, 6.4 mM 1-methylpiperazine, 13.7 mM
1,4-dimethylpiperazine, 5.8 mM bis-tris, 7.7 mM hydroxylamine, and
10 mM sodium chloride at pH=9.57; and final buffer B: 9.8 mM
methylamine, 9.1 mM 1,2-ethanediamine, 6.4 mM 1-methylpiperazine,
13.7 mM 1,4-dimethylpiperazine, 5.8 mM bis-tris, 7.7 mM
hydroxylamine, and 10 mM sodium chloride at pH=8.07. Mass
spectroscopy analysis of a specimen of the presumptive
MAI-containing pool from the initial cation exchange procedure
revealed that the peak contained significant amounts of one of the
homodimeric parental species. Mass spectroscopy analysis of the
presumptive MAI-containing peak that eluted from the subsequent
anion exchange column revealed that the pooled fractions
corresponding to this peak were contained the MAI and were
essentially devoid of either homodimeric parental species.
[0562] The results demonstrate that, for certain mixtures, using
both cation exchange and anion exchange sequentially can enhance
resolution and separation of MAIs from their corresponding
homodimeric parental species.
Example 15
[0563] It was next desirable to determine whether, for certain MAI
and corresponding homodimeric parental species mixtures, it might
be advantageous to employ different buffer systems or eluants,
which are designed more specifically for use with anion exchange
resins.
[0564] Accordingly, an experiment was designed in which an
MAI/homodimeric parental species mixture of the format as described
in Scheme A of Compositions and Formats tested in the Examples,
above, was subjected to anion exchange chromatography using the
following cation exchange buffer system: starting buffer A: 15.6 mM
CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM HEPPSO, 8.7 mM MOPSO, 11 mM
MES, 13 mM acetic acid, 9.9 mM formic acid, 10 mM NaCl, pH 9.20 and
final buffer B: 15.6 mM CAPS, 9.4 mM CHES, 4.6 mM TAPS, 9.9 mM
HEPPSO, 8.7 mM MOPSO, 11 mM MES, 13 mM acetic acid, 9.9 mM formic
acid, 10 mM NaCl, pH 8.20, under conditions as indicated in FIG.
25A. All three of the peaks illustrated in FIG. 25A were analyzed
by mass spectroscopy to determine peak composition, which was
observed to be as indicated in FIG. 25A. A separate aliquot of the
same MAI/homodimeric parental species mixture was then subjected to
anion exchange chromatography using the following anion exchange
buffer system: starting buffer A: 9.8 mM methylamine, 9.1 mM
1,2-ethanediamine, 6.4 mM 1-methylpiperazine, 13.7 mM
1,4-dimethylpiperazine, 5.8 mM bis-tris, 7.7 mM hydroxylamine, and
10 mM sodium chloride at pH=9.34; and final buffer B: 9.8 mM
methylamine, 9.1 mM 1,2-ethanediamine, 6.4 mM 1-methylpiperazine,
13.7 mM 1,4-dimethylpiperazine, 5.8 mM bis-tris, 7.7 mM
hydroxylamine, and 10 mM sodium chloride at pH=7.53 under
conditions as indicated in FIG. 25B. All three of the peaks
illustrated in FIG. 25B were analyzed by mass spectroscopy to
determine peak composition, which was observed to be as indicated
in FIG. 25B.
[0565] The results indicate that, for certain MAI/homodimeric
parental species mixtures, using anion exchange buffer systems or
eluants when employing anion exchange chromatographic procedures
may resolve and separate MAIs from the homodimeric parental species
to levels of purity that markedly improved relative to that
observed when using cation exchange buffer systems or eluants when
employing anion exchange chromatographic procedures.
[0566] Other chromatographic materials that may be employed with
similar results to that demonstrated in the Examples above are
provided in FIG. 26A and FIG. 26B.
[0567] Whereas particular embodiments of the invention have been
described above for purposes of illustration, it will be
appreciated by those skilled in the art that numerous variations of
the details may be made without departing from the invention as
described in the appended claims.
Sequence CWU 1
1
431150PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptideMISC_FEATURE(1)..(150)This sequence may
encompass 1-75 "Gly Ser" repeating units wherein some positions may
not be present 1Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly
Ser Gly Ser1 5 10 15Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser
Gly Ser Gly Ser 20 25 30Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly
Ser Gly Ser Gly Ser 35 40 45Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser
Gly Ser Gly Ser Gly Ser 50 55 60Gly Ser Gly Ser Gly Ser Gly Ser Gly
Ser Gly Ser Gly Ser Gly Ser65 70 75 80Gly Ser Gly Ser Gly Ser Gly
Ser Gly Ser Gly Ser Gly Ser Gly Ser 85 90 95Gly Ser Gly Ser Gly Ser
Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser 100 105 110Gly Ser Gly Ser
Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser 115 120 125Gly Ser
Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser 130 135
140Gly Ser Gly Ser Gly Ser145 1502225PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptideMISC_FEATURE(1)..(225)This sequence may encompass 1-75
"Gly Gly Ser" repeating units wherein some positions may not be
present 2Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
Ser Gly1 5 10 15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
Ser Gly Gly 20 25 30Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
Ser Gly Gly Ser 35 40 45Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
Ser Gly Gly Ser Gly 50 55 60Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
Ser Gly Gly Ser Gly Gly65 70 75 80Ser Gly Gly Ser Gly Gly Ser Gly
Gly Ser Gly Gly Ser Gly Gly Ser 85 90 95Gly Gly Ser Gly Gly Ser Gly
Gly Ser Gly Gly Ser Gly Gly Ser Gly 100 105 110Gly Ser Gly Gly Ser
Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly 115 120 125Ser Gly Gly
Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser 130 135 140Gly
Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly145 150
155 160Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly
Gly 165 170 175Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
Gly Gly Ser 180 185 190Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
Ser Gly Gly Ser Gly 195 200 205Gly Ser Gly Gly Ser Gly Gly Ser Gly
Gly Ser Gly Gly Ser Gly Gly 210 215 220Ser2253300PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptideMISC_FEATURE(1)..(300)This sequence may encompass 1-75
"Gly Gly Gly Ser" repeating units wherein some positions may not be
present 3Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly
Gly Ser1 5 10 15Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly
Gly Gly Ser 20 25 30Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
Gly Gly Gly Ser 35 40 45Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly
Ser Gly Gly Gly Ser 50 55 60Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly
Gly Ser Gly Gly Gly Ser65 70 75 80Gly Gly Gly Ser Gly Gly Gly Ser
Gly Gly Gly Ser Gly Gly Gly Ser 85 90 95Gly Gly Gly Ser Gly Gly Gly
Ser Gly Gly Gly Ser Gly Gly Gly Ser 100 105 110Gly Gly Gly Ser Gly
Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125Gly Gly Gly
Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 130 135 140Gly
Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser145 150
155 160Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly
Ser 165 170 175Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly
Gly Gly Ser 180 185 190Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly
Ser Gly Gly Gly Ser 195 200 205Gly Gly Gly Ser Gly Gly Gly Ser Gly
Gly Gly Ser Gly Gly Gly Ser 210 215 220Gly Gly Gly Ser Gly Gly Gly
Ser Gly Gly Gly Ser Gly Gly Gly Ser225 230 235 240Gly Gly Gly Ser
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 245 250 255Gly Gly
Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 260 265
270Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
275 280 285Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 290 295
3004375PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptideMISC_FEATURE(1)..(375)This sequence may
encompass 1-75 "Gly Gly Gly Gly Ser" repeating units wherein some
positions may not be present 4Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly 20 25 30Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly 35 40 45Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 50 55 60Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser65 70 75 80Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 85 90 95Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 100 105
110Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly 165 170 175Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly 180 185 190Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 195 200 205Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 210 215 220Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser225 230
235 240Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly 245 250 255Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly 260 265 270Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly 275 280 285Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly 290 295 300Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser305 310 315 320Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 325 330 335Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 340 345
350Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
355 360 365Gly Ser Gly Gly Gly Gly Ser 370 3755675PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptideMISC_FEATURE(1)..(675)This sequence may encompass 1-75
"Gly Gly Gly Gly Ser Gly Gly Gly Gly" repeating units wherein some
positions may not be present 5Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly1 5 10 15Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser 20 25 30Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly 35 40 45Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly 50 55 60Gly Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly65 70 75 80Gly Gly Gly
Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 85 90 95Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly 100 105
110Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
115 120 125Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly
Gly Gly 130 135 140Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly145 150 155 160Gly Gly Gly Gly Gly Gly Ser Gly Gly
Gly Gly Gly Gly Gly Gly Ser 165 170 175Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly 180 185 190Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly 195 200 205Gly Gly Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 210 215 220Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly225 230
235 240Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly 245 250 255Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly 260 265 270Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly 275 280 285Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly 290 295 300Gly Gly Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser305 310 315 320Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly 325 330 335Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly 340 345
350Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
355 360 365Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly 370 375 380Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly385 390 395 400Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly Gly Gly 405 410 415Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly 420 425 430Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly 435 440 445Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser 450 455 460Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly465 470
475 480Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly 485 490 495Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
Gly Gly Gly 500 505 510Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser Gly 515 520 525Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly 530 535 540Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly Gly Gly Gly545 550 555 560Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly 565 570 575Gly Gly
Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly 580 585
590Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
595 600 605Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly 610 615 620Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Gly625 630 635 640Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly 645 650 655Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly 660 665 670Gly Gly Gly
67561050PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptideMISC_FEATURE(1)..(1050)This sequence may
encompass 1-75 "Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly" repeating units wherein some positions may not be present 6Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly1 5 10
15Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
20 25 30Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
Gly 35 40 45Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly 50 55 60Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser65 70 75 80Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly 85 90 95Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly 100 105 110Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly 115 120 125Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly145 150 155 160Gly
Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 165 170
175Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
180 185 190Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly 195 200 205Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 210 215 220Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly225 230 235 240Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly 245 250 255Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 260 265 270Gly Gly Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 275 280 285Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 290 295
300Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly305 310 315 320Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 325 330 335Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly 340 345 350Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly 355 360 365Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 370 375 380Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly385 390 395 400Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 405 410
415Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
420 425 430Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 435 440 445Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Gly Gly 450 455 460Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Gly Gly Gly Gly465 470 475 480Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly 485 490 495Gly Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 500 505 510Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 515 520 525Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 530 535
540Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly545
550 555 560Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly 565 570 575Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly 580 585 590Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly 595 600 605Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly 610 615 620Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser625 630 635 640Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 645 650 655Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 660 665
670Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
675 680 685Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly 690 695 700Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly705 710 715 720Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly 725 730 735Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser 740 745 750Gly Gly Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 755 760 765Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 770 775 780Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly785 790
795 800Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly 805 810 815Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly 820 825 830Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly 835 840 845Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser 850 855 860Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly865 870 875 880Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 885 890 895Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly 900 905
910Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
915 920 925Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly 930 935 940Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly945 950 955 960Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser 965 970 975Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly 980 985 990Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 995 1000 1005Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly 1010 1015
1020Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
1025 1030 1035Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1040
1045 105071425PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptideMISC_FEATURE(1)..(1425)This sequence
may encompass 1-75 "Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly" repeating units wherein some positions
may not be present 7Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly1 5 10 15Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly 20 25 30Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 35 40 45Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly 50 55 60Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly65 70 75 80Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly 85 90 95Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 100 105 110Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 115 120 125Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130 135
140Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly
Gly145 150 155 160Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser 165 170 175Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly 180 185 190Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly 195 200 205Gly Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 210 215 220Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly225 230 235 240Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly 245 250
255Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
260 265 270Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly 275 280 285Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 290 295 300Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly305 310 315 320Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly 325 330 335Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 340 345 350Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly 355 360 365Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly 370 375
380Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly385 390 395 400Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 405 410 415Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly 420 425 430Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly 435 440 445Gly Gly Gly Ser Gly Gly
Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 450 455 460Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser465 470 475 480Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly 485 490
495Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
500 505 510Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser 515 520 525Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 530 535 540Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly545 550 555 560Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly 565 570 575Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly 580 585 590Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 595 600 605Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 610 615
620Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly625 630 635 640Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser 645 650 655Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser Gly Gly 660 665 670Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly 675 680 685Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly 690 695 700Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly705 710 715 720Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 725 730
735Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
740 745 750Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly 755 760 765Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser 770 775 780Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly785 790 795 800Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly 805 810 815Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 820 825 830Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 835 840 845Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly 850 855
860Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
Gly865 870 875 880Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly 885 890 895Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly 900 905 910Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly 915 920 925Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 930 935 940Gly Ser Gly Gly
Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser945 950 955 960Gly
Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly 965 970
975Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
980 985 990Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Gly 995 1000 1005Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly 1010 1015 1020Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly 1025 1030 1035Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly 1040 1045 1050Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly 1055 1060 1065Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1070 1075 1080Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1085 1090
1095Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1100 1105 1110Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
Gly Gly 1115 1120 1125Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly 1130 1135 1140Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly 1145 1150 1155Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 1160 1165 1170Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1175 1180 1185Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 1190 1195 1200Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly 1205 1210
1215Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1220 1225 1230Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly 1235 1240 1245Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
Gly Gly Gly Gly 1250 1255 1260Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser 1265 1270 1275Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Gly 1280 1285 1290Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1295 1300 1305Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 1310 1315 1320Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 1325 1330
1335Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
1340 1345 1350Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 1355 1360 1365Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser 1370 1375 1380Gly Gly Gly Gly Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly 1385 1390 1395Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly 1400 1405 1410Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly 1415 1420 142581800PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptideMISC_FEATURE(1)..(1800)This sequence may encompass 1-75
"Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly" repeating units wherein some
positions may not be present 8Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly 20 25 30Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly 35 40 45Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 50 55 60Gly Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly65 70 75 80Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 85 90 95Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 100 105
110Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 130 135 140Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly145 150 155 160Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly 165 170 175Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly 180 185 190Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 195 200 205Gly Gly Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 210 215 220Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly225 230
235 240Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly 245 250 255Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
Gly Gly Gly 260 265 270Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly 275 280 285Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly 290 295 300Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly305 310 315 320Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 325 330 335Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 340 345
350Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
355 360 365Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 370 375 380Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly385 390 395 400Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly 405 410 415Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly 420 425 430Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 435 440 445Gly Gly Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 450
455 460Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly465 470 475 480Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly 485 490 495Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly 500 505 510Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 515 520 525Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 530 535 540Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly545 550 555 560Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 565 570
575Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
580 585 590Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly 595 600 605Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 610 615 620Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly625 630 635 640Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly 645 650 655Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 660 665 670Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 675 680 685Gly
Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 690 695
700Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly705 710 715 720Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly 725 730 735Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly 740 745 750Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 755 760 765Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 770 775 780Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly785 790 795 800Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 805 810
815Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
820 825 830Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly 835 840 845Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 850 855 860Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly865 870 875 880Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly 885 890 895Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 900 905 910Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 915 920 925Gly
Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 930 935
940Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly945 950 955 960Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly 965 970 975Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly 980 985 990Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 995 1000 1005Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1010 1015 1020Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 1025 1030 1035Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1040 1045
1050Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1055 1060 1065Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly 1070 1075 1080Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly 1085 1090 1095Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly 1100 1105 1110Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 1115 1120 1125Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1130 1135 1140Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 1145 1150 1155Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1160 1165
1170Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1175 1180 1185Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly 1190 1195 1200Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly 1205 1210 1215Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly 1220 1225 1230Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 1235 1240 1245Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1250 1255 1260Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 1265 1270 1275Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1280 1285
1290Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1295 1300 1305Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly 1310 1315 1320Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly 1325 1330 1335Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly 1340 1345 1350Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 1355 1360 1365Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1370 1375 1380Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 1385 1390 1395Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1400 1405
1410Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1415 1420 1425Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly 1430 1435 1440Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly 1445 1450 1455Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly 1460 1465 1470Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 1475 1480 1485Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1490 1495 1500Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 1505 1510 1515Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1520 1525
1530Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1535 1540 1545Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly 1550 1555 1560Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly 1565 1570 1575Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly 1580 1585 1590Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 1595 1600 1605Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1610 1615 1620Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 1625 1630 1635Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1640 1645
1650Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1655 1660 1665Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly 1670 1675 1680Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly 1685 1690 1695Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly 1700 1705 1710Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 1715 1720 1725Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1730 1735 1740Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 1745 1750 1755Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1760 1765
1770Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1775 1780 1785Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1790
1795 180092175PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptideMISC_FEATURE(1)..(2175)This sequence
may encompass 1-75 "Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly" repeating units wherein some positions may not be present 9Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10
15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly
20 25 30Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly 35 40 45Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly 50 55 60Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly65 70 75 80Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly 85 90 95Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 100 105 110Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 130 135 140Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly 165 170
175Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
180 185 190Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser 195 200 205Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly 210 215 220Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly225 230 235 240Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly 245 250 255Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 260 265 270Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 275 280 285Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 290 295
300Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly305 310 315 320Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 325 330 335Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Gly Gly Gly Gly 340 345 350Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser 355 360 365Gly Gly Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly 370 375 380Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly385 390 395 400Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 405 410
415Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
420 425 430Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly 435 440 445Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 450 455 460Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly465 470 475 480Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly 485 490 495Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 500 505 510Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 515 520 525Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 530 535
540Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
Gly545 550 555 560Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser 565 570 575Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly 580 585 590Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly 595 600 605Gly Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 610 615 620Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly625 630 635 640Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 645 650
655Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
660 665 670Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly 675 680 685Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly 690 695 700Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly705 710 715 720Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly 725 730 735Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 740 745 750Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 755 760 765Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly 770 775
780Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly785 790 795 800Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly 805 810 815Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 820 825 830Gly Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly 835 840 845Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 850 855 860Gly Ser Gly Gly
Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser865 870 875 880Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 885 890
895Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
900 905 910Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 915 920 925Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly 930 935 940Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Gly Gly Gly945 950 955 960Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly 965 970 975Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 980 985 990Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 995 1000
1005Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
1010 1015 1020Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly 1025 1030 1035Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
Gly Gly Gly Gly 1040 1045 1050Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly 1055 1060
1065Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1070 1075 1080Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser 1085 1090 1095Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly 1100 1105 1110Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly 1115 1120 1125Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly 1130 1135 1140Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 1145 1150 1155Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 1160 1165 1170Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 1175 1180
1185Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
1190 1195 1200Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 1205 1210 1215Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser 1220 1225 1230Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Gly 1235 1240 1245Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly 1250 1255 1260Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly 1265 1270 1275Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 1280 1285 1290Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly 1295 1300
1305Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
1310 1315 1320Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly 1325 1330 1335Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 1340 1345 1350Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser 1355 1360 1365Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser 1370 1375 1380Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 1385 1390 1395Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1400 1405 1410Gly
Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly 1415 1420
1425Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1430 1435 1440Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly 1445 1450 1455Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly 1460 1465 1470Gly Ser Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly 1475 1480 1485Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 1490 1495 1500Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1505 1510 1515Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1520 1525 1530Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1535 1540
1545Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1550 1555 1560Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly 1565 1570 1575Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 1580 1585 1590Gly Gly Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly 1595 1600 1605Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly 1610 1615 1620Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1625 1630 1635Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1640 1645 1650Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1655 1660
1665Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
1670 1675 1680Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly 1685 1690 1695Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Gly Gly 1700 1705 1710Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly 1715 1720 1725Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Gly Gly Gly 1730 1735 1740Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 1745 1750 1755Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly 1760 1765 1770Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1775 1780
1785Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
1790 1795 1800Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser 1805 1810 1815Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly 1820 1825 1830Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly 1835 1840 1845Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly 1850 1855 1860Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 1865 1870 1875Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 1880 1885 1890Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 1895 1900
1905Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly
1910 1915 1920Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 1925 1930 1935Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser 1940 1945 1950Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 1955 1960 1965Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly 1970 1975 1980Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1985 1990 1995Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 2000 2005 2010Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 2015 2020
2025Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
2030 2035 2040Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly 2045 2050 2055Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 2060 2065 2070Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly 2075 2080 2085Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser 2090 2095 2100Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly 2105 2110 2115Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 2120 2125 2130Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly 2135 2140
2145Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
2150 2155 2160Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 2165
2170 2175102550PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptideMISC_FEATURE(1)..(2550)This sequence
may encompass 1-75 "Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly" repeating units wherein some positions may not
be present 10Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 20 25 30Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly 35 40 45Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 50 55 60Gly Gly Gly Gly Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly65 70 75 80Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly 85 90 95Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 100 105 110Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 130 135
140Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly145 150 155 160Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly 165 170 175Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly 180 185 190Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly 195 200 205Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 210 215 220Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly225 230 235 240Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 245 250
255Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
260 265 270Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly 275 280 285Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 290 295 300Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly305 310 315 320Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser 325 330 335Gly Gly Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 340 345 350Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 355 360 365Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 370 375
380Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly385 390 395 400Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly 405 410 415Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly 420 425 430Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Gly Gly Gly Gly Ser Gly 435 440 445Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 450 455 460Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly465 470 475 480Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 485 490
495Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
500 505 510Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly 515 520 525Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 530 535 540Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly545 550 555 560Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly 565 570 575Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 580 585 590Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 595 600 605Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 610 615
620Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly625 630 635 640Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser 645 650 655Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly 660 665 670Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly 675 680 685Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 690 695 700Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly705 710 715 720Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 725 730
735Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
740 745 750Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser 755 760 765Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Gly Gly 770 775 780Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly785 790 795 800Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly 805 810 815Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 820 825 830Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 835 840 845Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 850 855
860Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser865 870 875 880Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 885 890 895Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly 900 905 910Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser 915 920 925Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 930 935 940Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly945 950 955 960Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 965 970
975Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly
980 985 990Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly 995 1000 1005Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly 1010 1015 1020Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly 1025 1030 1035Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly 1040 1045 1050Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1055 1060 1065Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1070 1075 1080Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1085 1090
1095Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1100 1105 1110Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly 1115 1120 1125Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly 1130 1135 1140Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly 1145 1150 1155Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly 1160 1165 1170Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 1175 1180 1185Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 1190 1195 1200Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 1205 1210
1215Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly
1220 1225 1230Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 1235 1240 1245Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser 1250 1255 1260Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 1265 1270 1275Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Gly 1280 1285 1290Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1295 1300
1305Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1310 1315 1320Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly 1325 1330 1335Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 1340 1345 1350Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly 1355 1360 1365Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly 1370 1375 1380Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly 1385 1390 1395Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1400 1405 1410Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1415 1420
1425Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1430 1435 1440Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser 1445 1450 1455Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly 1460 1465 1470Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly 1475 1480 1485Gly Gly Gly Ser Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly 1490 1495 1500Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 1505 1510 1515Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly 1520 1525 1530Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 1535 1540
1545Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
1550 1555 1560Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 1565 1570 1575Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 1580 1585 1590Ser Gly Gly Gly Gly Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 1595 1600 1605Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser 1610 1615 1620Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 1625 1630 1635Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1640 1645 1650Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly 1655 1660
1665Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1670 1675 1680Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly 1685 1690 1695Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly 1700 1705 1710Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly 1715 1720 1725Gly Ser Gly Gly Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly 1730 1735 1740Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1745 1750 1755Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser 1760 1765 1770Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1775 1780
1785Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly
1790 1795 1800Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly 1805 1810 1815Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly 1820 1825 1830Gly Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly 1835 1840 1845Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly 1850 1855 1860Gly Gly Ser Gly Gly
Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 1865 1870 1875Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 1880 1885 1890Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly 1895 1900
1905Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
1910 1915 1920Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 1925 1930 1935Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser 1940 1945 1950Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 1955 1960 1965Gly Gly Gly Gly Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly 1970 1975 1980Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1985 1990 1995Gly Gly Gly
Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly 2000 2005 2010Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 2015 2020
2025Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly
2030 2035 2040Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly 2045 2050 2055Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly 2060 2065 2070Gly Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly 2075 2080 2085Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 2090 2095 2100Ser Gly Gly Gly Gly
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 2105 2110 2115Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 2120 2125 2130Gly
Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly 2135 2140
2145Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
2150 2155 2160Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Gly Gly 2165 2170 2175Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 2180 2185 2190Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly 2195 2200 2205Gly Gly Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly 2210 2215 2220Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 2225 2230 2235Gly Ser Gly
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly 2240 2245 2250Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 2255 2260
2265Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser
2270 2275 2280Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser 2285 2290 2295Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Gly 2300 2305 2310Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly 2315 2320 2325Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly 2330 2335 2340Gly Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 2345 2350 2355Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 2360 2365 2370Gly
Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 2375 2380
2385Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
2390 2395 2400Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly
Gly Gly 2405 2410 2415Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 2420 2425 2430Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly 2435 2440 2445Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser 2450 2455 2460Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 2465 2470 2475Gly Gly Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 2480 2485 2490Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 2495 2500
2505Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly
2510 2515 2520Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly 2525 2530 2535Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly 2540 2545 2550114PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 11Gly Gly Gly
Gly1125PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 12Gly Gly Gly Gly Gly1 5138PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 13Gly
Gly Gly Lys Gly Gly Gly Gly1 5148PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 14Gly Gly Gly Asn Gly Ser
Gly Gly1 5158PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 15Gly Gly Gly Cys Gly Gly Gly Gly1
5165PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 16Gly Pro Asn Gly Gly1 517150PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptideMISC_FEATURE(1)..(150)This sequence may encompass 1-75
"Gly Glu" repeating units wherein some positions may not be present
17Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu1
5 10 15Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly
Glu 20 25 30Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu
Gly Glu 35 40 45Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly
Glu Gly Glu 50 55 60Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu
Gly Glu Gly Glu65 70 75 80Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu
Gly Glu Gly Glu Gly Glu 85 90 95Gly Glu Gly Glu Gly Glu Gly Glu Gly
Glu Gly Glu Gly Glu Gly Glu 100 105 110Gly Glu Gly Glu Gly Glu Gly
Glu Gly Glu Gly Glu Gly Glu Gly Glu 115 120 125Gly Glu Gly Glu Gly
Glu Gly Glu Gly Glu Gly Glu Gly Glu Gly Glu 130 135 140Gly Glu Gly
Glu Gly Glu145 15018225PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptideMISC_FEATURE(1)..(225)This
sequence may encompass 1-75 "Gly Gly Glu" repeating units wherein
some positions may not be present 18Gly Gly Glu Gly Gly Glu Gly Gly
Glu Gly Gly Glu Gly Gly Glu Gly1 5 10 15Gly Glu Gly Gly Glu Gly Gly
Glu Gly Gly Glu Gly Gly Glu Gly Gly 20 25 30Glu Gly Gly Glu Gly Gly
Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu 35 40 45Gly Gly Glu Gly Gly
Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly 50 55 60Gly Glu Gly Gly
Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly65 70 75 80Glu Gly
Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu 85 90 95Gly
Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly 100 105
110Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly
115 120 125Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly
Gly Glu 130 135 140Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu
Gly Gly Glu Gly145 150 155 160Gly Glu Gly Gly Glu Gly Gly Glu Gly
Gly Glu Gly Gly Glu Gly Gly 165 170 175Glu Gly Gly Glu Gly Gly Glu
Gly Gly Glu Gly Gly Glu Gly Gly Glu 180 185 190Gly Gly Glu Gly Gly
Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly 195 200 205Gly Glu Gly
Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly Glu Gly Gly 210 215
220Glu22519300PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptideMISC_FEATURE(1)..(300)This sequence
may encompass 1-75 "Gly Gly Gly Glu" repeating units wherein some
positions may not be present 19Gly Gly Gly Glu Gly Gly Gly Glu Gly
Gly Gly Glu Gly Gly Gly Glu1 5 10 15Gly Gly Gly Glu Gly Gly Gly Glu
Gly Gly Gly Glu Gly Gly Gly Glu 20 25 30Gly Gly Gly Glu Gly Gly Gly
Glu Gly Gly Gly Glu Gly Gly Gly Glu 35 40 45Gly Gly Gly Glu Gly Gly
Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu 50 55 60Gly Gly Gly Glu Gly
Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu65 70 75 80Gly Gly Gly
Glu Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu 85 90 95Gly Gly
Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu 100 105
110Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu
115 120 125Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly
Gly Glu 130 135 140Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu
Gly Gly Gly Glu145 150 155 160Gly Gly Gly Glu Gly Gly Gly Glu Gly
Gly Gly Glu Gly Gly Gly Glu 165 170 175Gly Gly Gly Glu Gly Gly Gly
Glu Gly Gly Gly Glu Gly Gly Gly Glu 180 185 190Gly Gly Gly Glu Gly
Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu 195 200 205Gly Gly Gly
Glu Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu 210 215 220Gly
Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu225 230
235 240Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly
Glu 245 250 255Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly Glu Gly
Gly Gly Glu 260 265 270Gly Gly Gly Glu Gly Gly Gly Glu Gly Gly Gly
Glu Gly Gly Gly Glu 275 280 285Gly Gly Gly Glu Gly Gly Gly Glu Gly
Gly Gly Glu 290 295 30020375PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptideMISC_FEATURE(1)..(375)This
sequence may encompass 1-75 "Gly Gly Gly Gly Glu" repeating units
wherein some positions may not be present 20Gly Gly Gly Gly Glu Gly
Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly1 5 10 15Gly Gly Gly Glu Gly
Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly 20 25 30Gly Gly Glu Gly
Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly 35 40 45Gly Glu Gly
Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly 50 55 60Glu Gly
Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu65 70 75
80Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly
85 90 95Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly
Gly 100 105 110Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu
Gly Gly Gly 115 120 125Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly
Glu Gly Gly Gly Gly 130 135 140Glu Gly Gly Gly Gly Glu Gly Gly Gly
Gly Glu Gly Gly Gly Gly Glu145 150 155 160Gly Gly Gly Gly Glu Gly
Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly 165 170 175Gly Gly Gly Glu
Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly 180 185 190Gly Gly
Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly 195 200
205Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly
210 215 220Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly
Gly Glu225 230 235 240Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly
Gly Gly Gly Glu Gly 245 250 255Gly Gly Gly Glu Gly Gly Gly Gly Glu
Gly Gly Gly Gly Glu Gly Gly 260 265 270Gly Gly Glu Gly Gly Gly Gly
Glu Gly Gly Gly Gly Glu Gly Gly Gly
275 280 285Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly
Gly Gly 290 295 300Glu Gly Gly Gly Gly Glu Gly Gly Gly Gly Glu Gly
Gly Gly Gly Glu305 310 315 320Gly Gly Gly Gly Glu Gly Gly Gly Gly
Glu Gly Gly Gly Gly Glu Gly 325 330 335Gly Gly Gly Glu Gly Gly Gly
Gly Glu Gly Gly Gly Gly Glu Gly Gly 340 345 350Gly Gly Glu Gly Gly
Gly Gly Glu Gly Gly Gly Gly Glu Gly Gly Gly 355 360 365Gly Glu Gly
Gly Gly Gly Glu 370 37521150PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptideMISC_FEATURE(1)..(150)This
sequence may encompass 1-75 "Gly Asp" repeating units wherein some
positions may not be present 21Gly Asp Gly Asp Gly Asp Gly Asp Gly
Asp Gly Asp Gly Asp Gly Asp1 5 10 15Gly Asp Gly Asp Gly Asp Gly Asp
Gly Asp Gly Asp Gly Asp Gly Asp 20 25 30Gly Asp Gly Asp Gly Asp Gly
Asp Gly Asp Gly Asp Gly Asp Gly Asp 35 40 45Gly Asp Gly Asp Gly Asp
Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp 50 55 60Gly Asp Gly Asp Gly
Asp Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp65 70 75 80Gly Asp Gly
Asp Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp 85 90 95Gly Asp
Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp 100 105
110Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp
115 120 125Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp Gly Asp
Gly Asp 130 135 140Gly Asp Gly Asp Gly Asp145 15022225PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptideMISC_FEATURE(1)..(225)This sequence may encompass 1-75
"Gly Gly Asp" repeating units wherein some positions may not be
present 22Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly
Asp Gly1 5 10 15Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly
Asp Gly Gly 20 25 30Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly
Asp Gly Gly Asp 35 40 45Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly
Asp Gly Gly Asp Gly 50 55 60Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly
Asp Gly Gly Asp Gly Gly65 70 75 80Asp Gly Gly Asp Gly Gly Asp Gly
Gly Asp Gly Gly Asp Gly Gly Asp 85 90 95Gly Gly Asp Gly Gly Asp Gly
Gly Asp Gly Gly Asp Gly Gly Asp Gly 100 105 110Gly Asp Gly Gly Asp
Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly 115 120 125Asp Gly Gly
Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp 130 135 140Gly
Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly145 150
155 160Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly
Gly 165 170 175Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly Asp
Gly Gly Asp 180 185 190Gly Gly Asp Gly Gly Asp Gly Gly Asp Gly Gly
Asp Gly Gly Asp Gly 195 200 205Gly Asp Gly Gly Asp Gly Gly Asp Gly
Gly Asp Gly Gly Asp Gly Gly 210 215 220Asp22523300PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptideMISC_FEATURE(1)..(300)This sequence may encompass 1-75
"Gly Gly Gly Asp" repeating units wherein some positions may not be
present 23Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly
Gly Asp1 5 10 15Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp Gly
Gly Gly Asp 20 25 30Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp
Gly Gly Gly Asp 35 40 45Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly
Asp Gly Gly Gly Asp 50 55 60Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly
Gly Asp Gly Gly Gly Asp65 70 75 80Gly Gly Gly Asp Gly Gly Gly Asp
Gly Gly Gly Asp Gly Gly Gly Asp 85 90 95Gly Gly Gly Asp Gly Gly Gly
Asp Gly Gly Gly Asp Gly Gly Gly Asp 100 105 110Gly Gly Gly Asp Gly
Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp 115 120 125Gly Gly Gly
Asp Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp 130 135 140Gly
Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp145 150
155 160Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly
Asp 165 170 175Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp Gly
Gly Gly Asp 180 185 190Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly
Asp Gly Gly Gly Asp 195 200 205Gly Gly Gly Asp Gly Gly Gly Asp Gly
Gly Gly Asp Gly Gly Gly Asp 210 215 220Gly Gly Gly Asp Gly Gly Gly
Asp Gly Gly Gly Asp Gly Gly Gly Asp225 230 235 240Gly Gly Gly Asp
Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp 245 250 255Gly Gly
Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp 260 265
270Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp
275 280 285Gly Gly Gly Asp Gly Gly Gly Asp Gly Gly Gly Asp 290 295
30024375PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptideMISC_FEATURE(1)..(375)This sequence may
encompass 1-75 "Gly Gly Gly Gly Asp" repeating units wherein some
positions may not be present 24Gly Gly Gly Gly Asp Gly Gly Gly Gly
Asp Gly Gly Gly Gly Asp Gly1 5 10 15Gly Gly Gly Asp Gly Gly Gly Gly
Asp Gly Gly Gly Gly Asp Gly Gly 20 25 30Gly Gly Asp Gly Gly Gly Gly
Asp Gly Gly Gly Gly Asp Gly Gly Gly 35 40 45Gly Asp Gly Gly Gly Gly
Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly 50 55 60Asp Gly Gly Gly Gly
Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp65 70 75 80Gly Gly Gly
Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly 85 90 95Gly Gly
Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly 100 105
110Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly
115 120 125Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly
Gly Gly 130 135 140Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly
Gly Gly Gly Asp145 150 155 160Gly Gly Gly Gly Asp Gly Gly Gly Gly
Asp Gly Gly Gly Gly Asp Gly 165 170 175Gly Gly Gly Asp Gly Gly Gly
Gly Asp Gly Gly Gly Gly Asp Gly Gly 180 185 190Gly Gly Asp Gly Gly
Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly 195 200 205Gly Asp Gly
Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly 210 215 220Asp
Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp225 230
235 240Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp
Gly 245 250 255Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly
Asp Gly Gly 260 265 270Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly
Gly Asp Gly Gly Gly 275 280 285Gly Asp Gly Gly Gly Gly Asp Gly Gly
Gly Gly Asp Gly Gly Gly Gly 290 295 300Asp Gly Gly Gly Gly Asp Gly
Gly Gly Gly Asp Gly Gly Gly Gly Asp305 310 315 320Gly Gly Gly Gly
Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly 325 330 335Gly Gly
Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly 340 345
350Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly Gly Asp Gly Gly Gly
355 360 365Gly Asp Gly Gly Gly Gly Asp 370 37525150PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptideMISC_FEATURE(1)..(150)This sequence may encompass 1-75
"Gly Lys" repeating units wherein some positions may not be present
25Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys1
5 10 15Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly
Lys 20 25 30Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys
Gly Lys 35 40 45Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly
Lys Gly Lys 50 55 60Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys
Gly Lys Gly Lys65 70 75 80Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys
Gly Lys Gly Lys Gly Lys 85 90 95Gly Lys Gly Lys Gly Lys Gly Lys Gly
Lys Gly Lys Gly Lys Gly Lys 100 105 110Gly Lys Gly Lys Gly Lys Gly
Lys Gly Lys Gly Lys Gly Lys Gly Lys 115 120 125Gly Lys Gly Lys Gly
Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys 130 135 140Gly Lys Gly
Lys Gly Lys145 15026225PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptideMISC_FEATURE(1)..(225)This
sequence may encompass 1-75 "Gly Gly Lys" repeating units wherein
some positions may not be present 26Gly Gly Lys Gly Gly Lys Gly Gly
Lys Gly Gly Lys Gly Gly Lys Gly1 5 10 15Gly Lys Gly Gly Lys Gly Gly
Lys Gly Gly Lys Gly Gly Lys Gly Gly 20 25 30Lys Gly Gly Lys Gly Gly
Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys 35 40 45Gly Gly Lys Gly Gly
Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly 50 55 60Gly Lys Gly Gly
Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly65 70 75 80Lys Gly
Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys 85 90 95Gly
Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly 100 105
110Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly
115 120 125Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly
Gly Lys 130 135 140Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys
Gly Gly Lys Gly145 150 155 160Gly Lys Gly Gly Lys Gly Gly Lys Gly
Gly Lys Gly Gly Lys Gly Gly 165 170 175Lys Gly Gly Lys Gly Gly Lys
Gly Gly Lys Gly Gly Lys Gly Gly Lys 180 185 190Gly Gly Lys Gly Gly
Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly 195 200 205Gly Lys Gly
Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly 210 215
220Lys22527300PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptideMISC_FEATURE(1)..(300)This sequence
may encompass 1-75 "Gly Gly Gly Lys" repeating units wherein some
positions may not be present 27Gly Gly Gly Lys Gly Gly Gly Lys Gly
Gly Gly Lys Gly Gly Gly Lys1 5 10 15Gly Gly Gly Lys Gly Gly Gly Lys
Gly Gly Gly Lys Gly Gly Gly Lys 20 25 30Gly Gly Gly Lys Gly Gly Gly
Lys Gly Gly Gly Lys Gly Gly Gly Lys 35 40 45Gly Gly Gly Lys Gly Gly
Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys 50 55 60Gly Gly Gly Lys Gly
Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys65 70 75 80Gly Gly Gly
Lys Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys 85 90 95Gly Gly
Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys 100 105
110Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys
115 120 125Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly
Gly Lys 130 135 140Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys
Gly Gly Gly Lys145 150 155 160Gly Gly Gly Lys Gly Gly Gly Lys Gly
Gly Gly Lys Gly Gly Gly Lys 165 170 175Gly Gly Gly Lys Gly Gly Gly
Lys Gly Gly Gly Lys Gly Gly Gly Lys 180 185 190Gly Gly Gly Lys Gly
Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys 195 200 205Gly Gly Gly
Lys Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys 210 215 220Gly
Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys225 230
235 240Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly
Lys 245 250 255Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly Lys Gly
Gly Gly Lys 260 265 270Gly Gly Gly Lys Gly Gly Gly Lys Gly Gly Gly
Lys Gly Gly Gly Lys 275 280 285Gly Gly Gly Lys Gly Gly Gly Lys Gly
Gly Gly Lys 290 295 30028375PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptideMISC_FEATURE(1)..(375)This
sequence may encompass 1-75 "Gly Gly Gly Gly Lys" repeating units
wherein some positions may not be present 28Gly Gly Gly Gly Lys Gly
Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly1 5 10 15Gly Gly Gly Lys Gly
Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly 20 25 30Gly Gly Lys Gly
Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly 35 40 45Gly Lys Gly
Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly 50 55 60Lys Gly
Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys65 70 75
80Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly
85 90 95Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly
Gly 100 105 110Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys
Gly Gly Gly 115 120 125Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly
Lys Gly Gly Gly Gly 130 135 140Lys Gly Gly Gly Gly Lys Gly Gly Gly
Gly Lys Gly Gly Gly Gly Lys145 150 155 160Gly Gly Gly Gly Lys Gly
Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly 165 170 175Gly Gly Gly Lys
Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly 180 185 190Gly Gly
Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly 195 200
205Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly
210 215 220Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly
Gly Lys225 230 235 240Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly
Gly Gly Gly Lys Gly 245 250 255Gly Gly Gly Lys Gly Gly Gly Gly Lys
Gly Gly Gly Gly Lys Gly Gly 260 265 270Gly Gly Lys Gly Gly Gly Gly
Lys Gly Gly Gly Gly Lys Gly Gly Gly 275 280 285Gly Lys Gly Gly Gly
Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly 290 295 300Lys Gly Gly
Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys305 310 315
320Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly
325 330 335Gly Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly Lys
Gly Gly 340 345 350Gly Gly Lys Gly Gly Gly Gly Lys Gly Gly Gly Gly
Lys Gly Gly Gly 355 360 365Gly Lys Gly Gly Gly Gly Lys 370
37529150PRTArtificial SequenceDescription of Artificial Sequence
Synthetic
polypeptideMISC_FEATURE(1)..(150)This sequence may encompass 1-75
"Gly Arg" repeating units wherein some positions may not be present
29Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg1
5 10 15Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly
Arg 20 25 30Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg
Gly Arg 35 40 45Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly
Arg Gly Arg 50 55 60Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg
Gly Arg Gly Arg65 70 75 80Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg
Gly Arg Gly Arg Gly Arg 85 90 95Gly Arg Gly Arg Gly Arg Gly Arg Gly
Arg Gly Arg Gly Arg Gly Arg 100 105 110Gly Arg Gly Arg Gly Arg Gly
Arg Gly Arg Gly Arg Gly Arg Gly Arg 115 120 125Gly Arg Gly Arg Gly
Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg 130 135 140Gly Arg Gly
Arg Gly Arg145 15030225PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptideMISC_FEATURE(1)..(225)This
sequence may encompass 1-75 "Gly Gly Arg" repeating units wherein
some positions may not be present 30Gly Gly Arg Gly Gly Arg Gly Gly
Arg Gly Gly Arg Gly Gly Arg Gly1 5 10 15Gly Arg Gly Gly Arg Gly Gly
Arg Gly Gly Arg Gly Gly Arg Gly Gly 20 25 30Arg Gly Gly Arg Gly Gly
Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg 35 40 45Gly Gly Arg Gly Gly
Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly 50 55 60Gly Arg Gly Gly
Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly65 70 75 80Arg Gly
Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg 85 90 95Gly
Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly 100 105
110Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly
115 120 125Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly
Gly Arg 130 135 140Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg
Gly Gly Arg Gly145 150 155 160Gly Arg Gly Gly Arg Gly Gly Arg Gly
Gly Arg Gly Gly Arg Gly Gly 165 170 175Arg Gly Gly Arg Gly Gly Arg
Gly Gly Arg Gly Gly Arg Gly Gly Arg 180 185 190Gly Gly Arg Gly Gly
Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly 195 200 205Gly Arg Gly
Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly 210 215
220Arg22531300PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptideMISC_FEATURE(1)..(300)This sequence
may encompass 1-75 "Gly Gly Gly Arg" repeating units wherein some
positions may not be present 31Gly Gly Gly Arg Gly Gly Gly Arg Gly
Gly Gly Arg Gly Gly Gly Arg1 5 10 15Gly Gly Gly Arg Gly Gly Gly Arg
Gly Gly Gly Arg Gly Gly Gly Arg 20 25 30Gly Gly Gly Arg Gly Gly Gly
Arg Gly Gly Gly Arg Gly Gly Gly Arg 35 40 45Gly Gly Gly Arg Gly Gly
Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg 50 55 60Gly Gly Gly Arg Gly
Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg65 70 75 80Gly Gly Gly
Arg Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg 85 90 95Gly Gly
Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg 100 105
110Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg
115 120 125Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly
Gly Arg 130 135 140Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg
Gly Gly Gly Arg145 150 155 160Gly Gly Gly Arg Gly Gly Gly Arg Gly
Gly Gly Arg Gly Gly Gly Arg 165 170 175Gly Gly Gly Arg Gly Gly Gly
Arg Gly Gly Gly Arg Gly Gly Gly Arg 180 185 190Gly Gly Gly Arg Gly
Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg 195 200 205Gly Gly Gly
Arg Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg 210 215 220Gly
Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg225 230
235 240Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly
Arg 245 250 255Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly Arg Gly
Gly Gly Arg 260 265 270Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly
Arg Gly Gly Gly Arg 275 280 285Gly Gly Gly Arg Gly Gly Gly Arg Gly
Gly Gly Arg 290 295 30032375PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptideMISC_FEATURE(1)..(375)This
sequence may encompass 1-75 "Gly Gly Gly Gly Arg" repeating units
wherein some positions may not be present 32Gly Gly Gly Gly Arg Gly
Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly1 5 10 15Gly Gly Gly Arg Gly
Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly 20 25 30Gly Gly Arg Gly
Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly 35 40 45Gly Arg Gly
Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly 50 55 60Arg Gly
Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg65 70 75
80Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly
85 90 95Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly
Gly 100 105 110Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg
Gly Gly Gly 115 120 125Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly
Arg Gly Gly Gly Gly 130 135 140Arg Gly Gly Gly Gly Arg Gly Gly Gly
Gly Arg Gly Gly Gly Gly Arg145 150 155 160Gly Gly Gly Gly Arg Gly
Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly 165 170 175Gly Gly Gly Arg
Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly 180 185 190Gly Gly
Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly 195 200
205Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly
210 215 220Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly
Gly Arg225 230 235 240Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly
Gly Gly Gly Arg Gly 245 250 255Gly Gly Gly Arg Gly Gly Gly Gly Arg
Gly Gly Gly Gly Arg Gly Gly 260 265 270Gly Gly Arg Gly Gly Gly Gly
Arg Gly Gly Gly Gly Arg Gly Gly Gly 275 280 285Gly Arg Gly Gly Gly
Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly 290 295 300Arg Gly Gly
Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg305 310 315
320Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly
325 330 335Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly Arg
Gly Gly 340 345 350Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Gly
Arg Gly Gly Gly 355 360 365Gly Arg Gly Gly Gly Gly Arg 370
37533375PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptideMISC_FEATURE(1)..(375)This sequence may
encompass 1-75 "Glu Ala Ala Ala Lys" repeating units wherein some
positions may not be present 33Glu Ala Ala Ala Lys Glu Ala Ala Ala
Lys Glu Ala Ala Ala Lys Glu1 5 10 15Ala Ala Ala Lys Glu Ala Ala Ala
Lys Glu Ala Ala Ala Lys Glu Ala 20 25 30Ala Ala Lys Glu Ala Ala Ala
Lys Glu Ala Ala Ala Lys Glu Ala Ala 35 40 45Ala Lys Glu Ala Ala Ala
Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala 50 55 60Lys Glu Ala Ala Ala
Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys65 70 75 80Glu Ala Ala
Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu 85 90 95Ala Ala
Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala 100 105
110Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala
115 120 125Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala
Ala Ala 130 135 140Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu
Ala Ala Ala Lys145 150 155 160Glu Ala Ala Ala Lys Glu Ala Ala Ala
Lys Glu Ala Ala Ala Lys Glu 165 170 175Ala Ala Ala Lys Glu Ala Ala
Ala Lys Glu Ala Ala Ala Lys Glu Ala 180 185 190Ala Ala Lys Glu Ala
Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala 195 200 205Ala Lys Glu
Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala 210 215 220Lys
Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys225 230
235 240Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys
Glu 245 250 255Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala
Lys Glu Ala 260 265 270Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala
Ala Lys Glu Ala Ala 275 280 285Ala Lys Glu Ala Ala Ala Lys Glu Ala
Ala Ala Lys Glu Ala Ala Ala 290 295 300Lys Glu Ala Ala Ala Lys Glu
Ala Ala Ala Lys Glu Ala Ala Ala Lys305 310 315 320Glu Ala Ala Ala
Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu 325 330 335Ala Ala
Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala 340 345
350Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala
355 360 365Ala Lys Glu Ala Ala Ala Lys 370 3753415PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 34Glu
Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1 5 10
153520PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 35Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala
Ala Ala Lys Glu1 5 10 15Ala Ala Ala Lys 203625PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 36Glu
Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu1 5 10
15Ala Ala Ala Lys Glu Ala Ala Ala Lys 20 25375PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 37Gly
Gly Gly Gly Ser1 5386PRTArtificial SequenceDescription of
Artificial Sequence Synthetic 6xHis tag 38His His His His His His1
53910PRTArtificial SequenceDescription of Artificial Sequence
Synthetic 10xHis tag 39His His His His His His His His His His1 5
10404PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 40Ile Ala Glu Tyr1414PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 41Ile
Ala Gln Tyr1424PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 42Ile Ser Lys Tyr1434PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 43Val
Ala Lys His1
* * * * *